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Zusammenfassung  
 
GABAA Rezeptoren (GABAAR) sind für die schnelle hemmende Neurotransmission im ZNS 
verantwortlich und synchronisieren die Aktivität von neuronalen Netzen. Die Verfügbarkeit 
dieser Rezeptoren an Synapsen wird reguliert durch die postsynaptische Dichte (PSD), die das 
Gerüstprotein Gephyrin enthält. Gephyrin ist ein multifunktionelles Protein, das auch ein 
hexagonales Gerüst unter den Rezeptoren bildet und dadurch Veränderungen der Plastizität 
GABAerger Synapsen vereinfacht. Post-translationelle Modifizierung von Gephyrin durch 
Phosphorylierung, Acetylierung und SUMOylierung spielen eine essentielle Rolle für die 
Eigenschaften und Stabilität des Gerüsts. In dieser Studie zeigen wir, dass SUMOylierung und 
Phosphorylierung von Gephyrin verbunden sind und dass SUMOylierung ein wichtiger Faktor ist 
für die Gerüstbildung von Gephyrin. Wir identifizieren den Wachstumsfaktor Brain Derived 
Neurotrophic Factor (BDNF) als den vorgeschalteten Modulator der E3 Ligase PIAS-3, die 
ihrerseits die SUMOylierung von Gephyrin reguliert. Diese Wirkung von BDNF entfaltet sich 
durch die subzelluläre Lokalisierung und durch funktionelle Änderungen von spezifischen 
Proteinen des SUMO Signalwegs, im Speziellen PIAS-3. Im Folgenden decken wir zwei 
unabhängige Mechanismen auf, über die PIAS-3 die Gerüstbildung von Gephyrin moduliert. Ein 
Mechanismus benötigt die SUMO E3 Ligase-Funktion von PIAS-3; ein zweiter Mechanismus 
beinhaltet die C-terminale Sequenz und ist abhängig von der ERK1/2 Kinase. Interessanterweise 
sind SUMO-defiziente Gephyrin-Mutanten nicht empfindlich gegenüber PIAS-3 und dem BDNF 
Signalweg. 
Des Weiteren bauen wir auf Beobachtungen in organotypischen Schnittkulturen auf, kombiniert 
mit einem Oxygen Glucose Deprivation (OGD) in vitro Modell, in dem wir die morphologische 
und funktionelle Bedeutung des BDNF Signalwegs für den Verlust des Gephyringerüsts 
nachweisen. Wir zeigen dass die Aktivierung von TrkB PIAS-3 rekrutiert, was zur 
Herabregulierung von Gephyrin und GABAAR in der CA1 Region des Hippocampus führt. 
OGD-induzierte Herabregulierung von Gephyrin kann durch die transgene Expression der 
SUMO-defizienten Mutationen K148R/K724R in CA1-Neuronen verhindert werden. 
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Zusammenfassend decken wir einen neuen zellulären Mechanismus auf, der Gephyrin und die 
Integrität von GABAergen Synapsen unter Ischämie und ähnlichen neurologischen Erkrankungen 
reguliert. 
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Abstract 
 
GABAARs mediate fast inhibitory neurotransmission in the CNS to control and synchronize 
network activity. The availability of the receptors at synaptic locations is tightly regulated by the 
postsynaptic density (PSD) containing the main scaffolding protein gephyrin. Gephyrin is a 
multifunctional protein that also forms a lattice underneath of the receptors to facilitate structural 
and functional plasticity of GABAergic synapses. Gephyrin post-translational modifications via 
phosphorylation, acetylation and SUMOylation play an essential role in determining its 
scaffolding properties and also scaffold stability. In this study, we demonstrate that SUMOylation 
and phosphorylation of gephyrin are coupled, and that SUMOylation is an important determinant 
for gephyrin scaffolding. We identify brain derived neurotrophic factor (BDNF) as an upstream 
modulator of the E3 ligase PIAS-3, in turn regulating gephyrin SUMOylation. BDNF signaling 
affects the subcellular localization and induces functional changes of specific proteins of the 
SUMO pathway, especially PIAS-3. Subsequently, we uncover two independent mechanisms by 
which PIAS-3 can modulate gephyrin scaffolding. One mechanism, requiring the SUMO E3 
ligase function of PIAS-3; and the second mechanism involving the C-terminus sequence in 
ERK1/2 kinase-dependent manner. Interestingly, gephyrin SUMO defective mutants are 
insensitive to BDNF signalling. 
We further build on our observations by using organotypic slice cultures as an in vitro model of 
oxygen glucose deprivation (OGD), and demonstrate morphological and functional implications 
of BDNF signaling for gephyrin scaffold loss. We show that TrkB activation results in PIAS-3 
recruitment to transiently downregulate gephyrin and GABAARs in hippocampal CA1 area. 
OGD-induced downregulation of gephyrin can be blocked via the transgenic expression of 
SUMO defective mutations K148R/K724R in CA1 neurons. Taken together, we uncover a novel 
cellular mechanism regulating gephyrin and GABAergic synapse integrity in brain pathology like 
ischemia. 
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I/ General Introduction 
 
The majority of inhibitory neurotransmission is mediated by γ-aminobutyric acid (GABA) and 
the regulation of the neurotransmitter release is crucial for the maintenance of GABAergic 
function. GABA is present abundantly in the central nervous system (CNS) and is necessary for 
maintaining the excitation/ inhibition balance. Gaining knowledge about assembly, maintenance 
and regulation of GABAergic synapses in the CNS has a crucial relevance for understanding the 
pathophysiology of multiple neurological and neurodevelopmental and psychiatric diseases. 
Altered GABAergic transmission has been related to multiple psychiatric disorders such as 
anxiety, mood disorders [1], schizophrenia [2] in addition to epilepsy [3] and neurodevelopment 
disorders [4]. In addition, increased inhibitory transmission is associated with Rett, Down 
syndromes [5] and sedation [6]. Modulation of GABAergic transmission is also clinically 
relevant, as GABAA receptors (GABAARs) are the target of allosteric modulators, such as 
benzodiazepines (BZs). BZ-mediated enhancement of GABAergic inhibition is a widely used 
prescription for the treatment of anxiety and insomnia.  
Inhibitory synapses are symmetric synapses based on the thickness of the postsynaptic membrane 
and located primarily at the dendritic shafts [7]. This clear evidence of synaptic contact has been 
identified for the first time by electron microscopy then by immunochemistry [8]. Electron 
microscopy allows distinguishing inhibitory neurons from excitatory neurons by the morphology 
of their synapses. Interneurons possess symmetric electron dense regions whereas excitatory 
neurons have asymmetric electron dense regions due to the presence of a higher density of 
macromolecular complexes at the postsynaptic site [7]. 
Interneurons release GABA from the presynaptic terminals to evoke activation of the 
postsynaptic GABAARs. The large cellular varieties of GABAergic interneurons confer them to 
be classified in 21 classes in the hippocampus. Importantly, they have an essential role in 
innervating the neighbouring principal cells, also called excitatory pyramidal neurons, in addition 
to local GABAergic interneurons. Through this innervation, GABAergic interneurons control 
pyramidal neurons firing pattern thereby synchronising their activity. This process is part of the 
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regulation of a general network activity by keeping a balance between excitation and inhibition 
[9]. 
Changes in neuronal activity lead to changes in synapse gain and functions corresponding to the 
definition of synaptic plasticity. Two forms of synaptic plasticity have been characterized, local 
or global. Local plasticity changes, following the Hebbian theory, are described as changes in 
synaptic strength or number of the presynaptic neurons inducing adaptation at the postsynaptic 
neurons within a short period of time. However, global changes are long lasting changes and are 
essential for long-term stability and function of neuronal networks. Thereby, maintain the balance 
between excitation/inhibition. Interestingly, this homeostatic plasticity allows, in the meantime, 
local changes at a level of a synapse. It is highly postulated that both type of synaptic plasticity 
would depend on diverse signaling cascades converging onto the main scaffolding protein at 
postsynaptic densities (PSD). Therefore, a large variety of studies had been conducted for 
investigating the importance of gephyrin scaffolding regulation at inhibitory PSDs. 
The aim of my thesis is to characterize a novel post-translational modification on gephyrin that 
modulates its scaffolding properties, leading to functional changes at GABAergic synapses in 
physiological and pathology. 
1. Overview of GABAergic neurotransmission 
 
The rich diversity of interneurons provides inhibition and regulates spatio-temporally the 
pyramidal cells activity. According to the interneuron cell type, the innervations can be at the 
level of the soma, at the axon initial segment and at distinct dendritic domains of the pyramidal 
cells. The classification of the GABAergic interneurons has been made according to their firing 
pattern and molecular expression profiles [9]. In cerebral cortex, Parvalbumin (PV) interneurons 
preferentially innervate the somatic compartment of principal cells. Similarly, the axonal initial 
segment is innervated by the axo-axonic cells, the perisomatic region by basket cells, and the 
distal and oblique dendrites are innervated by bistratified cells. The apical dendrites located at the 
stratum lacunosum-moleculare (S.LM) of pyramidal cells are innervated by the O-LM cells. 
Interestingly, GABAergic interneurons contribute temporally to the network activity through 
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their axonal target specificity and intrinsic properties. They contribute in synchronising 
pyramidal cells activity by controlling their firing rate and spike timing [10]. Furthermore, by 
synchronising their activity they also synchronise the general neuronal networks to generate 
oscillations, in high frequency range, involved in high cognitive functions of the brain such as 
sleep homeostasis and consciousness.  
GABA is synthesized from glutamate by decarboxylation mediated by glutamic acid 
decarboxylase (GAD). Then GABA is loaded into synaptic vesicles by the vesicular GABA 
transporter (vGAT) [11]. Upon action potential firing, GABA is released by exocytosis into the 
synaptic cleft where it can binds to pre- or postsynaptic GABA receptors, followed by reuptake 
by GABA transporters found pre-synaptically (GAT1) or on the neighbouring glial cell (GAT3). 
The glial cells metabolise GABA back to glutamate and glutamine, which are then transferred to 
neurons.   
The presynaptic release GABA in the synaptic cleft can act either on the ionotropic GABAARs or 
on the metabotropic GABAB receptors. GABAARs belong to the Cys-loop ligand-gated ion 
channel family and are ionotropic channels permeable to chloride (and bicarbonate) [12]. They 
are responsible for most of the fast inhibitory neurotransmission in the CNS and mediate two type 
of inhibitory transmission according to their localization relative to the postsynaptic density [13, 
14]. Synaptic GABAARs mediate direct rapid phasic conductance in response to GABA released 
in the synaptic cleft. Extrasynaptic receptors mediate low persistent tonic conductance in 
response to ambient concentration of GABA [14, 15]. The function of extrasynaptic receptors is 
still an emerging concept compared to our current understanding of the synaptic GABAAR 
regulation. Both types of GABAergic inhibitions are important for brain function and their 
dysfunction are implicated in neuronal disorders and diseases [6]. GABAARs are widespread 
throughout the CNS and each GABAAR-subunit is expressed in specific brain regions [16, 17] 
which implicate them in the majority, if it is not all, physiological functions. Our current 
understanding of the cellular processes that facilitate GABAARs function is limited in 
comparison to glutamatergic synapse regulation. A multitude of interacting proteins has emerged 
since the past decade helping understanding the receptor trafficking, clustering and their stability 
at the postsynaptic membrane. Interestingly various interacting proteins are implicated in the 
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membrane insertion and removal which tightly regulate the receptor number at inhibitory 
synapses [15]. 
Trapping the receptors at the postsynapse is necessary for efficient neurotransmission and 
involved downstream signaling concentrated at the level of GABAergic PSD. GABAARs binding 
partners contribute to the organization of the inhibitory PSD [8]. Among the various GABAARs 
binding proteins are, cell adhesion molecules like Neuroligins (NLs), various cytoskeletal 
associated proteins, a RhoGEF collybistin (CB) and a scaffolding protein gephyrin [18]. 
Cooperativity between these molecules is necessary for the maintenance of inhibitory 
postsynapse [6, 8]. Furthermore, NL2 and CB are important regulators of gephyrin scaffold and 
in turn GABAARs clusters at postsynaptic sites [19]. These GABAARs interacting molecules 
have been associated with different neurological disorders such as epilepsy, schizophrenia and 
autism [20, 21]. 
Regulation of GABAARs is not only dependent on receptor composition, interacting protein 
partners, but is influenced by diverse PTMs. In general, both direct and indirect modulations of 
GABAARs contribute to the dynamic modulation of synaptic inhibition [8].  
 
2. Molecular organization of GABAA receptors 
 
The molecular heterogeneity of GABAARs represents a key element in understanding their 
functions and the regulation of inhibitory neurotransmission in the CNS.   
GABAARs are pentameric receptors assembled from 19 different subunits genes grouped into 
seven subunit classes; 1-6), 1-3), 1-3), , ε,   and (1-3), which offer an extensive 
heterogeneity in their composition [22-24]. GABAARs are composed of 5 subunits surrounding a 
central pore that form the ion channel through the membrane. Each subunit is formed of a large 
extracellular N-terminus, four hydrophobic transmembrane helices (TM1-4) and a large 
intracellular loop located between transmembrane 3 and 4. The N-terminus contains the 
information for subunit assembly and the intracellular domain mediates the interaction with 
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cytoplasmic proteins [25, 26]. The transmembrane TM2 forms the channel pore and is involved 
in ion selectivity [27] (Fig. 1a). Despite the numerous combination possibilities provided by the 
various GABAARs subunits and the expression of those subunits in specific brain region, the 
existing receptors are refined to 30 different subtypes. GABAARs are predominantly formed 
with 2 copies of , 2 copies of  and 1 copy of either  or  subunits [25, 28, 29] having 
homologous sequences important for the assembly process [30] (Fig. 1b). The subunit 
composition influences the feature of the receptors such as their neuronal localisation. GABAARs 
can either be found at the postsynaptic site or at the extrasynaptic sites. The synaptic receptors are 
containing 1, 2, 3,  and 2 whereas at the extrasynaptic sites receptors contain 4, 5, or 6 
subunits (Fig. 3) [20, 31]. Interestingly, the synaptic receptors need GABA at mM range [32] 
whereas the extrasynaptic receptors need GABA at M level to be activated [33]. At a cellular 
level, no neuronal population has been observed with only the expression of either extrasynaptic 
or synaptic receptors.  
 
 
Figure 1: GABAARs structure (from Jacob et al. 2008). 
a/ GABAAR subunit structure composed of an extracellular N-terminal domain, 4 hydrophobic transmembrane 
helices (TM1-4) and a large intracellular loop located between transmembrane 3 and 4. b/ Hetero-pentameric 
assembly of GABAARs subunits forming a chloride permeable channel formed of 2, 2 and1. 2 GABA binding 
site are at the interface between  and and benzodiazepines (BZs) at the interface between  andsubunits. BZs 
are allosteric modulator of GABAergic transmission [34].  
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The receptors stabilization at synaptic sites is partly dependent upon 2 subunit [31, 35]. 
However, some receptors containing 2 subunit are also localised at the extrasynaptic sites and 
indeed recruited by lateral diffusion for then be at the synaptic site [36]. 
Therefore, 2 subunit being abundantly expressed in the brain play a crucial role for GABAARs 
clustering [37], for its activity [38] and is essential in conferring benzodiazepine sensitivity [13, 
39, 40].  
The functional significance of GABAARs heterogeneity is unclear but it endows them with 
unique functional and pharmacological properties [12, 20]. Moreover, the expression of each 
subunit is spatio-temporally expressed throughout the CNS and alterations in GABAARs 
expression is directly linked with developmental and neurological diseases [8]. The functional 
relevance of each subunit has been studied by targeted gene deletion. The existence of different 
mice strains lacking a specific GABAAR subunit has allowed the characterization of the 
physiological relevance of GABAAR-subunit for GABAergic inhibition. Those studies 
contributed I the amelioration of drug development [12].  
1 subunit is the most abundant  subunit in the brain [24] and its knockout (KO) causes 50% 
loss of total GABAARs. This is similar to the observations made using subunit KO mice. 
Despite significant loss of GABAAR expression levels, both 1 and 2 KO strains show little 
behavioural consequence [41]. Interestingly, deficient mice exhibit a compensatory 
mechanism by increasing the expression levels of certain GABAARs subunits such as 3 and 4 
accompanied by a disruption of 2 subunits and gephyrin clustering [42] in addition to a decrease 
in GABA currents [43].  
Differently to KO or KO, mice lacking or 2 subunits do not survive. Those genetic 
mutations are neonatal lethal [40]. deficient mice show a decrease in GABAARs containing 
2/3 surface expression and no compensatory upregulation of the others  subunits [44].  
GABAARs containing 2 subunits are the most predominant in the brain and its deletion is lethal 
[31, 40]. The disruption of its gene didn’t show any upregulation in one of the other subunits but 
induces severe behavioural and sensorimotor dysfunctions [40]. The lethally can be prevented by 
overexpressing either the long or the short splice isoform of 2 subunit in the 2-KO mice. In the 
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surviving mutants mice, the loss of subunits was reflected by a general loss of GABAARs and the 
scaffolding protein gephyrin expression; which can also be rescued by one of the isoforms 
overexpression [45]. In2-KO mice, ones see a similar loss of postsynaptic current and a 
decrease in gephyrin expression. However, there is no replacement of the missing subunit with 
1 or 3 subunit. A specific loss of 1-GABAARs, gephyrin and NL2 can be seen in the axon 
initial segment but not in the perisomatic synapses of the 2 KO mice. These striking effects can 
be explained by the presence of dystrophin-glycoprotein complex at the perisomatic site, known 
to be involved in the regulation of GABAARs clustering at these sites [24]. 
It follows from those KO studies that GABAARs-containing 1 subunits possess potential role in 
sedation, anticonvulsant and are involved in addiction and memory functions. However, 
GABAARs-containing  or 3 subunits are implicated in sleep and have an anxiolytic and 
myorelaxation roles. Moreover, 2 has an antidepression action [46].  
On the other hand2-KO mice show a down-regulation of 4 subunits associated with an up-
regulation of 2 subunits. Behavior experiment highlights the decreased sensitivity of these KO 
mice to neurosteroïds. This functional deficit is accompanied with a reduction in tonic inhibition 
while its consequence remains unclear  [47].  
The characterization of the GABAARs subunit specific KO mice show adaptive change in the 
subunit composition and compensatory expression changes in the brain leading to the 
reorganization of GABAergic circuits. Interestingly, the receptor subunit composition is a key 
determinant for their pharmacological profile [23].  
 
2.1 Pharmacology of GABAARs  
 
GABAARs are macromolecular complexes regulated by different pharmacological reagents.  The 
opening of the channel is achieved through the binding of two molecules of GABA on sites 
located between  and  subunits [48]. The receptors can also be activated via a selective agonist 
called muscimol [49], whereas competitive antagonists include bicuculline, picrotoxine, gabazine 
or 3-amino-propane sulfonic acid [50]. In contrast, the application of GABAAR antagonist, 
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gabazine, leads to an increase in the number of receptors at the synapse by slowing down the 
diffusion of the receptors [51]. The effect of gabazine is only on the synaptic GABAARs as the 
extra-synaptic receptors are insensitive to gabazine [52]. GABAARs also represent major sites of 
action of BZs, barbiturates, neurosteroids, ethanol and some general anaesthetics [13, 49]. They 
all modulate, in an allosteric manner, the GABA binding therefore modulate the channel opening 
probability and current [50, 53]. Many of these drugs are involved in the enhancement or 
reduction of GABAergic neurotransmission, depending on the ligand used, for their clinical 
actions [54, 55].  
BZs bind at the interface between  and  subunits of GABAARs and modulate GABA responses 
(Fig. 1b). GABAARs containing 1, 2, 3 and 5 are highly sensitive to classical BZs, such as 
diazepam, in contrary to the one containing 4 and 6. 4 and 6 are diazepam-insensitive. This 
difference could be explained by the presence of a conserved histidine amino acid relevant for 
BZs sensitivity whereas the other subunits carry an arginine at the equivalent residue position 
[56]. Interestingly, the disruption of 2 gene (2-KO mice) leads to non-detectable BZs binding, 
which do not affect the embryonic development [40]. Therefore, 2 subunits are postnatally 
necessary for BZs modulation and for normal brain function.  
BZs are allosteric modulators used in clinical therapies for their anxiolytics, sedatives, 
anticonvulsants and muscles relaxant properties. In general, BZs, such Diazepam, Lorazepam or 
Flunitrazepam are positive allosteric modulators, enhancing GABA responses. To investigate 
which of the GABAARs subunits were responsible of the anti-hyperalgesic action in condition of 
inflammation, transgenic mice harboring a point mutation (H/R) on the conserved histidine 
amino-acid in GABAAR  subunit into an arginine was generated. H/R mutation in 1, 2, 3 
and 5-GABAARs subunits variants shows a loss of specific effect of diazepam in those knock-in 
mice. The receptors containing point-mutated subunit variants became insensitive to diazepam 
[57, 58]. Moreover, by these studies it could be determined that the effect of sedation is mainly 
via 1 subunit, the effect of anxiolytics is via 2 subunit [56, 59] and the effect of myo-
relaxation is via 3 subunit [60].  
Besides BZs, GABAARs are also target of barbiturates, depressant drugs enhancing or mimicking 
GABA response. Barbiturates are positive modulators prolonging and potentiating the effect of 
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GABA but at high dosage they can act as an agonist of GABA and directly activate GABAARs 
[61]. They are derived from barbituric acid and have a wide spectrum of effects such as 
hypnotics, anxiolytics and anticonvulsants. However, because of tolerance induction, they have 
been medically replaced by BZs. 
Among the variety of drugs modulating GABAARs are the endogenous neuroactive steroids or 
neurosteroids [62] synthesised during stress, pregnancy and alcohol intoxication, which act at 
different levels of a synapse. At the presynapse, neurosteroids modulate vesicular release whereas 
at the postsynapse they modulate the excitability of the neurons in response to stress via 
activation of diverse mechanism. Neurosteroids have the ability to activate GABAARs by binding 
to the GABA binding site and/or to potentiate the GABA response by binding GABAAR in a 
hydrophobic pocket present in -subunit. Moreover, one of the main targets of the neurosteroids 
is the extrasynaptic GABAARs containing the  subunit. By occupying the activation and 
potentiation sites, steroids are able to enhance GABA response, therefore fine tune neuronal 
inhibition. However, the neurosteroids activity is dependent on residues located at M1 and/or M2 
transmembrane domains of -subunit [62]. Neurosteroids synthesis is related to sex-differences 
in the genomic regulation of their own synthesis and degradation [63]. Moreover, neurosteroids 
can regulate GABAARs at the transcriptional level under pathological conditions such as 
epilepsy, stress, schizophrenia and Alzheimer disease (reviewed in [64, 65]). Rapid declines in 
circulating neurosteroids are correlated with increased seizures and anxiety susceptibility. 
Thereby, they represent a potential therapeutic treatment of seizures and diverse psychologic 
disorders. Interestingly, there is a direct correlation between the concentration of neurosteroids 
and GABAARs gene expression (mRNA levels). The increase in neurosteroids during pregnancy 
is observed in parallels with a decrease 2 subunits mRNA levels. In this case, neurosteroids 
exert a positive allosteric modulation on GABAARs surface expression, subsequently, act on 
GABAergic transmission. This effect is reversed after parturition where the neurosteroids levels 
are decreased [64].  Neurosteroids play an important role in the modulation of neuronal plasticity 
related to divers’ biological functions such as mood, stress and emotional responses. 
Interestingly it has been shown that changes in the level neurosteroids are not associated with 
changes in the scaffolding molecule gephyrin [66].  
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2.2 GABAARs-trafficking   
 
GABAAR subunits are synthesized and assembled in the endoplasmic reticulum (ER) and 
matured in the Golgi [67]. During the maturation stage the receptor  availability is regulated by 
endoplasmic reticulum quality control machinery (ERAD) via ubiquitination and degradation 
[68]. After the initial quality control the receptors traverse the secretory pathway to reach the 
plasma membrane extrasynaptically, later getting recruited to the postsynaptic sites via lateral 
diffusion [25] (Fig. 2). Therefore, dynamic regulation of reserve pool of extrasynaptic receptors 
is an important determinant of phasic synaptic inhibition [36, 69]. Nevertheless, receptor 
trafficking and accumulation at synaptic sites is controlled by endocytosis and exocytosis which 
also regulate GABAARs synaptic inhibition efficacy (reviewed in [15]).  
At the level of the ER, receptor assembly is limited by constitutive ER association degradation 
(ERAD). Afterwards, maturation of the assembled receptors in the Golgi via post-translational 
modification (PTM) influences receptor accumulation. For example, GABAARs 2 subunit is 
subject to palmitoylation in the Golgi apparatus, promoting receptor progression to the secretory 
vesicles. This PTM is facilitated by the Golgi-specific DHHC zinc finger protein (GODZ) 
promoting GABAARs translocation from the Golgi apparatus to the plasma membrane [70]. The 
exit of GABAARs from the Golgi is facilitated by a number of proteins interacting with the 
receptors. Amongst these diverse proteins, GABAAR-associated protein (GABARAP) has gained 
prominence over the past decade. GABARAP interacts with all receptors through their  subunits 
and with the microtubules and facilitates GABAARs translocation to cell surface [71]. The 
importance of GABARAP interaction with GABAARs for receptor function is still a subject of 
debate as GABARAP-KO mice show normal cell surface expression of GABAARs containing 2 
subunits. In addition, GABARAP has a multitude of interacting partners, which complicates our 
current understanding of the regulation process [15], and moreover GABARAP is absent at 
synapses [72].  
Endocytosis of GABAARs is a critical step that tightly regulates the physiological and 
pathological adaptations for neuronal excitability. For effective endocytosis, GABAARs have to 
reach the dendritic endocytic zones, where they interact with clathrin-adaptor protein AP2. By 
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interfering with AP2 binding motif within the intracellular loop of GABAAR-3 subunit the 
receptors are stabilized at the plasma membrane. Moreover, phosphorylation of GABAAR- 
subunits negatively regulates AP2 interaction, influencing the residency time at the endocytic 
zones and steady-state synaptic receptor levels [73]. Independent studies using single particle 
tracking have demonstrated that GABAARs are trafficked along the plasma membrane in an 
activity-dependent mechanism and PTM of specific receptor subunits might play a role in this 
regulation [74, 75]. The PTM of GABAARs could also influence interaction with the main 
scaffolding molecule gephyrin restraining GABAARs mobility at GABAergic postsynaptic sites 
[76].  
Interestingly, activating GABAARs by muscimol causes a decreased interaction between 
GABAARs and gephyrin leading to an increase in the lateral diffusion of the receptors at the 
postsynapse. However, a treatment with the BZ antagonist like flumazenil regulates GABAARs 
trafficking and decreases their surface expression leading to a decrease in inhibitory 
neurotransmission [77]. Therefore, BZ contribute in stabilisation of the receptors at the synapse 
[78]. 
The diffusion coefficient of GABAARs is dependent on Ca
2+
 influx and therefore is directly 
linked to the rapid adaptations in GABAergic transmission. Increase in Ca
2+
 influx, upon 
neuronal activity, reduces evoked inhibitory postsynaptic potentials (eIPSPs) [79] and mIPSCs, 
due to the dispersion of synaptic GABAARs to the extrasynaptic sites. The increased diffusion 
coefficient of GABAARs involves activation of the Ca
2+
 -sensitive phosphatase calcineurin [74]. 
Calcineurin reduces the resident time of quantum dot-labeled single GABAAR molecules via 
dephosphorylation of the  subunit at Serine 327 [80]. In addition, by increasing extrasynaptic 
diffusion coefficient, the receptors are subsequently internalised. This process has been correlated 
with a loss of GABAAR function after status epilepticus [81]. This observation is contradicted by 
an earlier study showing calcineurin induced long-term depression of GABAergic inhibition [82].  
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Figure 2: GABAA receptors trafficking (adapted from Tretter and Moss, 2008).  
GABAARs are synthesized and assembled in the reticulum endoplasmic. After maturation in the Golgi the receptors, 
through the secretory path, reaches the plasma membrane. By lateral movement, synaptic receptors reach their 
destination. Trapping and removal of the receptors are regulated by phosphorylation. AP2 dephosphorylation lead to 
clathrin endocytosis of the receptors. In the endosomal system, either the receptors are recycled or send to lysosomal 
degradation [25].  
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One way to reconcile these regulatory differences could be that short chemical (NMDA) 
stimulation leads to enhancement of GABAARs surface expression and GABAergic transmission. 
Whereas a strong stimulation (high frequency stimulation of glutamatergic afferents) would 
depress GABAergic inhibition by endocytosis of the receptors [15]. 
Endocytosed receptors are either recycled and sent back to the plasma membrane or sorted for 
lysosomal degradation. Studies exploring the endocytic lysosomal pathway have mainly focused 
on GABAAR- subunit containing receptors as they consist of majority of the synaptic receptors. 
They observed that prior to degradation the  subunit is ubiquitinated on series of lysine residues 
located within the intracellular domain [83]. Moreover, a decrease in GABAARs ubiquitination 
by increasing the neuronal activity leads to stability of the receptors at the plasma membrane [83, 
84]. However, the ubiquitin ligases involved in ubiquitin-mediated GABAARs degradation 
remain unknown. 
These studies on GABAARs trafficking prove that receptors number at the synapses is determined 
by local trapping and lateral diffusion [85]. The receptor trafficking modulation requires 
essentially the participation of different post-translational modifications (PTMs), such as 
phosphorylation of different GABAARs subunits. Moreover, the main scaffolding protein 
gephyrin, in cooperation with other synaptogenic molecules, contributes in GABAARs diffusion 
properties by trapping the receptors at the postsynapse sites [76]. Thus, dynamic trafficking of the 
receptors represents prevalent form of GABAergic neuronal plasticity [15]. 
 
2.3 GABAARs post-translational modifications 
 
GABAARs are subjected to post-translational modifications, which have been well established to 
be key modulators of the receptor number and localization therefore contributing to the 
heterogeneity in the GABAergic transmission regulation. The main PTMs involved in this tight 
regulation are phosphorylation and ubiquitination. The best characterized GABAARs PTM is 
phosphorylation [86]. Multiple phosphorylation mechanisms act in concert to modulate the 
receptors kinetics properties or channel gating, the receptors stability, their cell surface 
integration and their internalisation [15, 34]. 
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Interestingly, only one site of phosphorylation has been reported at -subunits to be of high 
interest. A proline-directed kinase phosphorylation site has been identified at-subunits 
regulating the interaction between GABAARs- subunits and gephyrin. Dephosphorylation of 
the threonine 375 prevents the interaction of the subunit with gephyrin thereby increasing its 
diffusion at the membrane. This study confirms the importance of gephyrin binding to the 
receptors for modulating their diffusion properties therefore regulating their accumulation at the 
postsynapse [87]. 
2, 3 and 2 subunits represent the main phosphorylated subunits and substrates of various 
kinases, including protein kinase A (PKA), protein kinase C (PKC) and Ca
2+
/calmodulin-
dependent protein kinase II (CaMKII) [38, 88]. PKC have been shown to phosphorylate 1 and 
3 subunits and PKA to phosphorylate 2 subunits. Phosphorylation by both kinases occurs at 
the subunits AP2 interacting sites, altering GABAARs internalisation and trafficking [89]. PKA-
mediated phosphorylation at GABAARs subunits is reverted by protein phosphatase 1 (PP1). 
Endocytosis of GABAARs subunits is further regulated by the phospholipase C-related 
catalytically inactive proteins 1 and 2 (PRIP1/2). PRIP 1/2 act as adaptors for PP1 and PP2A by 
activating them subsequently; hence, dephosphorylating the GABAARs subunits at the AP2 
interaction site. Thereby, PRIP1/2 facilitates GABAARs endocytosis.  
Interestingly, CaMKII can phosphorylate at the same sites than PKC or PKA [88] regulating the 
functional properties and membrane insertion of 2 and 3 subunits at postsynaptic sites. 
Consequently, phosphorylation by CaMKII enhances GABAARs surface expression and 
GABAergic tonic currents [90]. CaMKII is normally localised at dendritic spines suggesting that 
CaMKII might translocate from spines to the dendritic shaft. Therefore, these findings highlight 
the possibility that excitatory transmission on the target neurons increases GABAergic activity. 
Phosphorylation of the 3 subunit at S408 and S409 residues enhances GABAARs channel 
activity whereas phosphorylation of 2 subunits regulates GABAergic tonic and phasic inhibition 
[91]. The 2 subunit can be phosphorylated by PKC and CaMKII at two residues, on their 
cytoplasmic loop, which are important in the regulation of receptor internalisation [88]. The 
generation of knock-in mice carrying point mutations on two tyrosine sites Y365/Y367 
mimicking their dephosphorylation lead to embryonic lethality. Heterozygote mice show sex-
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specific increase in tonic-inhibition, as only female are affected, which present an upregulation of 
the extrasynaptic GABAARs containing andsubunits [91] Interestingly, the Y365/Y367 
tyrosine residues have been shown to be phosphorylated by the tyrosine kinase Src [38].  
In addition to all those kinase cited above, the serine/threonine kinase Akt is required for 
GABAARs cell surface activation. Akt phosphorylate a conserved phosphorylation site on 
GABAAR- subunits. Phosphorylation of the  subunit at S410 or  subunits at S409 
enhances GABAARs surface expression and regulates GABAergic synaptic strength [92]. 
Interestingly, Akt activation leads to inhibition of GSK3 kinase activation. The inhibition of 
GSK3 activity has been linked to a reduction in gephyrin phosphorylation state contributing 
indirectly to the enhancement of GABAergic inhibition [93].  
Thus, de-phosphorylation increases the lateral mobility of the receptors but without involving 
endocytosis [80]. However, this process is often subsequently followed by their removal from the 
surface and thereafter their internalisation [15]. Another negative regulator of GABAAR 
clustering at synaptic sites is the phosphatase peptidyl-propyl isomerase NIMA interacting 
protein1 (Pin-1) [94].  
In general, dynamic mechanisms such as PTMs regulate the receptor complexity, stability and 
internalisation. Thereby, regulate GABAergic transmission efficacy, thus neuronal excitability in 
the CNS. Consequently, PTMs contribute to the formation and function of GABAergic synapse 
[70, 95, 96]. 
 
2.4 Regulation of GABAergic transmission by BDNF 
 
BDNF regulates the development and plasticity of GABAergic synaptic transmission in the CNS 
[97-100], in part through the regulation of surface expression of GABAARs (Fig. 4) [101, 102].  
BDNF is stored in dense core vesicles of excitatory neurons [103] and is synthesized as a 
precursor named proBDNF. proBDNF is then proteolytically cleaved either inside the cell or 
after its secretion in the synaptic cleft to form mature BDNF (mBDNF). Independent studies 
brought evidence that mBDNF is secreted in response to neuronal depolarisation thereby 
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influencing neuronal activity [104]. mBDNF bound to its high-affinity tropomyosin-related 
kinase B (TrKB) receptor localised at pre- and post- synaptic sites [105] acting, hence, on 
excitatory and inhibitory synapses. BDNF/TrKB interaction induces the dimerization of the 
receptor which thereafter auto-phosphorylate and activates different intracellular downstream 
signaling cascades (Fig. 3). So far, three signaling transduction pathways have been well 
characterized: the phosphatidyl-inositol 3 kinase (PI3K), the mitogen-activated protein kinase 
(MAPK) and the phospholipase C(PLC) [106]. PI3K activates Akt which in turn inhibits the 
glycogen synthase 3 (GSK3 activity, contributing to neuronal survival. MAPK pathway 
would lead to the activation of the extracellular signal related kinase (ERK) involved in the 
activation of several downstream effectors implicated in cell growth and differentiation. In the 
case of PLC, this pathway leads to the activation of inositol-triphosphates (IP3) and thereafter 
calmodulin kinase (CamK) activity, crucial during synaptic plasticity. Interestingly, all three 
signaling cascades converge onto the activation of the transcriptional factor cAMP response-
element binding protein (CREB), subsequently upregulating gene expression [106] (Fig. 3).  
 
Figure 3: Overview of BDNF signaling through TrkB receptors (adapted from Autry & Monteggia, 
2012).  
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In mature neurons, BDNF has dual opposite effects depending on the duration of its application 
producing a biphasic effect on GABAergic transmission. Acute and chronic BDNF effects on 
GABAergic synapses occur via modulation of the phosphorylation state of GABAARs. 
 
 
 
 
Figure 4: BDNF modulation of GABAergic transmission in hippocampal neurons.  
The coloured line represent the variation of GABAergic mIPSCs amplitude trough the time. Following the literature 
result, it could be observe that BDNF has different effect according to its time application. Are added examples 
average amplitude and frequency of GABAergic inhibitory postsynaptic currents (mIPSCs, eIPSCs) illustrating 
BDNF bidirectional modulation. Only acute treatment of BDNF has induced variation in GABAARs surface 
expression. 
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Acute BDNF exposure weakens GABAergic transmission [107, 108] and GABAARs surface 
expression [101] in hippocampal neuronal cultures. Application of 100ng/mL of BDNF is 
sufficient to induce significant reduction, within 5min, in mIPSCs in a subset of hippocampal 
neurons [101]. Unexpectedly, an amplitude increase was observed within the first two min, 
followed by a decrease (Fig. 4). In a later study, it was also shown that 200ng/mL of BDNF 
induced a rapid increase in the mIPSCs amplitude of CA1 neurons, followed by long lasting 
depression within the next 20min [109]  (Fig. 4). In both these studies approximately 70% of the 
cells were shown to express the TrKB receptors. So by the use of the TrKB antagonist: K252a 
(200nM), they could inhibit the BDNF effect on GABAergic transmission [101, 108]. K252a is a 
membrane-permeable tyrosine kinase inhibitor [110, 111], which, among others blocks TrKB 
phosphorylation.  
Subsequent studies have shown that BDNF/TrKB signaling involves the activation of different 
kinases to influence the phosphorylation state of different GABAAR subunits. A short application 
of BDNF (100ng/mL) induces a reduction of 2, 2, 3 and 2 subunits immunoreactivity [108]; 
however, only the 3 subunit shows a reduction in phosphorylation state. PKC phosphorylation 
of the residues S408/S409 in 3 subunit could enhance the binding of the receptors to PP2A and 
the phosphatase adaptor PRIP, in turn causing dephosphorylation of the receptors at those sites at 
a later stage [109]. Therefore, these phosphatases would facilitate clathrin-mediated endocytocis 
of the receptors. This acute modulation of GABAergic mIPSCs by BDNF involves biphasic 
modulation of phosphorylation state of GABAAR-3 subunits at S408/S409 sites. Recent studies 
also implicate  phospholipase C (PLC) in the downstream signaling  pathway in addition to PKC 
and PP2A [112]. In addition, rapid degradation of gephyrin could also contribute towards the 
rapid internalisation of GABAARs in the amygdala [113, 114].  
 
Contrary to acute BDNF application, chronic BDNF application enhances GABAARs surface 
expression and the efficacy of GABAergic inhibition (Fig. 4) [115, 116]. The chronic effect of 
BDNF at GABAergic synapses is mediated trough the phosphorylation of 2 subunits at two 
tyrosine residues 365 and 367 (Y365/7) leading to an increase in the residence time of the 
receptors at synaptic sites [117]. However, first messengers, downstream of BDNF, that 
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eventually influence 2 subunit phosphorylation at remains unidentified. Otherwise, it has been 
shown, in non BDNF-condition, that phosphorylation of 2 subunits at Y365/7 residues is 
mediated by PKC and CaMKII [88]. In response to a long-term alteration of neuronal activity, 
BDNF can modulate inhibitory synaptic strength[118]. Independent studies have shown that 
chronic BDNF availability preserves GABAAR density [115] without affecting the synapse 
density but increasing their size [116].  
 
3. GABAergic postsynaptic density 
3.1 Gephyrin  
 
Our current understanding of the GABAergic PSD is still incomplete. However, the main 
scaffolding protein gephyrin has been studied in some detail to gain insights into inhibitory 
synapse assembly and maintenance. Its relevance at GABAergic synapse has gained much from 
these findings.  
Gephyrin is a well conserved multifunctional protein of 93kDa that is essential for Molybdenum 
cofactor biosynthesis. Within mammals, gephyrin is widely expressed in all tissue types with its 
diverse alternative splice variants [119]. The deletion of GPHN leads to neonatal death [120, 
121]. Gephyrin was first identified as a glycine receptor interacting protein [122] then at 
GABAergic synapses [123, 124]. Its genetic deletion induces the lack of postsynaptic glycine 
receptors and some GABAARs at the synapses, leading to a reduction of respiratory motoneuron 
survival thereby affecting the respiratory system. Much of the synaptic gephyrin function has 
been attributed to its self-oligomerizing property [18] (Fig. 5). More importantly gephyrin serves 
as a reliable GABAergic postsynaptic marker [20]. 
Gephyrin is composed of two conserved domains: N-terminus G-domain (20kDa) and the C-
terminus E-domain (43kDa) connected by a linker domain or central C-domain (18-21kDa) [18, 
125]. Gephyrin structure is not clearly defined as the two conserved domains were crystallized 
but not the C-linker domain. It is well accepted that gephyrin G-domain can form trimers and the 
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E-domain forms dimers [126], providing the basis for a putative hexagonal sublattice gephyrin 
organization at GABAergic synapses [127, 128].  
The gephyrin C-domain linker is sensitive to proteolytic degradation and contains multiple 
consensus sites for phosphorylation. In addition, it also carries binding sites for various gephyrin-
interacting proteins, like Collybistin (CB), Pin1, Dynein light chains (Dlc) and microtubules 
[119]. Thus, gephyrin at the PSD may organise the spatial distribution of the receptors and others 
proteins by forming a microfilament-associated hexagonal protein lattice. The G and E-domains 
also carry binding sites and possess, as the C-linker domain, post-translational sites important for 
the regulation of gephyrin oligomerization properties. Moreover, the E-domain of gephyrin is 
crucial for regulating the clustering function. Mutating or depleting the E-domain prevents the 
clustering of gephyrin and the formation of 2-GABAARs at the plasma membrane. However, 
over-expressing a specific sequence of the E-domain enhances gephyrin cluster density [125]. 
The oligomerized forms of gephyrin are found at GABAergic and glycinergic PSDs visualised as 
distinct punctate structures by immunochemistry [87, 129]. Gephyrin interaction with diverse 
GABAARs subunits such as 1, 2, 3, 2, 3 and 2 subunits have been reported [25, 72, 87, 
130, 131]. Super resolution microscopy-based quantification places gephyrin molecules 
associated with GABAAR is in a stoichiometry  of 1:1 [132]. Further, inhibitory PSDs comprised 
between 3000-10000 gephyrin molecules and the number of GABAARs at the synapse is 
dependent on gephyrin abundance [132]. Furthermore, by trapping and accumulating the 
receptors at the synaptic sites, gephyrin does play a role on the surface dynamic of GABAARs at 
the membrane. Deficiency in gephyrin leads to a loss of GABAARs surface expression [31, 124], 
correlating with the concept that changes in the number of gephyrin molecule are mirrored with 
changes in the receptors number. Interestingly, the 2 subunit, for which there is still no evidence 
for direct gephyrin interaction, somehow facilitates  gephyrin recruitment and clustering at 
postsynaptic sites  [45].   
In addition to the GABAARs, gephyrin can interact and be regulated by various synaptogenic 
molecules such as (CB) [19], neuroligin 2 (NL2) and cytoskeletal associated proteins such as 
microtubules and profilin 1/2 [133].   
Gephyrin is subject to diverse PTM and its relevance is emerging slowly. Some of the intra-
cellular signaling cascades converging on to the gephyrin scaffold has been identified and 
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characterized in literature. Since gephyrin scaffolding and GABAARs function are coupled, it is 
therefore conceivable that gephyrin PTM regulates the efficacy of GABAergic transmission at 
synaptic sites.  
 
3.2 Gephyrin regulation by RNA splicing  
 
GPHN gene encodes several introns that are alternatively spliced generating different splices 
isoforms [119]. Expression of specific gephyrin splice cassettes in distinct tissue types has been 
reported. The splice cassettes in the case of GPHN are as short as 33 amino acids, leading to 
difficulties in specifically identifying isoform specific functions in vivo. Gephyrin variants 
containing the G2 (formerly C5) cassette exhibit a specific preference for glycinergic synapses as 
they prevent Glycine receptors to cluster at GABAergic synapses [134]. It has been shown that 
insertion of G2 cassette produces the dimerization of the G-domain. Similarly, expression of C3 
cassette seems to be responsible of E-domain oligomerization [135]. Thus, gephyrin splicing is an 
additional regulatory step essential for ensuring the proper sorting of the receptors to appropriate 
synapses. Moreover, it has been noticed that the gephyrin splice variants expression is dependent 
on the tissue and species [136]. Nevertheless, in vivo all gephyrin splice variants contain C2 and 
C6 splice cassettes. 
Temporal lobe epilepsy had been linked to an abnormal splice variant of GPHN mRNA lacking 
exons coding for the G-domain of gephyrin. The presence of those exons is essential for 
gephyrin/ GABAARs clustering and stability [137].  
 
3.3 Gephyrin interacting proteins 
 
Gephyrin has been discovered as the main scaffolding protein at glycinergic synapses and is 
essential for the clustering of glycine receptors. However, at GABAergic synapses gephyrin is in 
part dispensable for the clustering of GABAARs [138, 139]. Gephyrin interacts with several 
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proteins within the GABAergic PSD, which in turn contribute in regulating the maintenance of 
proper function and localisation of GABAARs [18] (Fig. 5).  
Gephyrin has been first identified as a membrane associated protein and binding to polymerised 
tubulin at glycine postsynapse via its C-terminus domain [140]. Gephyrin trafficking has been 
investigated in detail and independent studies show that Dynein light chain (Dlc) 1 and 2 binds to 
gephyrin C-domain and contributes to transport of gephyrin along the microtubules. 
Consequently, Dlc is indispensable for normal localisation of gephyrin at GABAergic synapses 
[141]. Moreover, the membrane associated protein Profilin 1 and 2 contribute to anchor gephyrin 
at the actin cytoskeleton through its’ binding at the E-domain. The complex formed between 
Profilin and gephyrin allows interaction with the microfilament adaptors of mammalian enabled/ 
vasodilator stimulated phosphoprotein (Mena/VASP) family [142, 143]. Mena/VASP is known to 
be regulating actin polymerisation; therefore regulating indirectly gephyrin transport (Fig. 5). 
 
CB is a neuron-specific guanine exchange factor (GEF), belonging to the RhoGEF family and 
specifically activating the small Rho GTPase Cdc42. By binding to gephyrin E-domain, CB can 
translocate gephyrin from the cytoplasm to submembrane compartment [144]. Moreover, CB is 
important, if not essential, for gephyrin cluster formation at GABAergic PSD as in CB-deficient 
mice gephyrin clusters are undetectable in principal cells of the hippocampus. The impairment of 
gephyrin clustering in addition to a loss of GABAARs expression lead to a decrease in 
GABAergic transmission and enhance LTP [145]. In hippocampal cell culture, over-expression 
of CB enhances gephyrin clustering at GABAergic PSD [146]. However elucidating the exact 
role and function of CB at the synapse remain complicated due to the existence of multiple splice 
variant of CBs. Disruption in mice and human CB gene hPEM2 leads to multiple and variable 
clinical symptoms such as epilepsy, mental retardation and anxiety [145, 147, 148].  
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Figure 5:  Schematic organization of GABAergic postsynaptic density (from Tretter and Moss 
2008). 
Dystrophin-glycoprotein (DGC) complex stabilizes the synapse. Neuroligin 2 contributes in this stabilization by 
contacting Neurexins at the presynaptic terminals. Synaptic GABAARs are stabilised by their interaction with the 
scaffolding gephyrin at GABAergic post-synapses. Gephyrin is proposed to form a hexagonal lattice therefore a 
submembranous scaffold. Gephyrin, by its interaction with diverse proteins contributes to the structural organisation 
of the postsynaptic cytoskeleton. Collybistin interacts with gephyrin and activates Cdc42 which will initiate actin 
filaments remodelling. Cytoskeleton associated protein Dlc, profilin and Mena/VASP contributes  in transportation 
of gephyrin along the microtubules [25]. 
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NL2, through gephyrin and CB regulates the PSD assembly and maintenance at GABAergic 
synapses. NL2 is a trans-synaptic adhesion molecule anchored selectively at the GABAergic 
postsynaptic membrane and interacting with the presynaptic Neurexins [149]. This synaptogenic 
interaction is required and sufficient for initiating the formation and the functional maturation of 
new GABAergic synapses [25, 150]. NL2-KO mice show a reduction in GABAergic synapses in 
the hippocampus [19]. The interaction NL2 /gephyrin can be disrupted by the dephosphorylation 
of NL2 by Pin1, leading to a decrease in GABAergic synapse formation [94]. Interestingly, Pin1 
can also bind directly gephyrin and enhance its ability to bind  subunits of glycine receptors 
[151]. Like for CB, the impairment of NL is associated to cognitive disorders such as 
schizophrenia and autism [21]. 
 
3.4 Gephyrin regulation by post-translational modifications 
 
Gephyrin PTM is emerging as an important mechanism regulating gephyrin scaffolding 
properties: size and density, at GABAergic synapses (Table 1), thereby affecting structural and 
functional properties of GABAergic synapses [18]. It has been established long ago that gephyrin 
is a phosphor-protein [152]. Subsequently, it has shown that gephyrin undergoes proline-directed 
kinase phosphorylation at consensus serine residues. Subsequent to gephyrin phosphorylation 
Pin1 is recruited to induce a cis/trans conformational change, which is essential for gephyrin to 
bind  subunits of glycine receptors allowing the clustering of the receptors [151]. 
Subsequent studies identified another proline-directed kinase regulation of gephyrin via 
GSK3signaling. GSK3 phosphorylates gephyrin at the serine 270 (S270) site to control the 
cluster density, by inducing proteolytic cleavage-induced turnover of gephyrin scaffold. The 
gephyrin
S270A 
mutation, mimicking the dephosphorylation status at the GSK3site, increases 
gephyrin clustering density in primary hippocampal neurons [153]. Inhibition of GSK3might 
occurs through activation of PI3K/Akt pathway followed by the reducing in gephyrin 
phosphorylation at S270 site. Therefore, reduced gephyrin phosphorylation favours the increase 
in GABAARs containing 2 subunits and enhances GABAergic transmission. GSK3-induced 
gephyrin phosphorylation is also relevant within the context of neuronal development, as 
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gephyrin phosphorylation by GSK3site leads to reduced surface expression of GABAARs, 
causing neuronal hyper-excitability and dendritic shrinkage [154]. The S270 site seems to be 
modulated also by the Cycline-dependent kinase 5 (CDK5) in a CB-dependent manner. Inhibition 
of CDK5 reduces gephyrin cluster formation at GABAergic PSD [155].  
Activated ERK causes gephyrin clustering downregulation at GABAergic synapses via 
phosphorylation at the Serine 268 site. Whereas, blocking ERK or the use of phosphorylation-
defective gephyrin mutant constructs (gephyrin
S268A
), in primary hippocampal neuronal cultures, 
enhances gephyrin cluster size and density [156].  
Both GSK3andERK phosphorylations induce gephyrin cleavage and degradation via activation 
of Ca
2+
 dependent cysteine protease calpain 1 [156]. More recently, it has been demonstrated that 
gephyrin is a substrate for CaMKII and PKA phosphorylation at S305 and S303 respectively. 
These two kinases phosphorylate gephyrin in response to NMDA receptor activation to facilitate 
adaptive enhancement of GABAergic inhibition. The expression of gephyrin
S303A/S305A
 blocks 
activity-dependent adaptations at GABAergic synapses [157].  
In addition to kinases, gephyrin also interacts with phosphatases, such as protein phosphatase 1 
(PP1). While the inhibition of PP1 induces a loss of synaptically localised gephyrin (reduction in 
size) with an enhancement of cytoplasmic gephyrin [158], the specific residues regulated by PP1 
is still unclear. A new PTM has been identified in a unique study demonstrating gephyrin 
undergoing palmitoylation at two Cystein residues: C212/C284. This PTM seems to be part of the 
molecular mechanism necessary for anchoring and clustering gephyrin at GABAergic PSD. 
Palmitoylated gephyrin forms stable clusters at the PSD and potentiates GABAergic 
transmission; however, inhibition of this PTM reduces gephyrin clusters size [159].  
Several acetylation sites have been identified on gephyrin using mass spectrometry analysis 
(MS/MS) of gephyrin from rat brain homogenate [18]. Several of the phosphorylation residues 
also a target for acetylation; however, the biochemical basis for such modifications is unclear. In 
addition, some of the lysine residues have also been shown to be acetylated on gephyrin [156]. A 
recent study showed that acetylation of gephyrin at K666 regulates SUMOylation of gephyrin 
(see next Section). Gephyrin is a substrate for SUMO-1 and SUMO-2, which act upstream of 
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phosphorylation and acetylation pathways to regulate gephyrin scaffolding at GABAergic 
synapses [Ghosh et al., Submitted].  
 
PTM of gephyrin represent important cellular mechanisms for regulating the structure and 
function of GABAergic synapses in mature neurons; thereby ensuring homeostatic synaptic 
plasticity [18].  
 
PTM sites Effectors Consequences on gephyrin references 
C212/C284 palmitoylation Regulates gephyrin cluster number [159] 
S268 ERK1/2 ERK1/2 regulates gephyrin cluster size growth 
and density 
[156] 
S268 acetylation unknown [156] 
S270 GSK3 and 
CdK5 
GSK3 regulates gephyrin cluster number and 
CDK5 modulates gephyrin phosphorylation at 
S270 site 
[153] 
[155] 
S268E/S270E Calpain-1 Phosphorylated gephyrin allow calpain 
cleavage 
[156] 
S303/S305 PKA/ CaMKII Modulates gephyrin cluster number in activity-
dependent mechanism 
[157] 
K666 acetylation Important for gephyrin cluster formation [Ghosh et 
al. , 
Submitted] 
S268E/K666A Phosphorylation
/ deacetylation 
Dominant negative gephyrin disrupting 
gephyrin clustering formation 
K148 SUMO-1 SUMOylation modulates gephyrin cluster size 
and its stability at the synapse K724 SUMO-2 
Table 1: Summary of gephyrin PTM 
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4. Post-translational modification by SUMOylation 
4.1 Background  
 
Small Ubiquitin-related Modifiers or SUMOs proteins are covalently attached to their substrates 
and the consequences of SUMOylation varies between substrates. SUMO PTM is a labile 
process, and often only a subset of proteins is SUMOylated at a given point making SUMO-
modified proteins difficult to detect. Moreover, the roles of SUMOs are described to be 
amazingly versatile and uncover a variety of effects which are still being discovered. In brief, 
SUMO modulates protein-protein interactions, sub-cellular localisation, and activity and stability 
of its target substrate [160-164]. Therefore, it triggers multiple functional outcomes. 
SUMOylation regulates diverse cellular processes, such as DNA repair [165, 166], transcriptional 
regulation [167-170], nuclear transport [171, 172] and cell migration [173-175].  
SUMOylation can occur not only on nuclear proteins, but also on cytoplasmic proteins implicated 
in neuronal function. In neurons, SUMOylation regulates synapse development and plasticity. 
Therefore, SUMOylation affects many fundamental pathways often related to pathological 
conditions (see section 4.3) [164, 176, 177].  
The SUMO proteins share ~18% sequence similarity with ubiquitin family members and each 
SUMO protein is ~100 amino-acids in length and 14KDa in mass. Four SUMO isoforms have 
been reported in literature. SUMO-1 shares about 50% homology sequence with SUMO-2 and 
SUMO-3 [178]. Whereas, SUMO-2 and SUMO-3 only differ by 3 amino-acids [179, 180]. 
SUMO-4 is similar to SUMO-2/3 but differs by the presence of a Proline instead of a Glutamine 
residue at position 90. Consequently, SUMO-4 is not processed [181] which make it the least 
characterized of the family members [182]. The expression of SUMO-1 and SUMO-2/3 is found 
in all human tissue whereas SUMO-4 seems to be restricted to the kidney, lymph nodes and 
spleen [163, 183].  
Interestingly, SUMO proteins are indispensable for development and their role is crucial for 
embryonic development [184-186]. Alkuraya et al. demonstrate sumo-1 as a key gene for mouse 
embryonic development and its knock-down is lethal [185]. Moreover, the data obtained by 
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Zhang et al. suggest the fact that sumo-2 and sumo-3 genes do not compensate for sumo-1 gene 
loss but SUMO-2/3 proteins might compensate for SUMO-1 function [186]. Therefore, both 
studies highlight the importance of the role played by each SUMO paralogs. Although SUMO-1 
and SUMO-2/3 isoforms recruit the same SUMO conjugation machinery, their often differ in 
their functionality [160, 187-189]. SUMO proteins are de-conjugated from protein substrates by 
sentrin proteases also called SENP. There seems to be a certain specificity of SENPs to specific 
SUMO proteins and specific pathological condition [190]. SUMO proteins can be further 
distinguished by their capability to form chains [188, 191]. SUMO-1 is unable to form chains, but 
SUMO-2/3 has the capability to form chains, via internal SUMOylation sites located at its N-
terminus [188, 192-194]. While the SUMO-2/3 chain formation is also reversible, SUMO-1 can 
be often found at the end of a poly-SUMO-2/3 chain.  
 
 
4.2 Overview of SUMOylation 
 
The protein SUMOylation cycle (Fig. 6) is similar to the Ubiquitin cycle and is an energy 
consuming cascade made in three steps but their physiological consequences are quiet distinct.  
SUMO isoforms are small polypeptides first translated as immature precursors. Free SUMO 
proteins are maturated by cleavage of their C-terminus via the SUMO-specific proteases (SENPs) 
in an endopeptidase reaction. Then get activated by the SUMO E1 activating enzyme in an ATP-
dependent manner. The SUMO E1 enzyme is a heterodimer made of SAE1/SAE2 proteins that 
activate SUMO by forming a high energy thioester bond between its catalytic cystein and the C-
terminal di-glycine (GG) of the SUMOs. Activated SUMO is transferred to the unique E2 
conjugating enzyme, ubiquitin-like conjugating enzyme 9 (Ubc9). A trans-ester reaction allows 
Ubc-9 to conjugate SUMO to its substrate covalently through the di-glycine residue of the 
SUMO and the lysine residue (K) of the substrate. The E2 conjugation can be sufficient for 
SUMOylation to occur as long as the SUMO consensus sequence is present on the substrate 
[162]. However, the binding specificity to the K residue is often mediated by specific SUMO E3 
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ligase enzymes such as PIAS family [195] (see section 4.4). These ligases catalyse the transfer of 
the SUMO from Ubc9 to the target substrate protein.  
SUMOylation takes place on a lysine residue, usually within the core of a consensus motif 
comporting ΨKXD/E where Ψ is a large hydrophobic amino acid such as Phenylalanine (F), 
tryptophan (W) or tyrosine (Y); K is the lysine residue, x is any amino-acid and D or E is any 
acid such as either an aspartate or a glutamine [196, 197]. However, not all consensus motifs are 
SUMO sites.  
 
 
Figure 6: SUMO modification pathway (adapted from Rytinki et al. 2009). 
SUMO proteins bind covalently to their substrates via a sequential action of three enzymes: E1 activating enzyme, 
E2 conjugating enzyme and E3 ligase enzyme. SUMO-2, but not SUMO-1, has the capacity to form a poly-chain. 
SENPs regulate maturation of the SUMO precursors and release conjugated SUMO from their substrate protein 
[195]. 
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Some SUMO substrates possess longer sequences containing the SUMO consensus motif with 
additional elements such as negatively charged amino-acid dependent SUMO motifs (NSDM) or 
phosphorylation-dependent SUMO motifs (PDSM). In such cases, a phosphorylation site is found 
adjacent to the SUMO consensus motif: ΨKX(D/E)XXSP. SUMOylation at PDSM is enhanced 
by phosphorylation at the serine (S) residue. It has also been observed that the SUMOylation 
within the PSDM can convert transcription factors from activators to transcriptional repressors 
[198]. 
Interestingly, the SUMO conjugation does not necessarily requires this consensus motif but could 
also occur non-covalently at what has been called SUMO interaction motif (SIM). SIM motif is a 
hydrophobic core flanked by acidic amino-acid residues binding to a hydrophobic pocket at the 
surface of SUMO. Therefore, SUMO can modulate the activity and/or localisation of its target 
substrate. Interestingly, the SIM is also found on the SUMO E1 enzyme and PIAS family of 
SUMO E3 ligases. However, the E1 SIM functional relevance remains unclear; whereas in the 
PIAS family it is clear that SIM is not necessary for the E3 ligase activity but can be the binding 
site of SUMO.   
The consequences of SUMOylation are dependent on the target protein. Therefore, three major 
effects retained are: first SUMO can increase the number of binding sites on its target. Second, it 
could mask a binding site and third it could induce change in conformation of its target protein 
[198].  
 
4.2.1 Ubc9 and its neuronal function   
 
In the mammalian system, Ubc9 is the unique SUMO E2 enzyme identified so far with the ability 
to recognise and conjugate SUMO to their substrate proteins [199, 200]. The lysine residue 
within consensus motif ΨKXD/E binds directly to Ubc9. One of the key regulators of Ubc9 
substrate specificity is acetylation. Acetylation of Ubc9, on the lysine K65, helps Ubc9 to 
specially bind SUMO to substrates containing the minimal motif ΨKXD/E. This process can be 
reversed by the deacetylase SIRT1 which lead Ubc9 to conjugate SUMO with extended NDSM-
containing substrates [201].  
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Ubc9 is the sole responsibility of SUMOylation conjugation and its expression is important for 
SUMOylation to happen. Interestingly, its expression level has been characterized via different 
molecular techniques as weak and spatio-temporally regulated. However, Ubc9 remains 
indispensable for embryonic development as its deletion is lethal [202].  
 
4.2.2 SUMO proteases: SENPs  
 
SUMOylation is a dynamic process controlled by the SUMO sentrines proteases (or SENPs) 
family, allowing only a small portion of proteins to be SUMO-modified at any given time [203]. 
The SENPs control the conjugation and de-conjugation of the SUMOs assuring the reversibility 
of the SUMOylation process [204] (Fig. 6).  
The SENP family counts 6 isoforms: SENP (1-3 and 5-7) which possess a non-conserved N-
terminal sequence thought to determine the substrate specificity and their subcellular localisation. 
SENP1, SENP6 and SENP7 are found in the nucleoplasm, SENP2 is confined to the nuclear pore 
complex and SENP3 and SENP5 are in the nucleolus [205]. They are responsible for maturating 
the free SUMOs precursors using their endopeptidase activity. In addition, the SENPs also 
catalyze the de-conjugation of the SUMO proteins from their substrates using their isopeptidase 
function. Furthermore, in the SUMOylation pathway all SENPs isoforms, with the exception of 
SENP1 and SENP2 show preference for SUMO-2/3 over SUMO-1. Moreover, SENP6 and 
SENP7 exhibit a high preference for SUMO-2/3 polychains [206]. 
SENPs in this way control the balance between SUMOylated and unSUMOylated proteins 
substrate. Therefore abnormal activities of the SENPs are related to pathologies, such as heart 
diseases and diverse types of cancers. Several compound targeting different SENP isoforms have 
been synthesized but their efficiency has not been clearly proven in clinical trials [207].  
Among all the SENP isoforms, SENP1 is major enzyme implicated in several diseases. Under 
hypoxic conditions, SENP1 plays a crucial role in releasing the hypoxic-inducible factor 1 
(HIF1) from SUMO proteins. Thereby, SENP1 regulates the stability of HIF1 expression 
during hypoxia and avoid its ubiquitination and degradation [208]. 
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4.3 PIAS family of SUMO E3 ligases 
 
In general, PIAS proteins play an important role in the regulation of different transcription factors 
or synaptogenic molecules essential for keeping a balance of their activities in physiological and 
pathological conditions.  
The specificity and enhancement of the SUMO-conjugation can be achieved through the 
recruitment of an E3 ligase enzyme such as PIAS family containing an SP-Ring domain. This 
domain is responsible for the SUMO E3 ligase function [195, 209]. The E3 enzyme binds to the 
E2thioester SUMO complex to enhance SUMO conjugation in vitro and in vivo (Fig. 7). 
The Protein inhibitor of activated STAT (PIAS) family consists of 4 different protein members: 
PIAS-1, PIAS-x (or PIAS-2), PIAS-3 and PIAS-(or PIAS-4). They share 5 conserved domains: 
Scaffold Attachment factor-A/B (SAP) domain, PINIT domain, Zn finger /SP-Ring domain, 
SUMO interactive motif (SIM) and C-terminus or Serine/Threonine (S/T) C-terminal rich region 
[195] (Fig. 7).  
The PIAS family proteins are described as regulators of gene-activation pathways in non-
pathological [195, 210] and pathological conditions involving an immune response [211, 212]. 
They were initially discovered as negative regulator of cytokines signaling  that inhibit the Signal 
transducer of activated transcription (or STATs) transcription factor and recently as SUMO E3 
ligase enzymes [195, 209, 210]. The function of transcriptional regulator is closely interlinked 
with the SUMO ligase function [210].  
The N-terminus SAP domain of PIAS is known to be involved in sequence and structure specific 
DNA binding (Fig. 7F), in addition to recognizing protein interactors, the SAP domain has been 
shown to be necessary for binding and repressing STAT-1 activity by PIAS- [213]. Downstream 
of SAP is the PINIT domain, which is required for subcellular localization of PIAS-3 [214] and 
for PIAS-3 inhibition of the transcription factors STAT-3 [215, 216] and Microphthalmia 
transcription factor (MITF) [217]. Moreover, the PINIT domain has been shown in some cases to 
be important for substrate binding. The PINIT domain changes the conformation of the PIAS 
protein allowing the attraction of the E2thioester SUMO complex and activation of conjugation 
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[198, 218]. The PINIT domain of PIAS- stimulates SUMO modification by SUMO-2 in some 
cases [195]. 
The RING-type zinc-binding structure or SP-Ring domain is essential for SUMO E3 ligase 
function and bind directly to Ubc9 [195, 209]. SP-Ring activity has variable functional 
consequences according to the protein substrate. It has been shown to alter the substrate function, 
to regulate its subcellular localisation and to modulate the interaction of the substrate with other 
proteins partner (Fig. 7A-D).  
 
 
 
Figure 7: PIAS proteins and their different domains’ functions. (Adapted from Rytinki et al. 2009). 
Schematic structure of PIAS-1 protein with the 5 different conserved domains. Schematic models of SP-
Ring, SIM and SAP-dependent mechanisms in transcription regulation. 
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PIAS proteins harbour a SIM motif between the SP-Ring motif and the C-terminus. The SIM 
motif provides to the protein the capacity to bind non-covalently the free SUMOs proteins 
without being necessary for the SUMO E3 ligase function [198]. Moreover, by binding to the 
substrate it can release the last one from its protein partner and allow transcription to happen, in 
the case of a transcription factor (Fig. 7E). 
 
Compared to the other domains, the S/T C-terminal region is the least conserved domain absent 
in PIAS-. It is a variable region which can serve as protein interaction domain. Interestingly, 
PIAS family of proteins are themselves subject to PTM. PIAS- is regulated by SUMOylation to 
enhance its enzymatic function. Ubiquitin E3 enzymes mediate proteasomal degradation of PIAS. 
During oxidative and nitrosative stress, PIAS-3 is target for S-nitrosylation enhancing its affinity 
for the Ubiquitin E3 enzyme tripartite motif-containing 32 (TRIM32) followed by ubiquitination 
and degradation of PIAS-3 [219].   
 
4.4 SUMO modification in neurons 
 
The importance of SUMOylation in neurons is still emerging; however, this PTM seems to have 
diverse implications, from transcriptional regulation in the nucleus to axonal RNA trafficking and 
synapse plasticity (Fig. 8) [190, 220, 221].  
It has been pointed out that the level of Ubc9 mRNA expression and SUMO-1 conjugation are 
the two mains SUMOylation members playing a critical role in neuronal development [222].  
Moreover, in neurodevelopment PIAS-3 is indispensable for photoreceptors differentiations in 
mouse retina. PIAS-3 promotes the formation of rods photoreceptors through SUMOylation of 
specific transcription factors. PIAS-3 SUMOylation of the transcription factor NR2E3 lead to 
activation of gene transcription involved in the favour of rod photoreceptor differentiation. In 
parallel, gene transcription necessary for cone-differentiation are repressed. This indicates the 
complexity via the fact that SUMOylation can regulate substrate specificity and differentiation of 
neuronal subtypes [220, 223]. 
 
45 
SUMOylation is an important regulator of synaptogenic proteins such as CASK and transcription 
factor myocyte enhancer factor 2A (MEF2A) thereby promoting or repressing synaptogenesis. 
CASK is a Ca
2+
/calmodulin-dependent serine protein kinase essential for formation, stabilisation 
and maintenance of dendritic spines. When CASK is SUMOylated by SUMO-1, at K679 site, it 
impairs spine formation in hippocampal neurons [224]. However, SUMOylation of MEF2A, by 
SUMO-1 (at K403 residue) and PIAS-x, promotes postsynaptic dendritic claw differentiation by 
repressing its transcriptional activity [225]. This last study suggests that PIAS-x might have a 
crucial role in the establishment of neuronal connectivity. Moreover, these results demonstrate 
that, depending on SUMO-1 protein substrate, SUMOylation can induce opposite effects on 
synaptogenesis (Fig.8).  
SUMO not only plays a role in synaptogenesis but has an important role in the regulation of 
synaptic plasticity by modulating presynaptic and postsynaptic mechanisms. Depending on the 
stimulus applied (Kainate or AMPA), it has been shown that SUMO might either up or 
downregulate presynaptic glutamate release. Nevertheless, these studies allowed identification of 
the SUMO substrates involved in controlling neurotransmitter release. Interestingly, at 
presynaptic sites group III mGluRs carry a SUMO consensus motif on their C-terminus and can 
be SUMOylated in vitro. However, SUMOylated mGluRs have not been detected directly in 
neurons. More work would be needed for understanding the relevance of SUMOylation of the 
mGluRs and to address whether they effectively influence synaptic release [221].   
At postsynaptic sites, SUMO regulates neurotransmitter receptors function and trafficking at 
glutamatergic PSDs in response to various forms of plasticity [221, 226]. Induction of long-term 
potential or depression (LTP/LTD) modulates the levels of SUMO-conjugated substrates, such as 
kainate and AMPA receptors (AMPARs).   
The kainate receptor GluK2 (formerly GluR6) is a SUMO-1 substrate, and binds both Ubc9 and 
PIAS-3. Upon kainate stimulation, GluK2 is SUMOylated at the lysine residue K886 on its C-
terminus contributing to its endocytosis at mossy fibers-CA3 synapses. Interestingly, 
SUMOylation of GluK2 is promoted by phosphorylation of the subunit by PKC at S868. 
Furthermore, phosphorylation and SUMOylation collaborate to regulate kainate receptor 
trafficking as endocytosis of GluK2 is an essential mechanism for LTD [221, 226].  
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In parallel, elevation of SUMOylation might be implicated in AMPARs upregulation as their 
insertion and removal is regulated by SUMOs. However, to our knowledge, no reports confirm 
the direct SUMOylation of AMPARs. Additionally, several proteins downstream of glutamate 
receptors are subjected to SUMOylation in turn regulating AMPARs function. During synaptic 
scaling or induction of LTP, SUMOylation of the immediate early gene product Arc regulates 
activity-dependent trafficking of AMPARs [221].  
Beside modulation of the pre- and postsynaptic response, SUMO regulates the general 
excitability of the neurons. Neuronal excitability is in part governed by voltage-gated ion 
channels such as potassium channels such as Kv2.1, K2p1 and K1.5.  
 
Taking together, these observations underscore the variety of effects due to SUMOylation of 
neuronal proteins. Even SUMO modification has been extensively investigated in cancer [227-
229], essentially for its contribution to the regulation of cell proliferation; SUMOs have been 
recently connected to a growing number of neurodegenerative diseases [190, 230-235]. 
For example, impairment of episodic and fear memory is observed after silencing by knock-down 
(KD) Sumo-1-3 in mice hippocampal and cortical neurons. Moreover, this impairment can also be 
observed following the KD of the E3 ligase PIAS-1 and decrease in CREB SUMOylation in 
hippocampal CA1 neurons [236, 237]. Interestingly, CREB SUMOylation plays an important 
role in sustained long-term memory by enhancing its DNA binding function, leading to an 
increase in bdnf transcription [236]. Hence, the SUMO pathway not only has substrates at 
dendritic synapses, but also links synaptic adaptations to specific transcriptional program within 
the nucleus.  
 
Interestingly, the global level of SUMOylation fluctuates according to an external stimulus such 
as cellular stress [231, 238-240]. SUMO-2/3 seems to be the more sensitive to various stress 
(osmotic stress, heat shock and oxidative stress) as the level of overall SUMO-2/3 conjugation is 
strongly raised compared to SUMO-1 conjugation level [187]. In the case of ischemic injury both 
SUMO-1 and SUMO-2/3 are increased and this effect is believed to be beneficial for recovery 
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[241, 242]. Over-expressing SUMO proteins or the use of Ubc9 transgenic mice, rising the 
general SUMO level, contribute to the protection against brain ischemia [240]. 
 
 
 
 
Figure 8: Emerging roles of proteins SUMOylation in neuronal function. (Adapted from Martin et 
al 2007) 
SUMOylation regulates various aspects of neuronal function and morphology. A question mark highlights the 
speculative and unconfirmed proteins functions. DRP1, dynamin-related protein 1; GluR6a, glutamate receptor 6a; 
GLUT, glucose transporter; GPCR, G-protein-coupled receptor. 
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5. Cross talk between different cellular pathways 
 
There is functional cross talk between the main PTM, including phosphorylation, SUMOylation, 
ubiquitination and acetylation for functional regulation [203, 243]. It has been known for some 
time that SUMOylation prevents its substrate from degradation, which is contrary to 
ubiquitination. However, SUMOylation and ubiquitination can influence each other to facilitate 
degradation of subset of proteins [244, 245]. A SUMO-targeted ubiquitin E3 ligase (STUbls), 
such as RNF4, can recognize, via its SIM motif, poly-SUMOylated substrates thereafter initiating 
their ubiquitination and proteasomal degradation [195].  
E3 ligase PIAS proteins are also subjected and regulated by ubiquitination. PIAS-1 and PIAS-
have been both reported to be ubiquitinated by the E3 ubiquitin ligase hSiah2 and Trim32, 
respectively. Therefore, direct them to protein degradation. However, ubiquitination onPIAS-2 
and PIAS-3 alters their subcellular localisation [195].  
SUMOylation is subjected to the PTM via acetylation and ubiquitination as the three SUMO 
paralogs compete for the same lysine residue on a substrate (Fig. 9). Phosphorylation does not 
compete for the same site than SUMOylation but can act as a positive or negative regulator of 
SUMOylation [203]. In an inverse manner, SUMOylation can also modulate the phosphorylation 
state of a substrate [243, 246]. As described above in 4.2 section, SUMO substrate protein 
carrying a PDSM can be phosphorylated at a site close to the SUMO consensus site leading to an 
enhancement of SUMOylation of those proteins [198]. However, phosphorylation can also lead 
to inhibition of SUMOylation to influence transcriptional regulation. 
The transcription factor MEF2A is phosphorylated within the PDSM motif thereby enhancing its 
SUMOylation, and inhibiting its transcription activity[225]. In contrast, dephosphorylation of 
MEF2A by calcineurin inhibits it SUMOylation. Moreover, in addition to phosphorylation and 
SUMOylation, MEF2A can undergo acetylation on the same Lysine residue targeted by SUMO. 
Interestingly, the switch from SUMOylation to acetylation is made by calcineurin. Moreover, 
acetylation process is promoted by phosphorylated histone deacetylases, hence regulating its 
transcriptional activity [198, 203].  Both deSUMOylation and acetylation lead to inhibition of 
synapse formation. 
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Phosphorylation of transcriptional regulators such as JUN, FOS or p53 prevents their 
SUMOylation thereby increasing their transcription activity [203]. Thus, both phosphorylation 
and SUMOylation regulate gene transcription. Moreover, this control of SUMOylation can be 
mediated by the MAPK pathway for certain subset of substrates [197]. 
 
 
 
 
Figure 9: Regulation of SUMOylation trough target modification. (Bossis and Melchior, 2006) 
Competition of acetylation and ubiquitination at the same lysine residue induces inhibition of SUMOylation. 
Interestingly, Ubiquitination and SUMOylation can join their force for regulating specific substrate proteins. 
Phosphorylation acts on a different site than SUMOylation and prevents  or promotes SUMOylation of the targeted 
substrate [203]. 
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6. GABAergic transmission in brain pathology  
 
Understanding the regulation of synaptic connectivity open new perspectives for elucidating 
patho-physiological mechanisms underlying psychiatric disorders and neurological diseases.  
Two non-related diseases such as schizophrenia and stroke are accompanied with a reduction in 
tonic inhibition, consequence of a reduction in extrasynaptic GABAARs; in addition to a 
reduction in synaptic receptors. Moreover, the alteration in GABAergic tonic inhibition and a 
decrease in mIPSCs induce hyper-excitability of the principal neurons [6]. Therefore, 
modulations of GABAARs trafficking play an important role in physiological and pathological 
conditions. 
Phosphorylation is the major PTM happening at GABAergic synapses and plays a crucial role in 
trapping the receptors at the synaptic sites. Reciprocally, the receptor dephosphorylation through 
activation of different kinases regulates receptors endocytosis. Endocytosis regulation depends on 
the phosphor-state of the two relevant GABAARs subunits:  and subunits. Those subunits are 
subjected to different kinases, phosphatases and their respective adaptors. Clinically, a reduction 
in the kinase PKC-mediated phosphorylation of GABAARs subunits induces a dramatic loss of 
GABAergic inhibition contributing in the prolongation of seizures. Interestingly, 
dephosphorylation of GABAARs subunits by generating knock-in mice with point mutation in 
those two tyrosine residues Y365/Y367 leads to embryonic lethality. Therefore, underscore the 
possibility that excessive GABAergic excitation is detrimental during early development [15].    
However, a reduction in GABAARs expression and function is also related to numerous diseases 
such as Huntington and non-neuronal development. In Huntington disease GABAARs number 
inserted at the plasma membrane and GABAergic transmission are reduced contributing to 
neurodegeneration.  
 
In pathology such as ischemic stroke, inhibitory synapses are downregulated via reduction of 
GABAergic transmission at the pre- and post- synaptic levels [247, 248]. More precisely, at 
inhibitory synapses, cerebral ischemia or OGD (in vitro model of ischemia) decreases cell surface 
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expression of GABAAR [247] by reducing the mRNA and proteins levels of different GABAAR 
subunits such as , 2, 3 and 2 [249]. This downregulation of the mRNA level of the different 
subunits is via a calpain-dependent mechanism [248] and can be prevented by blocking NMDA 
and non-NMDAR [250]. Moreover, OGD decreases surface expression of GABAARs by 
enhancing the de-phosphorylation of GABAAR 3 subunits therefore inducing internalisation of 
the receptors involved in the induction of neuronal cell death [73]. Moreover, extrasynaptic 
GABAARs expressions are decreased, in the pre-infarct zone, followed by a reduction in tonic 
inhibition thereby favour functional recovery [251]. These observations highlight the importance 
of GABAARs trafficking at the plasma membrane under physiological and pathological 
conditions.  
However, regulation of GABAARs surface expression is not only regulated by phosphorylation 
but also through the interaction with the main scaffolding protein gephyrin. After an ischemic 
insult it has been highlighted the loss of binding between GABAARs and gephyrin might 
contribute towards the loss of synaptic receptors. Gephyrin expression is decreased following 
OGD and its oligomerization might be affected. In addition, gephyrin is actively removed from 
GABAergic synapses by the action of protease calpain1 to limit GABAergic inhibition [252].  
Interestingly, gephyrin cleavage is facilitated by phosphorylation of gephyrin by ERK and 
GSK3 [156]. Given that phosphorylation and SUMOylation pathways converge on gephyrin to 
regulate its scaffolding properties [Ghosh et al., Submitted], it is therefore possible that both 
SUMOylation contributes to gephyrin scaffolding and in turn GABAARs function after OGD.   
Furthermore, SUMO modification is dynamic and SUMOylation levels are correlated with 
protection against cellular stress [190, 239]. In response to protein-damaging stimuli, such as 
ischemic stroke, the levels of SUMO-1 and SUMO-2/3 conjugation of cellular protein increases 
[253]. This suggests that SUMOylation might be neuroprotective against ischemic stroke as it can 
decrease neuronal excitability via the regulation of surface expression of the kainate receptor 
GluK2. Kainate receptors are responsible for glutamatergic excitotoxicity and by promoting its 
endocytosis SUMOylation might decrease the excitotoxic effect.   
Importantly, these studies highlight the importance of GABAARs-mediated transmission in 
normal and pathological brain function by controlling neuronal excitability.  
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II/ Hypothesis and aims of the thesis 
 
Research in the past decade has identified the scaffolding molecule gephyrin at the heart of 
mechanism underlying GABAergic synaptic plasticity. The regulation of gephyrin scaffolding is 
a direct correlate for GABAARs function at synaptic sites. Gephyrin is regulated by diverse 
molecular mechanisms such as RNA splicing, interacting proteins partners and PTM [18]. 
Gephyrin interaction with GABAAR subunits has been described in literature [254] ; however, 
the regulatory basis for this interaction is still unclear.    
Identification and characterization of cellular pathways that converge onto the gephyrin scaffold 
has shed some light into the molecular basis underlying adaptations at GABAergic synapses. 
Gephyrin phosphorylation by GSK3 at S270 and ERK1/2 at S268 influences GABAergic 
synapse density and size respectively. Furthermore, a recent study identified SUMOylation of 
gephyrin as a new PTM event that influences its phosphorylation status, whereby affecting its 
scaffolding property. The upstream signals that activate GSK3, ERK1/2 to phosphorylate 
gephyrin are currently unclear. Similarly, there is very little understanding about the upstream 
events regulating the protein SUMOylation machinery. The main tenet of this thesis proposal is 
to demonstrate that BDNF signaling influences gephyrin PTM(s) to facilitate structural and 
functional adaptations at GABAergic synapses by interacting with gephyrin SUMOylation.  
We specifically hypothesize that TrkB signaling downstream of BDNF activates ERK and 
GSK3 along with the SUMO pathway to modify the gephyrin scaffolding properties. To test our 
hypothesis we employed a multidisciplinary approach combining cellular biology, biochemistry, 
molecular pharmacology and electrophysiology in both primary hippocampal neurons and 
organotypic hippocampal slice cultures. 
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Study I: BDNF regulates PIAS-3 function for modulating gephyrin scaffolding at 
GABAergic postsynaptic sites. 
 
Gephyrin undergoes SUMOylation and its aggregation properties can be modulated by the 
SUMO E3 ligase enzyme called PIAS-3. E3 enzymes have the general properties to enhance 
specificity of the SUMO-conjugation. We have identified and characterized SUMO-1 and 
SUMO-2 conjugation sites on gephyrin. Mutation of the SUMO-1 and SUMO-2 lysine residues 
on gephyrin enhances its scaffolding property. Hence, we reasoned that gephyrin scaffolding via 
SUMOylation must influence plasticity change at GABAergic synapse. To address this issue we 
dissected the mechanistic basis for BDNF induced gephyrin clustering change at GABAergic 
synapse.    
 
Study II: SUMOylation-defective gephyrin mutant stabilizes GABAergic synapses in post-
ischemic CA1 hippocampal neurons 
 
Ischemia is a condition well known to activate the protein SUMOylation machinery and to 
strongly upregulate BDNF transcription. The aim of this study was to demonstrate that BDNF 
influences the SUMO pathway to affect gephyrin scaffolding at GABAergic synapses in 
pathology such as ischemia. The major tenet of our hypothesis is that in ischemic conditions 
BDNF signals through TrkB receptors to influence GABAergic synapses via gephyrin regulation. 
In order to test this idea, we employed organotypic hippocampal slice cultures to induce ischemia 
by transient oxygen-glucose deprivation (OGD). Using a combination of morphology and 
electrophysiology combined with pharmacology manipulation we uncover the molecular events 
that impinge on GABAergic postsynaptic apparatus in response to ischemic insult.  
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III/ Results 
 
 
Chapter 1: BDNF regulates PIAS-3 function for 
modulating gephyrin scaffolding at GABAergic 
postsynaptic sites. 
 
 
 
 
 
 
Authors:   Zahra S. Thirouin
1
, Simon Früh
1
, Shiva K. Tyagarajan
1
  
1:  Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. 
 
 
 
 
 
ZT performed the experiments, data analysis, and participated in writing the manuscript. S.F. 
performed some of the biochemical experiments.  
 
58 
Abstract 
 
The postsynaptic scaffolding protein gephyrin is a crucial component at GABAergic postsynaptic 
sites ensuring the efficiency of neurotransmission. Multiple independent studies demonstrated the 
implication of gephyrin PTM in remodelling gephyrin scaffolding properties thereby contributing 
to GABAergic synaptic plasticity. Here, we focused on SUMOylation of gephyrin and the 
regulation of gephyrin clustering by BDNF in primary hippocampal neuronal cultures. We 
identified BDNF as the upstream signaling molecule regulating the subcellular localisation and 
the function of specific members of the SUMO pathway, especially the E3 ligase PIAS-3. 
Moreover, using gephyrin mutant constructs that cannot be SUMOylated, we show BDNF 
inefficiency to downregulate gephyrin cluster. Additionally, we show that PIAS-3 affects 
gephyrin postsynaptic clustering via both a SUMO-dependent and a SUMO–independent 
function. Moreover, we provide evidence that gephyrin SUMOylation is dependent on its 
phosphorylation status by ERK1/2 and GSK3. Importantly, both PIAS-3-dependent mechanisms 
are under the control of BDNF signaling. Altogether, these results demonstrate the importance of 
gephyrin phosphorylation and SUMOylation for regulation of GABAergic function by BDNF.  
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 Introduction  
 
The neurotransmitter GABA mediates most inhibitory neurotransmission in the CNS by acting on 
its receptors GABAA (GABAARs) and GABAB receptors. The GABAARs are pentameric ligand- 
gated chloride channels that are assembled from a repertoire of 19 different subunits [23]. 
Deficits in GABAergic transmission have been implicated in several neuro-developmental and 
neuropsychiatric disorders [8, 255-257]. Hence, GABAARs represent a common class of 
pharmacological drug targets for the treatment of insomnia and anxiety disorders. 
In the past two decades it has become increasingly clear that GABAARs are regulated by a 
multitude of cellular signaling  processes, such as transcription, post-translational RNA editing 
and PTMs. In addition, several GABAARs interacting proteins, especially its main scaffolding 
protein gephyrin, have been identified as substrates for diverse PTMs [8, 20, 157]. However, the 
molecular underpinnings of synaptic plasticity at GABAergic synapse are poorly understood at 
present. 
In recent years it has become evident that multi-functional protein gephyrin is both a main 
organizer of GABAergic postsynaptic sites and a facilitator of downstream signaling  events [20, 
113, 124, 127, 131, 258]. Gephyrin undergoes PTMs by diverse signals transduction pathways to 
regulate its scaffolding properties [18, 131]. Our own research has demonstrated that gephyrin 
phosphorylation by GSK3 and ERK1/2 signaling  pathways alter the scaffold density and size 
respectively, in turn influencing GABAergic mIPSCs amplitude and frequency [93, 153]. 
Subsequently, it was demonstrated that gephyrin is a novel substrate for SUMO-1 and SUMO-2. 
Identification of specific SUMOylation residues on gephyrin demonstrated the significance of 
this modification for its scaffold formation at GABAergic synapse and for modulation of 
GABAergic strength [Ghosh et al., submitted]. In the same study it was also shown that complex 
cross-talk between phosphorylation, acetylation and SUMOylation determine gephyrin 
scaffolding dynamics. Expression of a gephyrin dominant negative mutation that disrupted 
gephyrin clustering in neurons showed significantly reduced mIPSCs amplitude and frequency 
[Ghosh et al., submitted], suggesting that gephyrin scaffold is essential for majority of the 
GABAergic synapses to function.  
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Signals upstream of cellular kinases and SUMO pathways and their relevance for GABAergic 
inhibition under pathophysiological conditions remain unclear. One of the potential upstream 
signaling molecules known to modulate GABAergic inhibition is the brain derived neurotrophic 
factor (BDNF). As the most abundant neurotrophin, BDNF has been shown to play an important 
role in synaptic plasticity and circuit maturation during brain development; however, it is still 
unclear how BDNF influences synaptic plasticity change in adult brain [99, 106, 259, 260]. At 
GABAergic synapse BDNF has been shown to exhibit a bidirectional effect depending on the 
duration of its application [99, 261]. Short-term application (acute) of BDNF reduces GABAergic 
postsynaptic responses [101, 102, 108, 113] with a significant reduction in the cell surface 
expression of 2 GABAARs subunit [101] and downregulation of gephyrin clusters [102, 108]. 
The acute effect of BDNF is via the high affinity receptor, tropomyosin-related kinase B (TrKB) 
[102, 108], and leading to internalization of GABAARs at the synapse. In contrast, chronic BDNF 
treatment was shown to strengthen GABAergic transmission accompanied by an increase in the 
cell surface expression of GABAARs [115, 116, 262, 263]. The molecular mechanism underlying 
BDNF induced short- and long- term synaptic plasticity changes remain to be identified. 
Independent studies have suggested the involvement of postsynaptic mechanisms; nevertheless, it 
is possible that this regulation at the level of GABAARs is via the regulation of gephyrin 
scaffolding.  
In support of this hypothesis, it was shown that acute BDNF application regulates the availability 
of postsynaptic GABAARs [101, 107, 108] by decreasing gephyrin interaction, leading to the 
internalization and degradation of the receptors [102]. Given the importance of gephyrin PTM via 
phosphorylation and SUMOylation for its scaffolding dynamics, in the current study we 
examined the role of BDNF signaling upstream of these signaling cascades.  
To test this idea we used primary hippocampal neurons and employed molecular biology, 
biochemistry and pharmacology to demonstrate that BDNF acts upstream of the SUMO pathway. 
BDNF regulates the sub-cellular localization and function of specific members of the SUMO 
pathway to influence gephyrin scaffolding. In particular, BDNF impinges on the function of E3 
ligase PIAS-3, which in turn influences gephyrin scaffolding via two independent pathways. The 
two independent pathways require the activation and inactivation of TrkB receptors specifically. 
Finally, we demonstrate that SUMOylation and phosphorylation of gephyrin at specific residues 
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converge at the level of PIAS-3 function. Together, our data identifies a novel mechanism 
involving BDNF-regulation of SUMOylation pathway for influencing GABAergic post-synapse 
plasticity. 
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Materials and Methods 
 
Plasmids 
EF1a-eGFPC2-gephyrin has been described earlier [93, 156], pCI-FLAG-(SENP-1, SENP-2, 
SENP-3, SENP-5, SENP-6) and pCS3±6xmyc (PIAS1, PIAS2, PIAS2, PIAS4) have been 
described earlier [264]. pCS3±6xmyc-PIAS-3 (1-584AA and C299S/H301A SP-Ring mutant) 
have been described earlier [265]; eGFP-PIAS-3 was a kind gift from Prof. Johar Yogil (Hebrew 
University, Jerusalem). The plasmids pCS3±6xmyc–PIAS-3 (1-273AA, 274-392AA, 274-
584AA, 393-584AA and 416-584AA) were kind a gift from Prof. Fang (Rutgers University, New 
Jersey, USA). pCS3±6xmyc-PIAS-3(1-406) was generated by deleting the C-terminus domain 
from pCS3±6xmyc-PIAS-3. pCS3±6xmyc-PIAS-3 (I200V/T201A or PINIT mutant) and 
pCS3±6xmyc-PIAS-3 (I200V/T201A, C299S/H301A or PINIT/Ring mutant) were generated 
using site directed mutagenesis in pCS3±6xmyc-PIAS-3 and sequence confirmed. eGFP-
gephyrin (S268E and S270E) are described earlier [93, 156]; eGFP-gephyrin SUMO-1 and 
SUMO-2 site mutations (K148R and K724R) are described in [Ghosh et al., submitted]. 
 
Primary hippocampal neuronal culture 
All animal experiments were approved by the cantonal veterinary office of Zurich. Dissociated 
embryonic (E17-E18) Wistar-rat hippocampal primary mixed cultures were prepared as described 
earlier [93, 156]. They were maintained in the culture media containing MEM (Gibco), 15% Nu-
serum (Becton-Dickinson,355500), B27 supplement (Invitrogen), 1M HEPES (pH7.2; 15mM), 
glucose monohydrate (0.45%), 1mM Na-pyruvate and 2mM L-Glutamine. The cells were 
transfected following the protocol described in T. Buerli et al. 2007 [266], at 8 days in-vitro 
(DIV) with 1g total plasmids DNA with up to a total of 3 different plasmids transfected 
simultaneously. We used Lipofectamine 2000 (Invitrogen, 11668-019), CombiMag (Oz 
Biosciences, CM21000) and OptiMEM medium (Invitrogen, 31985-070) as per the protocol.  
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Immunohistochemistry of primary cells culture 
7 days post-transfection the cells (8+7DIV) were fixed in 4% PFA for 10min then permeabilized 
for 5min with 0.1% TritonX100 in 10% Normal goat serum (NGS, BioRad, C07SA) and PBS pH 
7.4. The cells were quickly washed with PBS (pH7.4) before being labelled with the appropriate 
primary antibody cocktail (antibodies with 10%NGS and PBS) for 90min. After three washes of 
10min each with PBS the secondary detection was achieved with the secondary antibody mixture 
supplemented with DAPI (1:1000) for 30min. The cover-slips were mounted with Dako 
Fluorescence Mounting medium (Dako North America, Inc.). 
 
Antibodies  
Mouse anti-Gephyrin (1:1000, clones mAb7a, Synaptic Systems #147021), rabbit anti-SUMO-1 
(1:250, Epitomics#1563-1), mouse anti-SUMO-1 (1:100, SantaCruz#sc-5308), rabbit anti-
SUMO-2/3 (1:250, Cell signaling  #4974), rabbit anti-SUMO-2/3 (1:250, Epitomics #2970-1), 
mouse anti-PIAS-3 (1:500, Sigma #P0117), rabbit anti-vGAT (1:2000, Synaptic Systems 
#131011); mouse anti-Myc tag (1:5000,Roche #11667149001), rabbit anti-Myc tag (1:5000, Cell 
Signaling  #2278S), mouse anti-FLAG tag (1:5000, Sigma Aldrich #F3165). All the secondary 
antibodies were from Jackson ImmunoResearch: Goat anti-Mouse Cy3 IgG (1:500, #115165), 
Goat anti-Mouse IgG Cy5 (1:500, #115175), Goat anti-Rabbit IgG Cy3 (1:500, #111165) and 
Goat anti-Rabbit IgG Cy5 (1:500, #111175).  
 
Pharmacological treatments 
Transfected cells were treated 90min with hBDNF (10ng/mL, Alomone Labs #B-250), NT-3 
(10ng/mL, Alomone Labs #N-260), or NT-4 (10ng/mL, Alomone Labs #N-270), and/ or a BDNF 
scavenger: rh TrKB-Fc Chimera (1g/mL, R&D Systems #688-TK-100). Otherwise the cells 
were treated overnight with ERK 1/2 inhibitor: PD98059 (25M/mL, Calbiochem#513000) or 
GSK3 inhibitor: GSK3IX (5M/mL, Calbiochem #328007) or DMSO (equal volume; Sigma 
D2438). 
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Image analysis and quantification 
All imaging were acquired on confocal laser scanning microscope (LSM 710, Carl Zeiss) with 
objective lens of 40x or 63x lens (NA 1.4) with a pinhole set at 1 Airy unit and a pixel size of 
0.13m. For each condition, images from a minimum of 9 cells from 3 independent batches of 
neuronal culture were acquired using a z-stack (3-5 steps at 0.5m per step size). From each cell 
a dendritic segment was taken for analysis. Image analyses were performed with a custom written 
analysis for Image J software using maximal intensity z-projected images.  
Gephyrin clustering size area and density were analysed 7 days post-transfection in hippocampal 
primary neuronal culture following the protocol previously described [93, 156]. Only gephyrin 
cluster apposed to the presynaptic marker vGAT were considered for quantitative assessment. 
The generated data are then plotted using Excel software and Graphpad Prism software. 
 
Statistical analysis 
Morphological changes of eGFP-gephyrin clustering size were assessed using a pair-wise 
Kolmogorov-Smirnov (KS) cumulative distribution analysis using the online platform 
http://www.physics.csbsju.edu/stats/KS-test.n.plot_form.html. When multiple groups were 
compared a One-Way ANOVA followed by a Tukey test (PRISM software) was performed. 
Whereas changes in eGFP-gephyrin clustering density were assessed, using PRISM software, by 
either a Student T-test or a One-Way ANOVA. 
 
HEK 293 cell cultures and transfection 
Human Embryonic Kidney (HEK293) cells were maintained at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco 41966-029), supplemented with 10% fetal calf serum 
(FCS, Gibco #10270-106). They were transfected, 24h post-plating, with either 1g (for all 
gephyrin constructs) or 2 g (for all PIAS-3 constructs) of DNA using poly-ethylamine (PEI, 
Polysciences Inc., 23966) according to the manufacturer recommendation. 24h later, the cells 
were lysed in EBC buffer (50mM Tris pH 8.0, 120mM NaCl, 0.5% NP-40) containing 
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proteasome inhibitor or complete-mini protease inhibitor cocktail tablets (Roche diagnostic, 
#11836153001) and phosphatase cocktail 2 and 3 (Sigma #P5726 and #P0044).  
Transfected HEK293 cells were treated overnight with the general proteasome inhibitor: MG132 
(or ZLLal) form 5M/mL till 15M/mL (Tocris#1748) or with DMSO (equal volume, Sigma, 
D2438).  
 
Immunoprecipitation and Western Blotting 
Interaction between two proteins was determined using the heterologous cells HEK293. For the 
immunoprecipitation (IP) followed by Western blot (WB) assays the cell lysates were incubated 
90min at 4°C with 1-2g purified antibody followed by incubation with protein A/G UltraLink 
Resin (Thermo Scientific, #53133) 45min at 4°C. Unspecific binding to the resin was minimized 
by washing with EBC based high salt buffer (50mM Tris, 500mM NaCl, 1% NP-40) followed by 
washes with normal EBC buffer. The samples were boiled with SDS sample buffer containing 
15% fresh -mercaptoethanol at 90°C for 4min, and separated on appropriate acrylamide % SDS 
gel at 140V. The proteins were transferred onto a PVDF membrane on which the Western blot 
could be performed. The membrane was blocked with 5% Western blocking reagent (Roche, 
#11921681001) then incubated with the primary antibody mixture for 3hrs or overnight. After 
washing with Tris-buffered saline with Tween20 (TBS-T) the membranes were incubated with 
the secondary antibodies mixture containing either Donkey horse radish peroxidase antibodies 
(HRP 1:10000, form Jackson ImmunoResearch: mouse #715-035-150 and rabbit #711-035-152) 
or fluorescent secondary’s (1:30000): mouse IR680 (#926-68022) or rabbit IR 800 (#926-32213) 
from Odyssey-AB /Li-COR. For loading controls protein lysates were boiled with 5x SDS buffer 
before performing Western blot with the appropriate antibodies. 
 
Antibodies: Mouse anti-Myc tag (1:5000, Roche #11667149001), rabbit anti-Myc tag (1:1000, 
Cell Signaling #2278S), mouse anti-FLAG tag (1:5000, Sigma Aldrich #F3165), rat anti-FLAG 
tag (1:3000, Sigma Aldrich #SAB4200071). 
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Results  
 
BDNF plays an important role in regulating synapse formation and function during and after 
development of the CNS. However, the mechanistic basis for BDNF induced change at 
GABAergic synapse is poorly understood. Recent reports have shown that main scaffolding 
protein at GABAergic synapse, gephyrin, is regulated by phosphorylation at S268 and S270 
residues via ERK1/2 and GSK3 kinases [93, 146]. TrkB receptor is known to activate ERK and 
GSK3 pathways downstream of BDNF signaling. Hence, we rationalized that gephyrin could be 
a novel candidate for facilitating BDNF induced plasticity changes at GABAergic synapse. In 
addition to phosphorylation, cellular pathways such as SUMOylation and acetylation also 
converge on to gephyrin to regulate its scaffolding properties. It is likely that BDNF signaling 
also influences pathways other than ERK and GSK3.    
 
BDNF down-regulates gephyrin clustering in hippocampal neurons 
 
In order to better characterize BDNF signaling  induced change at GABAergic synapse we used 
eGFP-gephyrin transfected primary hippocampal neurons after 8 days in vitro and stained for 
specific markers 7 days later (8+7 DIV) (Fig. 1A). Confocal microscopy confirmed structural 
changes at GABAergic postsynapse in response to acute BDNF application (10ng, 90min) and/or 
BDNF scavenging (TrkB-Fc). Consistent with published literature [102, 108], acute application 
of BDNF was sufficient to downregulate eGFP-gephyrin from GABAergic synapses. 
Quantification for change in cluster area showed a significant reduction after BDNF treatment 
(Fig. 1B, D; 0.15µm²±0.009 versus 0.29µm²± 0.019, KS test, P<0.0001) compared to untreated 
eGFP-gephyrin. However, eGFP-gephyrin cluster density was not affected after BDNF treatment 
(Fig.1E; 2.85 ± 0.47 versus 2.52±0.4 clusters /20µm; Two-tailed Student t-test, P=0.73).  
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Figure 1: legend on the next page. 
 
69 
Scavenging BDNF using a chimera of TrkB extracellular domain conjugated to IgG fragment 
(TrkB-Fc) allowed us to study the effect of blocking BDNF signaling on eGFP-gephyrin 
scaffolding at GABAergic synapses. We treated transfected neurons with TrKB-Fc (1g/mL, 
90min) and noticed a pronounced increase in eGFP-gephyrin cluster size (Fig.1C-D; 
0.47µm²±0.318 versus 0.29µm²± 0.19, KS test P<0.0001). We did not notice any changes in 
cluster density (2.47±0.30 versus 2.52±0.4 clusters /20µm; Two-tailed Student t-test P=0.93). 
This suggested to us that scavenging BDNF strengthens GABAergic synapses, while activating 
BDNF signaling weakens GABAergic synapses. Nevertheless, TrKB can also be activated by 
ligands such as NT-3 and NT-4, and both these neurotrophins are implicated in GABAergic 
synapse formation and plasticity during development [97, 267-269]. In order to study the 
relevance of these neurotrophins for gephyrin-induced change at GABAergic synapses, we 
treated eGFP-gephyrin transfected neurons with NT-3 (Fig. 1F; 10ng/mL for 90min) or NT-4 
(Fig. 1G; 10ng/mL for 90min). Quantitative analyses revealed that eGFP-gephyrin cluster size is 
unaffected by NT-3 or NT-4 application (Fig. 1H; 0.31µm²±0.02 versus 0.31µm²±0.016 or 
0.32µm²±0.020; One-Way ANOVA, F(3, 640)=5.19; P=0.0015). In addition, both NT-3 or NT-4 
also did not affect eGFP-gephyrin cluster density (Fig.1I; One-Way ANOVA, F(3, 38)=0.27; 
P=0.84).  
 
 
Figure 1: BDNF down-regulates gephyrin clustering in hippocampal neurons.  
(A-C) Hippocampal neurons transfected (8+7) with eGFP-gephyrin treated with either BDNF (10ng/mL; 90min) or 
TrKB-Fc (1g/mL; 90min) and stained for endogenous gephyrin (blue), vGAT (red). Bottom panels’ show 
magnified dendritic segment; eGFP-gephyrin apposed to vGAT terminals were considered to be synaptic. (D) 
Cumulative probability distribution of eGFP-gephyrin cluster size, ****P<0.0001, *P<0.05 KS test. (E) 
Quantification of mean synaptic eGFP-gephyrin cluster density per 20m dendrite. (F-G) Representative dendritic 
sections of hippocampal neurons transfected (8+7) with eGFP-gephyrin treated with different neurotrophins 
(10ng/mL; 90min) such as NT-3 or NT-4. (H) Quantification of mean synaptic eGFP-gephyrin cluster size, 
****P<0.0001, ***P<0.005, **P<0.01; KS test. (I) Quantification of mean synaptic eGFP-gephyrin cluster density 
per 20m dendrite. (J-L) Representative dendritic sections of hippocampal neurons transfected (8+7) with eGFP-
gephyrin pretreated with TrKB-Fc (1g/mL; 90min) prior to treatment with BDNF, NT-3 or NT-4 (10ng/mL; 
90min). (M-N) Quantification of mean synaptic eGFP-gephyrin cluster size and cluster density per 20m dendrite. 
Scale bar 10m. 
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We next explored the mechanistic basis for TrKB-Fc mediated changes in eGFP-gephyrin 
clustering changes at GABAergic synapse. For this, we treated cultured primary neurons with 
BDNF, NT-3, NT-4 along with TrkB-Fc and observed for changes in eGFP-gephyrin 
morphology. Quantification for eGFP-gephyrin cluster size confirmed that the action of BDNF 
can be blocked effectively via TrKB-Fc (Fig. 1J, M; 0.35µm²±0.02 versus 0.30µm²±0.018, KS 
test P=0.08). Furthermore, NT-3 or NT-4 treatments in the presence of TrKB-Fc did not alter 
eGFP-gephyrin cluster size (Fig. 1K-M; One-Way ANOVA, F(3, 792)=2.4; P=0.065). None of the 
BDNF, NT-3 or NT-4 treatments affected the eGFP-gephyrin cluster density (Fig. 1J-L, N; One-
Way ANOVA, F(3, 40)=2.33; P=0.09). These results show that BDNF specifically acts on 
gephyrin to modulate its scaffolding at GABAergic postsynapse. 
 
Acute BDNF treatment affects proteins of the SUMO pathway 
 
Diverse signaling  pathways converge onto gephyrin scaffold and modify specific residue to 
regulate its scaffold size and density [18]. Of the phosphorylation, acetylation and SUMOylation 
signaling  cascades converging on to the gephyrin scaffold, SUMOylation seems to act upstream 
of the phosphorylation and acetylation.   
Hence, we tested the direct role of BDNF signaling in the modulation of SUMO pathway. For 
this, we either stained directly for the endogenous SUMO (SUMO-1, -2/3) or stained for the myc-
PIAS (myc-PIAS-1, -2, -3, -4), FLAG-SENP (SENP-1, -2, -3, -5, -6) either in the presence or 
absence of BDNF (10ng, 90min). The application of BDNF induced SUMO-1, SUMO-2/3, 
SENP-2, SENP-6 and PIAS-3 to translocate from the nucleus to soma and dendrites (Fig. 2A-E). 
To confirm the specificity of BDNF signaling in the translocation of specific proteins within the 
SUMO pathway, we tested the response of endogenous SUMO-1, SUMO-2/3 proteins to BDNF 
using two different antibodies, and found similar subcellular localization change in response to 
BDNF application (Fig. 2A).  
Only PIAS-3 responded to BDNF treatment; hence, we tested two different N-terminal tags on 
PIAS-3 to eliminate the possibility for experimental artefacts (Fig. 2C-D). Both our myc-PIAS-3 
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and eGFP-PIAS-3 proteins tested in primary neurons showed a clear dendritic enrichment after 
BDNF application. We next tested the endogenous PIAS-3 and found a similar subcellular 
localization change in the presence of BDNF (Fig. 2E). Interestingly, myc-PIAS-3 dendritic 
translocation is reversed 48hrs post BDNF application (Fig. 2F), showing that BDNF signaling 
and protein SUMOylation are dynamic. To test this idea, we examined resting state neurons for 
subcellular localization differences in myc-PIAS-3, and quantification showed us that around 
20% of PIAS-3 transfected neurons had both nuclear and dendritic distribution. However, after 
BDNF application, the number of transfected neurons with dendritic enrichment of PIAS-3 
significantly increased to 70% (Fig. 2C’). Our observations so far suggest that BDNF signal 
upstream of the SUMO pathway influencing PIAS-3 subcellular localization.    
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Figure 2: Legend on the next page 
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The SUMO-deficient gephyrin mutants are insensitive to BDNF 
 
Gephyrin is a SUMO substrate and can directly interact with PIAS-3; hence, it is likely that 
BDNF influences changes at GABAergic synapse via gephyrin SUMOylation. The knowledge 
that gephyrin is SUMO-1 modified at K148 and SUMO-2 modified at K724 sites allows us to test 
this hypothesis directly. Hence, we transfected gephyrin SUMO-deficient mutants: eGFP-K148R 
and eGFP-K724R into primary hippocampal neurons and analyzed for changes in gephyrin 
cluster size and density in the presence or absence of BDNF (90min; short term) (Fig. 3A-E).  
In absence of BDNF, quantification for cluster sizes of eGFP-K148R mutant showed a significant 
increase in the size compared to eGFP-gephyrin control (Fig. 3B, G; 0.42µm²±0.024 versus 
0.31µm²±0.02, KS test P=0.025). However, eGFP-K724R mutant only showed a tendency 
towards significantly bigger cluster size (Fig. 3C, G; 0.40µm²±0.02 versus 0.31µm²±0.02, KS test 
P=0.187). In condition of BDNF, quantification for cluster sizes showed that both SUMO-1 and -
2 mutants of gephyrin are insensitive to BDNF treatment (Fig. 3F; 0.42µm²±0.024 versus 
0.41µm²±0.02; and 0.40µm²±0.02 versus 0.35µm²±0.02; KS test P=0.606). Moreover, 
quantification for cluster density showed no change in density for eGFP-K148R and eGFP-
K724R SUMOs mutants before (Fig. 3G; One-Way ANOVA F(2, 33)=1.11; P=0.34) and after 
BDNF treatment (Fig. 3G; One-Way ANOVA F(4, 53)=2.33; P=0.067).  
These results confirm that BDNF facilitates plasticity change at GABAergic synapse via the 
regulation of gephyrin SUMOylation at K148 and K724 respectively.  
 
Figure 2: BDNF alters the specific sub-cellular localisation of specific proteins of the SUMO 
pathway. 
(A-C) Primary hippocampal neurons (8+7 DIV) stained for endogenous SUMO, FLAG-SENP, or myc-PIAS either 
with or without BDNF (10ng/mL; 90min). (D) eGFP-PIAS-3 transfected neurons showing dendritic enrichment after 
BDNF (10ng/mL; 90min) treatment. (E) Endogenous PIAS-3 in primary hippocampal neurons with or without 
BDNF (10ng/mL; 90min) or TrKB-Fc (1g/mL; 90min) treatments. (A’-E’) Quantification of neurons showing 
subcellular localisation changes after BDNF (10ng/mL; 90min) treatment. (F) Subcellular localisation of myc-PIAS-
3 in neurons is reversed 48hr post BDNF (10ng/mL) treatment. Scale bar 5m.  
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Figure 3: Gephyrin SUMO-1 and SUMO-2 site mutations are insensitive to BDNF.   
(A-E) Representative images of DIV (8+7) neurons expressing either eGFP-gephyrin, or eGFP-K148R or eGFP-
K724R in absence of BDNF (A, B, D) and after BDNF treatment (C, E). GABAergic terminals were identified by 
staining for the presynaptic marker vGAT (red). Synaptic eGFP-gephyrin clusters were analyzed based on their 
apposition to vGAT positive terminals. (F) Cumulative probability distribution of eGFP-gephyrin cluster size, 
*P<0.05 KS test. (G) Quantification of mean synaptic eGFP-gephyrin cluster density per 20m dendrite showing no 
differences between untreated and BDNF treated neurons. Scale bar 10m. 
 
 
BDNF regulates PIAS-3 function for gephyrin clustering change 
 
Substrate SUMOylation is facilitated by the presence of SUMO E3 ligase [195, 220, 270]. PIAS-
3 is an E3 ligase identified to influence gephyrin SUMO conjugation [Ghosh et al., submitted]. 
Given our observation that BDNF signaling influences PIAS-3 subcellular localization, we 
wondered if BDNF also influenced PIAS-3 function in neurons. In order to test this idea we co-
transfected myc-PIAS-3 with eGFP-gephyrin into DIV (8+7) neurons and assessed for myc-
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PIAS-3 function by looking at morphological changes in gephyrin clustering, in the presence or 
absence of BDNF (Fig. 4B-C). 
Neurons transfected with myc-PIAS-3 showed a significant increase in cluster size in comparison 
to eGFP-gephyrin alone control (0.79µm²±0.07 versus 0.33µm²±0.02; KS test P<0.0001). 
Moreover, in the presence of myc-PIAS-3 eGFP-gephyrin cluster density was also significantly 
reduced (Fig. 4B, H, I; 1.09±0.12 versus 2.74±0.46 clusters /20µm; Two-tailed Student’ T-test 
P=0.005). Addition of 10ng/mL BDNF for 90 min brought eGFP-gephyrin cluster size to base 
line level, suggesting BDNF influences PIAS-3 function (Fig. 4C; 0.4µm²±0.04 versus 
0.79µm²±0.07, KS test P=0.006). However, we did not observe any significant difference in 
eGFP-gephyrin cluster density when myc-PIAS-3 co-transfected neurons were treated with 
BDNF (Fig. 4I; 1.4±0.12 versus 1.09±0.12 clusters /20µm; Two-tailed Student’ T-test P=0.14). 
These results suggest that BDNF down-regulates eGFP-gephyrin clustering size via PIAS-3 
function.  
PIAS-3 belongs to a larger family of PIAS proteins and was first characterized as regulator of 
transcriptional activity of STAT3 proteins [216, 271]. Subsequently, it was demonstrated that 
PIAS-3 is also a SUMO E3 ligase [195]. PIAS family of proteins share 5 conserved domains, 
among which the SP-Ring domain is important for the SUMO E3 ligase function [195, 209]. In 
order to study the importance of PIAS-3 E3 ligase activity for eGFP-gephyrin clustering, we co-
transfected the SP-Ring domain mutant of PIAS-3 (myc-PIAS-3Rm), into neurons, along with 
eGFP-gephyrin. Interestingly, inactivation of the SUMO E3 ligase activity of PIAS-3 (myc-
PIAS-3Rm) still showed an increase in eGFP-gephyrin cluster size (Fig. 4E, H; 0.55µm²±0.05 
versus 0.33µm²±0.02, KS test P=0.002) and a decrease in density (Fig. 4F, I; 1.1±0.22 versus 
2.74±0.46 clusters/20µm; Two-tailed Student’ T-test, P=0.008), similar to myc-PIAS-3.  
The increase in eGFP-gephyrin cluster size in the presence of myc-PIAS-3Rm although 
significantly larger than eGFP-gephyrin alone, was still smaller than in neurons co-expressing 
myc-PIAS-3 (KS test P=0.037). This suggested us that myc-PIAS-3 and myc-PIAS-3Rm 
influence gephyrin clustering perhaps via two independent cellular mechanisms. In order to test 
this idea, we treated neurons co-transfected with myc-PIAS-3Rm and eGFP-gephyrin with BDNF 
and found that BDNF treatment had no effect on myc-PIAS-3Rm induced increase in eGFP-
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gephyrin cluster size (0.56µm²±0.04 versus 0.55µm²±0.05, KS test P=0.54). This implicated 
BDNF signaling for PIAS-3 SP-Ring domain function in gephyrin cluster size regulation. 
 
 
 
Figure 4: BDNF regulates PIAS-3 function for gephyrin cluster change. 
(A-G) Morphology of DIV (8+7) neurons co-transfected with eGFP-gephyrin alone, or with either myc-PIAS-3, or 
myc-PIAS-3Rm, with or without BDNF (10ng/mL; 90min) or TrKB-Fc (1g/mL; 90min) treatment. eGFP-gephyrin 
(green) clusters synaptic localization was determined based on their apposition to vGAT positive terminal (red). (H) 
Quantification of eGFP-gephyrin cluster size shows an increase with the co-expression of either myc-PIAS-3 or 
myc-PIAS-3Rm, ****P<0.0001, ***P<0.001, **P<0.01 KS test from the cumulative. (I) Quantifications of synaptic 
eGFP-gephyrin cluster density per 20m dendritic length shows a significant decrease in the presence of myc-PIAS-
3 or myc-PIAS-3Rm, ***P<0.001 One-Way ANOVA Kruskal Wallis test. Scale bar 10m. 
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If BDNF signaling is an important regulator of PIAS-3 SP-Ring domain, we wondered whether 
suppression of BDNF signaling would influence the SP-Ring domain independent function of 
PIAS-3 for eGFP-gephyrin cluster regulation. Hence, to sequester endogenous BDNF signaling 
we used TrKB-Fc. Neurons co-transfected with myc-PIAS-3 or myc-PIAS-3Rm along with 
eGFP-gephyrin were treated with TrKB-Fc and analyzed for change in eGFP-gephyrin clusters at 
vGAT positive terminals (Fig. 4D, G). Cells transfected with myc-PIAS-3 exhibited a similar 
phenotype of larger eGFP-gephyrin clusters in the presence of TrkB-Fc (Fig. 4D; 0.84µm²±0.09 
versus 0.79µm²±0.07, KS test P=0.84). When we compared changes in neurons expressing myc-
PIAS-3Rm in presence of TrkB-Fc, we could see a significant decrease in size compare to BDNF 
treated neurons (Fig. 4H; 0.41µm²±0.03 versus 0.56µm²±0.04, KS test P=0.03). Quantification 
for eGFP-gephyrin cluster density showed no change in myc-PIAS-3 or myc-PIAS-3Rm co-
expressing neurons (Fig. 4I; One-Way ANOVA Kruskal Wallis test, P=0.56). This confirms our 
idea that blocking BDNF signaling activates an alternative pathway to influence SP-Ring domain 
independent function of PIAS-3 for gephyrin cluster size regulation. 
 
PIAS-3 SP-Ring domain-independent regulation of gephyrin is via C-terminus sequence 
 
Our result so far identifies a PIAS-3 SP-Ring-dependent and independent function that is 
influenced by BDNF signaling. To understand the mechanistic basis of SP-Ring domain-
independent effect on eGFP-gephyrin clustering, we used different truncation mutations of myc-
PIAS-3 (Fig. 5A) and co-expressed each of them with eGFP-gephyrin. Analysis of eGFP-
gephyrin cluster size and density allowed us to determine the role of specific PIAS-3 domains 
(Fig. 5B-G). 
Consistent with our earlier observations, co-expression of myc-PIAS-3 led to an overall increase 
in eGFP-gephyrin cluster size (Fig. 5B). Our observations were confirmed by quantification (Fig. 
5H; 0.68µm²±0.06 versus 0.27µm²±0.02; KS test P<0.0001). In addition, we also saw a 
significant decrease in cluster density in neurons expressing myc-PIAS-3 (Fig. 5I; 1.09±0.12 
versus 2.8±0.29 clusters/20m; Two-tailed Student’ T-test P=0.0007). Co-expression of myc-
PIAS-3 N-terminus (1-273AA), containing the SAP and PINIT domains did not cause any 
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increase in eGFP-gephyrin cluster size compared to eGFP-gephyrin alone control neurons (Fig. 
5C, H; 0.36µm²±0.02 versus 0.27µm²±0.02; KS test P=0.006) or to myc-PIAS-3 (KS test 
P<0.0001). 
Consistent with these observations we also did not see any reduction of eGFP-gephyrin density in 
neurons co-expressing the myc-PIAS-3 (1-273) (Fig. 5I; 3.22±0.52 versus 1.09 ±0.12versus 
2.8±0.29 clusters/20m; One-way ANOVA, F(2, 27)=7.89,  P=0.002).  
 
 
 
Figure 5: PIAS-3 SP-Ring domain independent regulation of gephyrin is via C-terminus sequence 
 (A) Cartoon of various truncated myc-PIAS-3 used in the current study. (B-G) Morphology of DIV (8+7) neurons 
co-transfected with eGFP-gephyrin and one of the myc-PIAS-3 truncation mutants. (H) Quantification of synaptic 
eGFP-gephyrin cluster size, ****P<0.0001, KS test. (I) Quantifications of synaptic eGFP-gephyrin cluster density 
per 20m dendritic length, ****P<0.0001 One-Way ANOVA followed by a Tukey test. Scale bar 10m 
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When we compared the central fragment containing the SP-Ring domain myc-PIAS-3(273-392) 
we found a significant increase in eGFP-gephyrin cluster size compared to eGFP-gephyrin alone 
control (Fig. 5E, H; 0.9µm²±0.3 versus 0.27µm²±0.02; KS test P<0.0001), comparable to that 
seen in neurons co-expressing myc-PIAS-3 (KS test P=0.22). Similarly, we found a significant 
reduction of eGFP-gephyrin cluster density in neurons co-expressing myc-PIAS-3(273-392) (Fig. 
5I; 0.43±0.15 versus 2.8±0.29 clusters/20m; Two-tailed Student’ T-test P=0.01).  
Next, we tested two different myc-PIAS-3 C-terminus truncations; myc-PIAS-3 (274-584) and 
myc-PIAS-3(416-584). The co-expression of either of these two C-terminus fragment of PIAS-3 
significantly increased the eGFP-gephyrin cluster size (Fig. 5H; 0.9µm²±0.2 versus 
0.27µm²±0.02 and 0.74µm²±0.2 versus 0.27µm²±0.02; One-way ANOVA F(3, 23)=20.89, 
P<0.0001). In addition, we also saw a significant reduction of eGFP-gephyrin cluster density in 
neurons co-expressing either myc-PIAS-3 (274-584) or myc-PIAS-3(416-584) along with eGFP-
gephyrin (Fig. 5F-I; One-way ANOVA P<0.0001). These results identify PIAS-3 C-terminus 
between amino acids 416-584 as crucial determinant for SP-Ring domain independent regulation 
of eGFP-gephyrin clustering in neurons  
When we tested the neurons that co-expressed the N-terminus PINIT domain along with the 
central SP-Ring domain, myc-PIAS-3(1-406), the eGFP-gephyrin clusters did not grow in size 
(Fig. 5D, H; 0.27µm²±0.02 versus 0.34µm²±0.03 and 0.68µm²±0.06; One-Way ANOVA, 
Kruskal-Wallis test P<0.0001). Analysis for change in eGFP-gephyrin cluster density also did not 
show any significant reduction (Fig. 5I; 2.74±0.46 versus 2.89±0.76 and 1.09±0.12 
clusters/20m; One-Way ANOVA F(2, 23)=5.345, P=0.012). These results suggest to us that N-
terminus PINIT domain can suppress the SP-Ring domain function in the absence of the C-
terminus sequence. 
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BDNF affects both PIAS-3 SP-Ring domain and C-terminus function 
 
Given our observation that PIAS-3 SP-Ring domain (273-392AA) and C-terminus sequence 
(416-584AA) produce a similar morphological change in gephyrin clustering, we wondered 
whether BDNF signaling influenced both these phenotypes, albeit via distinct mechanisms. In 
order to test this idea, we co-transfected neurons with eGFP-gephyrin and myc-PIAS-3(273-392) 
and treated them with BDNF. The treatment of neurons co-expressing myc-PIAS-3(273-392) was 
sufficient to abrogate the SP-Ring domain activity as eGFP-gephyrin cluster size returned to base 
line levels (Fig. 6A, B; 0.26µm²±0.02 versus 0.9µm²±0.3; KS test P=0.006). The eGFP-gephyrin 
cluster density was returned to base line levels after BDNF treatment in myc-PIAS-3(273-392) 
expressing neurons (Fig. 6A, C; 3.25±0.6 versus 0.73±0.19 clusters/20m; Two tailed Student’ 
T-test, P=0.004). This demonstrates the importance of BDNF signaling in regulating SP-Ring 
domain function of PIAS-3.  
 
Our earlier results show that myc-PIAS-3Rm is sensitive to BDNF scavenging via TrKB-Fc 
treatment. Hence, it is possible that myc-PIAS-3Rm effect on eGFP-gephyrin clustering is via its 
C-terminus sequence. Therefore, we tested to see whether myc-PIAS-3(416-584)-mediated 
increase in eGFP-gephyrin clustering could be reversed by TrKB-Fc treatment. Neurons co-
transfected with eGFP-gephyrin and myc-PIAS-3(416-584) were treated with either BDNF or 
TrKB-Fc (Fig. 5D-D´) and analyzed for change in eGFP-gephyrin cluster size and density. 
Neurons co-expressing myc-PIAS-3(416-584) did not respond to BDNF treatment (Fig. 6D, E; 
0.6µm²±0.08 versus 0.79µm²±0.15; KS test P=0.097). Similarly, we did not observe any 
significant differences in eGFP-gephyrin cluster density after BDNF treatment (Fig. 6D, F; 
1.5±0.3 versus 1±0.3 clusters/20m; Two-tailed Student’ T-test P=0.18). However, TrKB-Fc 
treatment caused a significantly reduced eGFP-gephyrin cluster size in myc-PIAS-3 (416-584) 
co-expressing neurons (Fig. 6D’, E; 0.41µm²±0.003 versus 0.79µm²±0.15; KS test P=0.047). 
Analysis for eGFP-gephyrin cluster density also showed a significant upregulation (Fig. 6F; 3.8 
±0.5 versus 1±0.3 clusters/20m; Two-tailed Student’ T-test P=0.015) compare to untreated 
neurons. 
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Taken together, our results highlight the importance of BDNF signaling for PIAS-3 function and 
gephyrin scaffold regulation at GABAergic synapse. By identifying divergent roles in TrkB 
activation and inhibition for PIAS-3 function, our results uncover a novel bimodal basis for 
BDNF-induced plasticity at GABAergic synapses.  
 
 
 
Figure 6: BDNF affects both PIAS-3 SP-Ring domain and C-terminus function.  
(A) Morphology of neurons co-transfected with eGFP-gephyrin and myc-PIAS-3(273-392) and treated with BDNF 
(10ng/mL; 90min). (B) Quantification synaptic eGFP-gephyrin cluster size, ****P<0.0001, **P<0.01 KS test. (C) 
Quantifications of synaptic eGFP-gephyrin cluster density per 20m dendritic length, ***P<0.001 One-Way 
ANOVA. (D-D’) Morphological analysis of neurons co-transfected with eGFP-gephyrin and myc-PIAS-3(416-584) 
treated with either BDNF (10ng/mL, 90min) or TrKB-Fc (1g/mL, 90min). (E) Quantification of synaptic eGFP-
gephyrin cluster size, ****P<0.0001, *P<0.05 KS test. (F) Quantifications of synaptic eGFP-gephyrin cluster 
density per 20m dendritic length, **P<0.01 One-Way ANOVA. Scale bar 10m. 
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Gephyrin interacts with PIAS-3 at SP-Ring and SAP/PINIT domains 
 
We have identified direct interaction between myc-PIAS-3 and FLAG-gephyrin using the 
hertrologus HEK293 cells [Ghosh et al., submitted]. However, our current studies highlight the 
importance of PIAS-3 SP-Ring domain and C-terminus for gephyrin cluster regulation. Hence, 
we wondered if PIAS-3 harbored more than one gephyrin binding site. In order to test this we co-
transfected HEK293 cells with myc-PIAS-3 deletion fragments along with FLAG-gephyrin. IP 
for myc-PIAS variants followed by WB for FLAG-gephyrin showed gephyrin interaction with 
the full length PIAS-3, N-terminus PINIT (1-273AA) and SP-Ring domains (274-392AA) 
respectively (Fig. 7A-B, first panel). The protein loading controls are showed in the panels below 
(Fig. 7B, middle and lower panels).  
We then examined to identify the binding site for  PIAS-3 on gephyrin. In order to do this we co-
transfected myc-PIAS-3 and FLAG-gephyrin, or FLAG-G, or FLAG-GC or FLAG-E domains 
into HEK293 cells and immunoprecipitated myc-PIAS-3, followed by WB for FLAG-gephyrin or 
its domains (Fig. 7C). Our biochemical analysis showed multiple interaction sites for PIAS-3 on 
gephyrin as we could successfully pull down FLAG-G, FLAG-GC and FLAG-E fragments along 
with myc-PIAS-3. We identified and characterized two SUMOylation sites on gephyrin, K148 
situated in the N-terminus G-domain and K724 situated in the C-terminus E-domain. Hence, its 
not surprising that PIAS-3 can interact with both the G and E domains of gephyrin.  
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Figure 7: Gephyrin interacts with PIAS-3 at SP-Ring and SAP/PINIT domains.  
(A) Cartoon of different myc-PIAS-3 truncation mutations used for biochemical analysis of gephyrin interaction in 
HEK293 cells. (B) Interaction between FLAG-gephyrin and myc-PIAS-3. IP for myc-PIAS-3 followed by WB for 
FLAG-gephyrin. Protein loading controls are shown in the lower panels. (C) Interaction between myc-PIAS-3 and 
different domains of FLAG-gephyrin. IP for myc-PIAS-3 followed by WB for FLAG-gephyrin. Protein loading 
controls are shown in the lower panels 
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PIAS-3 function is autoregulated by its N-Terminal domain 
 
Our results thus far identify SP-Ring domain  and C-terminus of PIAS-3 for gephyrin cluster 
regulation at GABAergic synapses. In addition, we identify two interaction sites for gephyrin on 
PIAS-3, namely the PINIT domain and the SP-Ring domain. Hence, we next wanted to 
understand how PINIT and SP-Ring domains contributed to the C-terminus induced gephyrin 
cluster regulation. To understand this better we introduced two point mutations into the PINIT 
domain (I200V/T201A), and in addition we also generated the PINIT and SP-Ring domain 
combination mutation. We looked for clustering changes after co-transfected DIV 8+7 neurons 
with myc-PIAS-3PINITm or myc-PIAS-3PINITm/Rm along with eGFP-gephyrin (Fig. 8A-C). 
Rendering the PINIT domain inactive via two point mutations blocked myc-PIAS-3 induced 
eGFP-gephyrin clustering changes in size (Fig. 8D; 0.44µm²±0.04 versus 0.65µm²±0.07; KS test 
P=0.002) and eGFP-gephyrin cluster density (Fig. 8E; 1.4±0.16 versus 1.0±0.23 clusters/20m; 
Two-tailed Student’ T-test P=0.18) compared to myc-PIAS-3. The co-expression of myc-PIAS-
3PINIT/Rm mutant showed a significant reduction in eGFP-gephyrin cluster size (Fig. 8D; 
0.21µm²±0.03versus 0.44µm²±0.04 versus 0.65µm²±0.07, One way ANOVA P<0.0001) and a 
significant increase in eGFP-gephyrin cluster density (Fig. 8E; 1.9±0.3 versus 1.4±0.16 versus 
1.0±0.23 clusters/20m, One way-ANOVA F(2,33)=0.11, P=0.03) compared to myc-PIAS-
3PINITm and myc-PIAS-3.  
 
The influence of myc-PIAS-3PINIT mutation on the SP-Ring domain function was intriguing; 
hence, we decided to see how the PINIT domain mutation affected biochemical interaction with 
gephyrin. We co-transfected HEK293 cells with myc-PIAS-3, myc-PIAS-3PINITm, or myc-
PIAS-3PINIT/Rm along with FLAG-gephyrin. IP for myc-PIAS-3 followed by WB for FLAG-
gephyrin showed no gephyrin interaction in the presence of PINIT domain mutation (Fig. 8F, 
lanes 4-5). However, when we analyzed the protein loading control we noticed that myc-PIAS-
3PINITm protein levels were reduced. Furthermore, we noticed an additional protein band 
running at reduced molecular weight (~50 kDa). In contrast, gephyrin expression was unaffected 
(Fig. 8G, bottom panel). This suggests to us that PINIT domain is essential for the PIAS-3 protein 
integrity via proper 3D conformation.  
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Figure 8:  PIAS-3 function is autoregulated by its N-Terminal domain. 
(A-C) Morphology of neurons (8+7 DIV) co-transfected with eGFP-gephyrin and myc-PIAS-3, myc-PIAS-3PINITm 
or myc-PIAS-3PINIT/Rm. (D) Cumulative probability distribution of synaptic eGFP-gephyrin cluster size, 
***P<0.001, KS test. (E) Quantifications of synaptic eGFP-gephyrin cluster density per 20m dendritic length. 
*P<0.05 One-Way ANOVA. (F) Interaction between FLAG-gephyrin and myc-PIAS-3, myc-PIAS-3Rm, myc-
PIAS-3PINITm and myc-PIAS-3PINIT/Rm. IP for myc-PIAS-3 using anti-Myc antibody, and WB against FLAG-
gephyrin. The protein loading controls are shown below. (G) WB for myc-PIAS-3, myc-PIAS-3PINITm and myc-
PIAS-3PINIT/Rm in untreated versus MG132 treatments (5M, 10M and 15M; 6Hrs). The lower panel shows 
lower exposure. Scale bar 10m. 
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In order to determine the mechanistic basis for myc-PIAS-3PINITm and myc-PIAS-3PINIT/Rm 
degradation, we blocked 26S proteosome using the broad range inhibitior MG132. The use of 
MG132 at different concentration could not rescue myc-PIAS-3PINITm degradation in HEK293 
cells (Fig. 8G). However, at higher exposure we could see weak bands of full length myc-PIAS-
3PINITm in the presence of 10M or 15M of MG132 (Fig. 8G, white arrows, first panel). The 
mechanistic basis for PINIT mutation induced PIAS-3 proteolytic clipping and/or degradation 
needs further characterization.  
 
ERK and GSK3 signaling  regulate PIAS-3 activity for gephyrin clustering 
 
It has been shown earlier that ERK1/2 and GSK3 signal transduction pathways phosphorylate 
gephyrin at S268 and S270 residues to modulate GABAergic transmission [93, 156]. Independent 
reports have shown that BDNF signaling activate ERK1/2 and GSK3 pathways downstream of 
TrKB [106, 272] Furthermore, it has been shown that SUMOylation and ERK1/2 pathways 
cross-talk to regulate gephyrin postsynaptic clustering. Hence, we decided to further explore how 
BDNF induced ERK1/2 and GSK3 pathways influence PIAS-3 function.  
We first assesed the effect of ERK1/2 on myc-PIAS-3 modulation of eGFP-gephyrin clustering; 
for this, we treated neurons with the ERK1/2 inhibitor PD98059 (Fig. 9A-B). Overnight 
treatment of neurons with PD98059 (25M) induced a marked decrease in gephyrin cluster size 
in neurons co-expressing myc-PIAS-3 (Fig. 9D; 0.26µm²±0.01 versus 0.64µm²±0.068; KS test 
P<0.0001). Furthermore, PD98059 treatment also caused a significant increase in eGFP-gephyrin 
cluster density in presence of myc-PIAS-3 (Fig. 9E; 4.05±0.5 versus 1.14±0.19 clusters/20m; 
Two tailed Student’ T-test P<0.0001). These results indicate that inhibition of ERK1/2 signaling  
blocks PIAS-3 action on eGFP-gephyrin cluster size and density.  
In an attempt to define more precisely the ERK1/2 modulation domain on PIAS-3, we co-
transfected neurons with eGFP-gephyrin and myc-PIAS-3Rm (Fig. 9F) or myc-PIAS-3(416-584) 
(Fig. 9K) and treated the neurons with PD98059 (Fig. 9G-L). ERK1/2 inhibition significantly 
decreased eGFP-gephyrin clustering size in neurons co-expressing either myc-PIAS-3Rm (Fig. 
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9I; 0.38µm²±0.024 versus 0.54µm²±0.056; KS test P=0.009) or myc-PIAS-3(416-584) (Fig. 9N; 
0.3µm²±0.02 vs untreated 0.42µm²±0.04; KS test P=0.021). In addition, treating neurons with 
PD98059 increased eGFP-gephyrin cluster density in the presence of myc-PIAS-3Rm (Fig. 9J; 
2.01±0.26 versus 0.83± 0.14 clusters/20m; Two tailed Student’ T-test P<0.0001) or myc-PIAS-
3(416-584) (Fig. 9O; 3.5±0.43 versus 1.17±0.2 clusters/20m; Two tailed Student’ T-test 
P=0.0006). These results suggest a role for ERK1/2 phosphorylation of PIAS-3 C-terminus to 
influence gephyrin cluster regulation in a SUMO-independent mechansim.  
 
Next, we investigated the effect of GSK3 on myc-PIAS-3 for gephyrin clustering. For this we 
used the GSK3 inhibitor, GSK3IX (5M), overnight and stained for morphological change in 
postsynaptic eGFP-gephyrin clustering (Fig. 9A, C). GSK3IX treatment significantly decreased 
eGFP-gephyrin cluster size (Fig. 9D; 0.37µm²±0.025 versus 0.64µm²±0.068; KS test P<0.0001). 
Further, when we analyzed for change in eGFP-gephyrin cluster density we found that GSK3IX 
treatment significantly increased the density (Fig. 9E, 3.5±0.7 versus 1.14± 0.19 clusters/20m; 
Two tailed Student’ T-test P=0.0076). These effects are similar to those caused by ERK1/2 
inhibition. 
Then, we examined the effect of GSK3IX treatment in neurons co-expressing either myc-PIAS-
3Rm or myc-PIAS-3(416-584) along with eGFP-gephyrin. Interestingly, GSK3 inhibition 
reduced eGFP-gephyrin cluster size in the presence of myc-PIAS-3Rm (Fig. 9F, H, I; 
0.42µm²±0.03versus 0.54µm²±0.056; KS test P=0.033), again like seen upon ERK1/2 inhibition. 
However, when we analyzed for change in eGFP-gephyrin cluster density, we did not find any 
significant changes after GSK3 inhibition (Fig. 9J; 1.52±0.23 versus 0.83± 0.14 clusters/20m; 
Two tailed Student’ T-test P=0.073). In neurons co-expressing myc-PIAS-3(416-584) with or 
without GSK3IX (Fig. 9K, M), we did not observe any significant change in cluster size (Fig. 
9N; 0.35µm²±0.03 versus 0.42µm²±0.04; KS test P=0.082) or cluster density (Fig. 9O; 2.04±0.33 
clusters/20m versus 1.17±0.2; Two-tailed Mann Whitney test P=0.052). 
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Figure 9: legend on the next page 
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Taken together, these observations suggest that in addition to ERK1/2 modulation of PIAS-3 C-
terminus, there might either be an additional GSK3 modulation site on PIAS-3.  Or, the results 
reflect the phosphorylation status of gephyrin and the complexe cross talk existing between 
SUMOylation and phosphorylation PTM. 
 
Gephyrin ERK1/2 and GSK3 site mutants are insensitive to PIAS-3Rm and C-terminus 
fragment 
 
Gephyrin is an ERK1/2 substrate and it has been shown that S268 residue is phosphorylated by 
this kinase to modulate its scaffolding properties at GABAergic synapse [156]. Hence, we wanted 
to test whether inhibition of ERK1/2 pathway by PD98059 treatment in any way affected 
gephyrin phosphorylation site mutants. For this we co-transfected neurons with myc-PIAS-3 and 
eGFP-gephyrin or ERK1/2 site phospho-mimicking mutant, eGFP-268E. Morphology analysis 
showed eGFP-S268E is not affected by the co-expression of myc-PIAS-3 (Fig. 10D; 
0.28µm²±0.034 versus 0.68µm²±0.05; KS test: P<0.0001). However, analysis for cluster density 
showed that eGFP-S268E density is reduced in the presence of myc-PIAS-3 as with eGFP-
gephyrin (Fig. 10E; 1.69±0.39 versus 1.67±0.44 clusters/20m; Mann Whitney t-test: P=0.75).  
 
 
Figure 9: ERK1/2 and GSK3 signaling regulate PIAS-3 activity for gephyrin clustering. 
(A-C) Hipocampal neurons co-transfected with eGFP-gephyrin and myc-PIAS-3 treated overnight with either 
ERK1/2 inhibitor PD98059 (25M) or GSK3 inhibitor GSK3IX (5M) . (D) Quantification of mean synaptic 
eGFP-gephyrin cluster size, ****P<0.0001, KS test. (E) Quantifications of mean synaptic eGFP-gephyrin cluster 
density per 20m dendritic length, **P<0.01 One-Way ANOVA. (F-H) Neurons co-transfected with GFP-gephyrin 
and myc-PIAS-3Rm treated overnight with either PD98059 (25M) or GSK3IX (5M). (I) Quantification of mean 
synaptic eGFP-gephyrin cluster size, ****P<0.0001, KS test from the cumulative. (J) Quantifications of mean 
synaptic eGFP-gephyrin cluster density per 20m dendritic length, **P<0.01 One-Way ANOVA. (K-M) Neurons 
co-transfect with GFP-gephyrin and myc-PIAS-3(416-584) treated overnight with either PD98059 (25M) or 
GSK3IX (5M). (N) Quantification of mean synaptic eGFP-gephyrin cluster size. ****P<0.0001, KS test. (O) 
Quantifications of mean synaptic eGFP-gephyrin cluster density per 20m dendritic length, **P<0.01 One-Way 
ANOVA. Scale bar 10m. 
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Figure 10: legend on the next page. 
 
91 
We next tested whether myc-PIAS-3Rm influenced eGFP-S268E mutant gephyrin in any way. 
For this, we co-transfected eGFP-S268E along with myc-PIAS-3Rm and quantified for changes 
in gephyrin cluster size (Fig. 10G). Quantification showed in comparison to eGFP-gephyrin, 
eGFP-S268E exhibited smaller cluster size in the presence of myc-PIAS-3Rm (Fig. 10I; 
0.4µm²±0.03 versus 0.55µm²±0.05; KS test, P=0.025). eGFP-S268E cluster density was 
unchanged compared to eGFP-gephyrin in the presence of myc-PIAS-3Rm (Fig. 10J; 2.2±0.4 
versus 1.1±0.22 clusters/20m; Mann Whitney t-test, P=0.06).  
 
We co-expressed myc-PIAS-3(416-584) C-terminal fragment along with eGFP-S268E or eGFP-
gephyrin (Fig. 10K-L). Quantification showed that eGFP-S268E mutant cluster size is not 
influenced by myc-PIAS-3(416-584) co-expression, which is contrary to eGFP-gephyrin co-
expression (Fig. 10N; 0.24µm²±0.01 versus 0.8µm²±0.16; KS test, P<0.0001). Quantification for 
cluster density also showed that eGFP-S268E is not affected by myc-PIAS-3(416-584) co-
expression, in comparison to eGFP-gephyrin (Fig.10O; 4.7±0.3 versus 1.03±0.28 clusters/20m; 
Mann Whitney t-test, P=0.0032). 
 These results demonstrate the importance of S268 residue in myc-PIAS-3-mediated increase in 
cluster size. Moreover, based on the data obtained in Fig. 9, those data suggest that ERK 
phosphorylation of PIAS-3C-terminus and gephyrin might be two processes occurring 
independently to each other.  
  
Figure 10: Gephyrin ERK1/2 and GSK3 site mutants are insensitive to PIAS-3Rm and C-terminus 
fragment. 
(A-C) Neurons co-transfect with myc-PIAS-3 and GFP-gephyrin , eGFP-S268E or GFP-S270E . (D) Quantification 
of synaptic eGFP-gephyrin cluster size, ****P<0.0001, One-Way ANOVA. (E) Quantification of synaptic eGFP-
gephyrin cluster density per 20m dendritic length. (F-H) Neurons co-transfect with myc-PIAS-3Rm and either 
eGFP-gephyrin, eGFP-S268E or eGFP-S270E. (I) Quantification of synaptic eGFP-gephyrin cluster size, *P<0.05, 
KS test. (J) Quantifications of mean synaptic eGFP-gephyrin cluster density per 20m dendritic length. ***P<0.001 
One-Way ANOVA. (K-M) Neurons co-transfected with myc-PIAS-3(416-584) and eGFP-gephyrin, eGFP-S268E or 
eGFP-S270E. (N) Quantification of synaptic eGFP-gephyrin cluster size, ***P<0.001, KS. (O) Quantifications of 
synaptic eGFP-gephyrin cluster density per 20m dendritic length, ***P<0.001 One-Way ANOVA. Scale bar 10m. 
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Gephyrin is phosphorylated by GSK3 at Ser270 [93]. Hence, we co-transfected myc-PIAS-3 
along with eGFP-gephyrin or eGFP-S270E to observe the influence of PIAS-3 on gephyrin 
mutant. Quantification for eGFP-gephyrin or eGFP-S270E in the presence of myc-PIAS-3 
showed increase in cluster size for both the eGFP-gephyrin and eGFP-S270E (0.68µm²±0.05 
versus 0.76µm²±0.15, KS test, P=0.816). Quantification for cluster density showed that eGFP-
gephyrin and eGFP-S270E have similar density in the presence of myc-PIAS-3 (1.67±0.44 versus 
1.98±0.42 clusters/20m; Mann Whitney, P=0.29). 
 
We co-expressed myc-PIAS-3Rm along with eGFP-gephyrin or eGFP-S270E. Quantification for 
cluster size showed that myc-PIAS-3Rm co-expression affects eGFP-gephyrin and eGFP-S270E 
in a similar manner (0.55µm²±0.05 versus 0.67µm²±0.05; KS test, P= 0.009). However, when we 
quantified for cluster density change, we found that myc-PIAS-3Rm co-expression has higher 
density in eGFP-S270E neurons compared to eGFP-gephyrin neurons (Fig. 10H-J; 1.1±0.22 
versus 3.18±0.47 clusters/20m; Mann Whitney, P=0.0007). This suggests that SP-Ring domain 
independent mechanism of eGFP-gephyrin cluster reduction is influenced by S270 residue on 
gephyrin.  
 
We also tested the effect of myc-PIAS-3(416-584) on eGFP-S270E mutant. Quantification for 
cluster size showed a similar phenotype to eGFP-gephyrin in the presence of myc-PIAS-3(416-
584) (0.8µm²±0.16 versus 0.52µm²±0.036 KS test, P=0.15). When we quantified for cluster 
density change we find that eGFP-S270E shows an increased density compared to eGFP-
gephyrin (Fig. 10M-O; 1.03±0.28 versus 3.8±0.39 clusters/20m; Mann Whitney, P=0.0012). 
This confirms the importance of S270 site on gephyrin for PIAS-3 SP-Ring domain independent 
function and reduction in gephyrin cluster density. Furthermore, our data also confirm that cross-
talk between SUMO and phosphorylation pathways influence PIAS-3 regulation of gephyrin.   
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Figure 11: Schematic model of BDNF regulation of gephyrin clustering at GABAergic postsynaptic 
sites. 
Schematic of the complex formed through the binding between gephyrin (green), PIAS-3 (blue) and SUMO (pink) 
and summary of the regulation of this SUMO-conjugation complex by the BDNF pathway. (1) BDNF via TrKB 
activation phosphorylates PIAS-3 (C-terminus) and gephyrin (S268) via the MAP kinase pathway, thus preventing 
SUMOylation to occur at K148 and/or K724 sites. (2) BDNF via TrKB signaling also activates PI3K/ Akt pathway, 
in turn inhibiting the GSK3 activity. This would promote PIAS-3 (N-terminus) de-phosphorylation, and gephyrin 
de-phosphorylation at S270, leading to the prevention of SUMOylation at K148 and/or K724 sites. (3) Inactivation 
of the PIAS-3 N-terminus PINIT domain, probably via GSK3 signaling, reduces PIAS-3 protein stability. (4) This 
highly dynamic system would respond to the variation in BDNF levels to regulate gephyrin scaffolds at GABAergic 
synapses.  
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Discussion 
 
In the present study we used primary hippocampal neuronal cultures to highlight the molecular 
mechanism underlying acute BDNF facilitated changes at GABAergic postsynaptic sites. In this 
process, we uncovered a previously uncharaterized signaling pathway, SUMOylation, that 
converges onto the gephyrin scaffold at GABAergic synapses and is influenced by BDNF 
signaling . The effect of BDNF regulation of the SUMO pathway onto gephyrin scaffolding 
involves the SUMO E3 ligase, PIAS-3 via two independent mechanisms. One of the mechanism 
requires TrkB activation and the SP-Ring domain function of PIAS-3. ERK and GSK3 act 
downstream of TrkB to phosphorylate both PIAS-3 and gephyrin, mediating cross-talk between 
phosphorylation and SUMOylation pathways (Fig. 11).  
 
Acute BDNF signaling  influences kinase and SUMO pathways that converge on gephyrin 
scaffolds 
 
Although in recent years several neuronal proteins have been characterized as novel SUMO-1 
substrate in vivo [273], there is little mechanistic understanding of how SUMOylation is achieved 
at synaptic locations. 
Previous data from our laboratory revealed a direct interaction between PIAS-3 and gephyrin for 
SUMO modification of gephyrin [Ghosh et al., submitted]. In the current study, our biochemical 
analysis identified two interaction sites for PIAS-3 on gephyrin (G and E domains). Gephyrin is 
SUMO-1 conjugated at the K148 and SUMO-2 conjugated at K724 residues; hence, PIAS-3 
interaction close to the SUMO conjugation sites could facilitate gephyrin SUMOylation. Our data 
offers an elegant model for nucleo-dendritic shuttling of SUMO-1/-2, PIAS-3, SENP-2/-6 in 
response to BDNF signaling , thereby facilitating de-SUMOylation of synaptic proteins. BDNF-
mediated translocation of these proteins is prevented byapplication of TrKB-Fc (data not shown). 
We also provide evidence showing chronic BDNF treatment to primary neuron culture renders 
proteins of the SUMO pathway insensitive to BDNF and they again enrich within the nucleus. It 
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is well accepted in the field that protein SUMOylation is a labile process; however, within the 
neuronal context our data offers a mechanistic underpinnings of a dynamic regulatory process.    
Using specific SUMO-1 and SUMO-2 site gephyrin mutations (Fig. 3), and gephyrin ERK1/2 
and GSK3 phosphorylation site mutations (Fig. 10), we demonstrate the convergence of these 
two pathways onto gephyrin scaffold upon acute BDNF signaling . In addition, the 
phosphorylation status at S268 and S270 residues on gephyrin renders it insensitive to PIAS-3 
mediated increase in cluster size or reduction in density. This rise the question of whether 
SUMOylation acts upstream of phosphorylation. We have shown earlier that gephyrin 
phosphorylation via ERK1/2 and GSK3 pathways respectively leads to calpain-1-mediated 
gephyrin proteolysis and scaffold loss [258]. Taking these observations together, acute BDNF 
signaling -mediated downregulation of GABAergic transmission and gephyrin scaffolding can be 
mechanistically explained in a two step process. Step 1, BDNF activates TrkB receptors to 
activate ERK1/2 and GSK3 pathways that would then phosphorylate gephyrin at S268 and S270 
residues, leading to calpain-1 faciliated clipping and scaffold removal from synaptic membrane. 
Step 2, BDNF activation of TrkB would also cause PIAS-3 and SENP-2/6 inactivation, leading to 
the disruption of the dynamic interplay between phosphorylation and SUMOylation pathway and 
preventing membrane recruitment of gephyrin.   
 
ERK1/2 and GSK3 regulate PIAS-3 activity for gephyrin cluster regulation 
 
In this study we present data suggesting ERK1/2 and GSK3 phosphorylation pathways affect 
PIAS-3 function via its C-terminus and N-terminus sequence, respectively. Inhibition of the 
ERK1/2 pathway provokes a significant reduction of eGFP-gephyrin clusters in the presence of 
PIAS-3 (Fig. 9), suggesting ERK1/2 pathway influence on PIAS-3 is essential for its action on 
gephyrin.  
Interestingly, by looking at PIAS-3 sequence we could detect a potential ERK1/2 site in the C-
terminus and a GSK3 site in the N-terminus domain of PIAS-3. Point mutation of those two 
siteswould confirm the data found in Fig. 9 showing the control of PIAS-3 activity by those two 
 
96 
kinases for regulating gephyrin cluster formation. Furthermore, ERK1/2 and GSK3both seem 
to regulate differently PIAS-3 and gephyrin independently of each other. In order to help making 
the differences, it would be proposed to test the co-transfection of primary hippocampal neurons 
with myc-PIAS-3 full length and either eGFP-S268A with or without PD98059 treatment or 
eGFP-S270A with or without GSK3IX treatment. Untreated transfected cells would provide 
some evidence on the fact that ERK1/2 and GSK3 act directly on PIAS-3 when gephryin is 
dephophorylated by either of them. In addition, repeating the proposed experiment by replacing 
myc-PIAS-3 with myc-PIAS-3Rm or myc-PIAS-3(416-584) might confirm our speculation 
consisting of ERK1/2 affecting  PIAS-3C-terminus and GSK3 acting on PIAS-3 N-terminus.  
Moreover, if we take in consideration that ERK1/2 phosphorylates PIAS-3 on its C-terminal 
leading to a normal function of PIAS-3 therefore increasing gephyrin cluster size, phophorylation 
of gephyrin at S268 site might not occur at the same time. Furthermore, as BDNF signaling  leads 
to activation of ERK1/2 and down-regulation of gephyrin cluster size, it is therefore possible that 
activated ERK1/2, under BDNF signalling, would only act on gephyrin.  
 
PIAS-3 is a specific inhibitor of transcription factor STAT-3, and diverse signaling  pathways 
like IL6, EGF, NGF etc. activate STAT-3-induced gene transcription [216, 274]. The 
phosphorylation of STAT-3 at Y705 and S727 via JAK and ERK1/2, respectively, are well 
documented. STAT-3 phosphorylation at Y705 leads to PIAS-3/ STAT-3 complex formation and 
nuclear translocation, causing a reduction of STAT-3 mediated gene expression [275]. In a model 
of myocardial infraction for sympathetic nerve sprouting, it was shown that NGF phosphorylates 
STAT-3 at S727 via ERK1/2, promoting nerve regeneration in a STAT-3 transcription-
independent fashion. Furthermore, in the same study STAT-3 (pS727) was found to be localized 
both in the nucleus and neuronal processes [274]. It is likely that BDNF activation of ERK1/2 
causes STAT-3 (S727) phosphorylation leading to PIAS-3 binding and sequestration of PIAS-3 
activity. Taken together our data point towards a non-transcriptional role for PIAS-3 in gephyrin 
scaffold regulation.   
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It is conceivable that ERK and GSK3 pathways directly phosphorylate PIAS-3 affecting  its 
conformation and/or stability. In support of this idea, we provide data showing that both full 
length PIAS-3 and PIAS-3 C-terminal sequence (AA 416-584) are influenced by the inhibition of 
the ERK1/2 pathway (Fig. 9). Furthermore, introduction of point mutations into the N-terminal 
PINIT domain (Fig. 8) or inhibition of GSK3 (Fig. 9) is sufficient to reverse PIAS-3-mediated 
gephyrin cluster regulation. The C-terminus sequence and the N-terminal PINIT domain within 
PIAS-3 could influence the SP-Ring domain function via 3D protein confirmational change, 
thereby activating the SUMO-independent pathway, via currently unknown mechanisms.    
 
BDNF signaling  and gephyrin modulation for brain network integrity  
  
Dynamic regulation of gephyrin scaffolding at GABAergic synapses is especially relevant within 
the context of synaptic homeostasis, wherein individual neurons and/or synapses adapt to 
alterations in afferent activity. It has become increasingly clear that GABAergic inhibition is a 
dynamic process with rapid changes in gephyrin scaffolding in response to incoming stimuli; 
however, the underlying mechanisms for such adaptations in vivo are unknown. Our study not 
only characterizes the signaling network influencing specific PTM(s) on gephyrin, but, by 
identifying specific residues on gepyhrin at single amino acid resolution, we offer functional 
insights at unprecedented depth. It would be a major aim to investigate wether this mechanism 
still operates under pathological conditions, such as in ischemia, where elevated BDNF levels are 
known to downregulate GABAergic transmission, leading to adaptative changes and cognitive 
impairement [104].    
 
In the context of  ischemia, an elevation of the general level of SUMO-conjugated proteins as 
well as a significant increase of BDNF transcript and protein levels have been reported after an 
ischemic stroke [220, 242, 276-278]. However, these studies failed to explore possible link 
between BDNF and SUMO pathway. Our work provides the first evidence of BDNF regulates 
the SUMO pathway. Interestingly, the hippocampal formation is more sensitve to ischemic stroke 
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in comparison to other brain areas [279-281]; and one sees elevation in BDNF levels within 
hippocampal formation after stroke. Thus, it is conceivable that under ischemic conditions BDNF 
signals to promote gephyrin SUMOylation to dampen GABAergic inhibition post-ischemic 
injury.  
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Chapter 2: SUMOylation-defective gephyrin mutant 
stabilizes GABAergic synapses in post-ischemic 
CA1 hippocampal neurons 
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Abstract 
 
We have previously demonstrated that BDNF facilitates structural adaptations of gephyrin 
clusters at GABAergic postsynaptic sites trough activation of TrKB and modulation of gephyrin 
post-translational modification. Besides its key role during brain development, BDNF was shown 
to play an important role in recovery after an ischemic injury. The goal of the present study was 
to test whether BDNF mediates its effects by regulating GABAergic transmission and gephyrin 
clustering, using OGD as a model of ischemia in hippocampal organotypic slice cultures.  
We report that a brief period of OGD in mature slices induces both morphological and functional 
changes at hippocampal CA1 pyramidal neurons. OGD decreases surface expression of gephyrin 
and GABAARs-containing 1 and 2 subunits. Subsequently, OGD decreases GABAergic 
mIPSCs frequency. Interestingly these morphological and functional deficits recover 1 week 
post-OGD. Moreover, we provided evidence that these deficits were consequences of BDNF 
signaling activation as we could prevent them by the use of the BDNF scavenger TrKB/Fc. 
Furthermore, we could demonstrate that the availability of gephyrin expression was dependent of 
its SUMOylation regulation. 
Altogether, these results revealed the importance of BDNF regulation of gephyrin post-
translational modification to induce GABAergic synaptic plasticity, likely contributing in the 
recovery phase post-ischemic injury. 
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Introduction 
 
Homeostatic synaptic plasticity is a fundamental mechanism through which neurons adjust the 
strength of their synapses in response to global changes in neurotransmission. In order to 
maintain synaptic homeostasis, both excitatory and inhibitory circuits undergo adaptive changes 
affecting pre- and postsynaptic function. Changes in neuronal activity regulate a complex 
network of signaling cascades, which in turn adjust synaptic function. These signaling cascades 
induce post-translational modifications of synaptic proteins to regulate their targeting localization 
and functions. One of the major synaptic proteins undergoing PTM and in turn modulating 
synaptic function is the scaffolding protein. Scaffolding proteins can target, localize and build 
complexes of functionally related proteins to facilitate the formation of presynaptic active zone 
and postsynaptic density. The main scaffolding protein at GABAergic (and glycinergic) synapses 
is gephyrin, a highly conserved multifunctional protein that has been hypothesized to be the 
facilitator of postsynaptic density [18].  
Molecular mechanisms underlying gephyrin inter- and intra-molecular interactions are slowly 
emerging. In recent years multiple phosphorylation residues have been identified on gephyrin 
[93, 151, 156, 157]. However, understanding these PTMs has allowed us to explore the molecular 
mechanisms underlying gephyrin regulation and to determine how this regulation impacts the 
formation and plasticity of GABAergic synapses. It was recently reported that diverse PTMs on 
gephyrin such as phosphorylation, SUMOylation and acetylation regulate gephyrin scaffolding at 
GABAergic synapse. In the same study it was also shown that ERK1/2 and GSK3 kinase 
pathways cross-talk with the SUMO pathway to modulate gephyrin scaffolding [Ghosh et al., 
submitted].  
The heterologous SUMO-1/-2/-3 proteins are conjugated to cellular substrates in three steps: step 
one: SUMO protein is activated by the E1 activating enzyme Sae2/Uba2; step two: SUMO is 
transferred to the E2 conjugating enzyme Ubc9; step three: SUMO is ligated onto the substrates 
via E3 ligase PIAS family of proteins. SUMO conjugation is reversible and is facilitated via the 
function of sentrin family of SENP proteins. Although the SUMO pathway was discovered as a 
key regulator of DNA damage response [282], in the last decade SUMOylation of synaptic 
proteins has emerged as a critical regulator of neuronal plasticity [176, 220, 221]. It has been 
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demonstrated that protein SUMOylation increases with cellular stress [240]. Hence, several 
independent studies have demonstrated a transient increase in the overall levels of SUMO-
conjugated proteins in the brain following injury such as stroke [253, 283].  
During stroke, a brief period of ischemia causes cell death in the infarct area, causing disruption 
of network homeostasis via alterations at both excitatory and inhibitory synapses [284-286]. 
While mechanism(s) underlying synaptic changes at glutamatergic terminals is well characterized 
in literature [287-289], we lack a mechanistic understanding for changes at GABAergic synapses 
post ischemia [252, 290, 291]. In hippocampal formation GABAARs are down-regulated post 
ischemia, further exacerbating the excitotoxicity related cell death [248]. The observed 
downregulation of GABAARs from inhibitory synaptic terminals is linked to the regulation of 
gephyrin scaffolding via a currently unknown mechanism [252].  
In the current study we demonstrate that ischemia increases bdnf transcription specifically in CA1 
area of the hippocampus, leading to GABAergic synapse loss via gephyrin regulation. We use 
molecular biology, confocal microscopy and electrophysiology to investigate the mechanistic 
basis for gephyrin regulation under ischemic conditions. Our data identifies BDNF-induced 
GABAergic synaptic plasticity via gephyrin post-translational modification. Using specific 
gephyrin point mutations that are defective for SUMO-1 or SUMO-2 conjugation we demonstrate 
the importance of this PTM for ischemia-induced plasticity at GABAergic synapses.  
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Material and Methods  
 
Organotypic hippocampal slice cultures  
All experiments were performed in accordance with guidelines from the Swiss Vetinerary office, 
Canadian Council on Animal Care and the National Institutes of Health in the USA. They were 
all approved by the Animal Resource Committee of the School of Medicine at McGill University. 
Organotypic hippocampal slices (400m thickness) were obtained from post-natal day 7 
C57BL/6J mice or transgenic mice expressing MARCKs-enhanced GFP tagged to the CA1 
neuronal membrane. Tissue slices of 400m thickness were prepared following the roller-tube 
method from Gähwiler technique [292, 293]. The slices were incubated in an antibiotic-free 
serum medium containing 25% heat-inactivated horse serum, 25% Hank’s balanced salt solution, 
and 50% Basal Medium Eagle. They were maintained during 3 weeks minimum allowing 
maturation prior to experimentation at 36°C in a roller drum incubator.  
 
Organotypic slice transfection  
eGFP-gephyrin, eGFP-K148R or eGFP-K724R and pCR3-Td-Tomato were co-transfected into 
14 days in vitro (DIV 14) organotypic slices using the Helios Gene Gun (Bio-Rad laboratories), 
following the vendor protocol. 
 
Oxygen Glucose Depravation (OGD) treatment  
The slices were incubated in glucose-free Tyrode (ACSF) solution supplemented with 2mM 2-
deoxyglucose (2-DG), 8mM sucrose, and 3mM sodium azide (NaN3) and bubbled with 95%N2 
/5%CO2. The slices were incubated during 4min in the OGD solution or normal Tyrode solution 
(control conditions) and returned in normal culture medium 90min, 24H or 1week before 
experimenting as a model for ischemic injury in vitro [294].   
Pharmacological treatments: BDNF scavenger: TrKB/Fc Chimera (1g/mL, R&D Systems 
#688-TK-100).  
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Immunohistochemistry  
Slices were fixed with 4% paraformaldehydes (PFA) during 1 hr and washed with 0.1M 
phosphate buffer, prior to permeabilization with 0.4% Triton x100 and subsequently blocked with 
1.5% heat-inactivated horse serum overnight at 4°C. The primary antibody incubation (in 
permeabilizing buffer) was performed over 5 days at 4°C. The slices were then washed several 
times with 0.1M PBS during the whole day, followed by the incubation with the secondary 
antibody mixture overnight at 4°C. Slices were mounted using Dako Fluorescence Mounting 
medium (Dako Canada).  
 
Antibodies 
Mouse anti-Gephyrin (1:500, clones mAb7a, Synaptic Systems #147021), rabbit anti-SUMO-1 
(1:250, Abcam#ab11672), rabbit anti-SUMO-2/3 (1:250, Abcam#ab109005), mouse anti-PIAS-3 
(1:500, Sigma #P0117), rabbit anti-NeuN (Millipore #MAB377X). All the secondary antibodies 
were from Jackson ImmunoResearch: Goat anti-Mouse Cy3 IgG (1:250, #115165), Goat anti-
Mouse IgG Cy5 (1:250, #115175), Goat anti-Rabbit IgG Cy3 (1:250, #111165) and Goat anti-
Rabbit IgG Cy5 (1:250, #111175).  
 
Microscopy and Image processing  
Images were acquired on a Leica DM6000B laser scanning microscope (Leica Microsystems) 
with objective lens 63x NA 1.4 oil immersion. A minimum of 3 slices from 3 independent 
batches per condition were acquired using a z-stack (0.3m step size). Image analyses of 
gephyrin clustering in the hippocampal CA1 region were done, post-deconvolution with Hygens 
Essential software, using the Surpass and the Spot functions of Imaris 7.00 software (Biplane 
AG).  
Images for PIAS-3 quantifications  were acquired on confocal laser scanning microscope (LSM 
710, Carl Zeiss) with objective lens of 40x or 63x with a pinhole set at 1 Airy unit and a pixel 
size of 0.13m. A minimum of 9 cells from 3 independent batches per condition were acquired 
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using a z-stack (0.5m step size). Image analyses were performed with a custom written analysis 
for Image J software using maximal intensity z-projected images.  
 
Electrophysiological recordings 
Cells were held at a potential of -60mV with an Axopatch 200A amplifier (Molecular Devices) 
and perfused with a Tyrode solution containing: 137mM NaCl; 0.4 mM NaH2PO4.H2O; 2.7 mM 
KCl; 2.5 mM CaCl2.H2O; 2 mM MgCl2. H2O; 11.6 mM NaHCO3; 5.6 mM D-glucose (pH7.4, 
bubbled with 95%O2 and 5%CO2). Spontaneous GABAergic miniature postsynaptic currents 
(mIPSCs), from CA1 pyramidal neurons, were isolated by batch application of Tetrodotoxin 
(TTX 1M, Tocris); 3-[(R)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid (CPP 25M, 
Tocris); 6-cyano-7-nitroquinoxaline-2.3-dione (CNQX 5M, Tocris); CGP55845 hydrochloride 
(5M, Tocris); Strychnine (0.3M, Tocris).  
Whole-cell voltage-clamp recordings were performed at room temperature using borosilicate 
glass microelectrodes (3-5MΩ, GC150TC, Clark Instruments) refilled with an internal solution 
containing: 140 mM CsCl, 4 mM NaCl, 5 mM EGTA, 10 mM HEPES, 0.5 mM CaCl2, 0.5 mM 
Na-ATP, 2 mM Mg-GTP, 2 mM QX-314 (pH adjusted to 7.4 with CsOH). The cells were 
monitored for a min of 5min, after whole-cell configuration, for equilibration of the internal 
solution and ensure that the seal and opening were maintained. The cells were then recorded 
during 5 stable minutes. 
mIPSCs data acquisition was performed using pClamp 10 (Molecular devices) and recorded with 
a filtering of 2KHz and digitized at 20KHz with the Axon Digidata 1440 digitizer (Molecular 
devices). From every experiment, 3min of synaptic events from a minimum of 8 cells were 
analysed using Mini Analyses software (Synaptosoft).  
 
Real Time qPCR 
Areas CA1 and CA3 were micro-dissected from 5 to 6 slices from 3 independent litter and used 
for each experimental conditions.  Total mRNA was extracted using BioRad extraction kit. 
Subsequently, 1g of mRNA was reverse transcribed to cDNA following the manufacturer’s 
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protocol (Roche Diagnostic). The RT-qPCR was performed using 30ng of cDNA in a 20L 
reaction mixture containing EVA green mastermix (Solis BioDyne #08-24-00008). All qPCR 
reactions were performed under those conditions: 40 cycles; denaturation at 95°C for 15s, 
annealing at 62°C for 25s and extension at 72°C Primers. The following primer pairs were used 
for each reaction: bdnf Fwd: 5’-TGC AGG GGC ATA GAC AAA AGG-3’, Rev: 5’-CTT ATG 
AAT CGC CAG CCA ATT CTC-3’; Sumo-1 Fwd: 5'-GGCAAAACCTTCAACTGAGGA-3', 
Rev: 5'-CTCCATTCCCAGTTCTTTCGG-3'; Sumo-2 Fwd: 5'-ATTTGAAGGTGGCGGGAC-3', 
Rev: 5'-CTGTTTCGTTGATTGGCTGC-3'; PIAS-3 Fwd: 5'-GGA TGG TCT CCA GTA CAG 
CG-3', Rev: 5'-CAG GAA GTG GGA AGG GGT TC-3' and Gapdh Fwd: 5'-
TGCCCCCATGTTTGTGATG-3' Rev: 5'-TGTGGTCATCAGCCCTTCC-3'. 
 
Statistical analyses  
Numerical data are expressed as mean ± standard error of the mean (SEM). Statistical analyses of 
mean values were made, when appropriate, using the Student’s T-test of GraphPad Prism 
software. P<0.05 was considered statistically significant.  
Except for PIAS-3 puncta size in addition to cumulative probability distribution of mIPSCs 
(amplitude and IEI) were analysed by pair-wise using a Kolmogorov-Smirnov test. P<0.05 was 
considered statistically significant.  
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Results 
 
Organotypic cultures preserve the hippocampal network architecture, allowing the study of 
activity-dependent changes in a physiologically relevant context and also serve as a model for 
distinct pathological states [295]. In particular, OGD is considered to be a good in vitro model to 
mimic cerebral ischemia and study hippocampal synaptic plasticity at different time-points after 
the injury. Hence, we used organotypic hippocampal slice cultures and OGD to study the 
molecular basis of post-ischemic GABAergic synapse plasticity in the CA1 area.  
OGD-induced loss of gephyrin clusters recovers after one week 
 
As proof of principal, we tested our organotypic slice culture model for hippocampal OGD, by 
staining for propidium iodide (PI), a marker for cell death and for hypoxia-inducible factor 1 
(HIF1) [279-281, 296].  
 
 
Figure 1: Example of OGD inducing neuronal cell death accompanied by an increase in HIF1.  
(A) Staining for cell death using propidium iodide (red) in control+ 90min, OGD+ 90min, OGD+ one-week in 
organotypic hippocampal slice cultures. Control experiment using saturated KCL concentration. Scale bar,  200m. 
(B) Staining for HIF1 (white) in CA1 and CA3 in control+ 90min and OGD+90min. (C) Normalized mean 
intensity fluorescence of  HIF1 .*P<0.05 Student t-test. Scale bar, 10m. 
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We found that almost all the cultures showed elevated staining for HIF1however, only 20% of 
are immune-positive for PI. These observations confirm that in our model we can successfully 
induce ischemia with little cell death (Fig. 1A, B). 
 
Since we are interested in understanding both short- and long-term adaptations at GABAergic 
synapses after transient OGD, we exposed the slices to 4 min OGD, followed by either 90 min or 
one-week recovery prior to staining for gephyrin clusters. At 90 min post-OGD, we observed an 
overall decrease in the density of gephyrin clusters (Fig. 2C; OGD+90min 40.08±8.22 clusters/ 
512x512m image) compared to control+90min (Fig. 2A, F; 494.9±29.33, Two-tailed Mann 
Whitney-test P<0.0001). This difference represented a disappearance of 90% of gephyrin clusters 
from CA1 neurons. We also analyzed for changes in gephyrin cluster volume, as our earlier 
studies have shown this to be a direct correlate for availability of synaptic GABAARs [93, 156]. 
The decrease in cluster density post-OGD is accompanied by a decrease in the average cluster 
volume of the remaining gephyrin clusters at OGD+90min (0.09µm
3
±0.01) compared to 
control+90min (Fig. 2E; 0.27µm
3
±0.04, Two tailed Mann Whitney-test P=0.0008). Interestingly, 
all the remaining gephyrin clusters where apposed to vGAT (data not shown), which might also 
suggest that the synapses are likely functional and the presynaptic interneurons might not be 
spared (or not totally). We could also notice that many of the remaining gephyrin clusters have a 
large cluster volume.  
Importantly, the gephyrin clusters density recover one-week after OGD (Fig. 2D; OGD+1week 
413.67±33.7) compared to control+ one-week (Fig. 2B, F; 475.14±29.16, Two-tailed Mann 
Whitney-test P=0.27), suggesting the existence of a mechanism for re-establishing gephyrin 
clusters at GABAergic PSD during the recovery process. Moreover, gephyrin cluster volume also 
showed recovery after one-week recovery (OGD+1week 0.21µm
3
±0.03) compared to 
control+1week (Fig. 2B, F; 0.17µm
3
±0.01; Two-tailed Mann Whitney-test P=0.72). Interestingly, 
our control cultures did not show any significant differences in gephyrin cluster density (Fig. 2F; 
Two-tailed Mann Whitney-test P=0.82) or cluster volume (Fig. 2E; Two-tailed Mann Whitney-
test, P=0.074). 
Based on these initial observations, we could ascertain that in our OGD model gephyrin 
immunopositive expression dramatically disappeared and reappeared probably contributing to 
plasticity changes at GABAergic synapse.   
 
111 
 
 
Figure 2: Gephyrin cluster loss post-OGD recovers after 1Week. 
(A-B) Immunofluorescence staining for endogenous gephyrin in mock-treated DIV 21 and DIV 28 organotypic 
hippocampal slice cultures. (C-D) Immunofluorescence staining for endogenous gephyrin after 90 min and one-week 
recovery post-OGD. Scale bar =2m. (E) Gephyrin cluster volume in m3 per confocal stack (512x512 pixel 
images), ***P<0.001 One-Way ANOVA followed by a Kruskall-Wallis test. (F) Gephyrin cluster density per 
confocal stack, ****P<0.0001 One-Way ANOVA  followed by a Kruskall-Wallis test. 
 
 
 
Blocking BDNF signaling  prevents gephyrin clusters after OGD 
 
Many independent studies have demonstrated BDNF upregulation post-OGD [276, 297]. Hence, 
we wanted to determine whether BDNF signaling  induces gephyrin clustering loss after OGD. 
TrkB is the high affinity receptor for BDNF; we used TrKB/Fc, a chimera made of the 
extracellular domain of TrKB receptor and an Fc fragment of human IgG to scavenge exogenous 
BDNF.  
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TrKB/Fc (1g/mL) was added immediately after transient OGD in the culture medium and the 
slices were placed in the incubator for 90min before proceeding with morphology analysis. The 
addition of TrKB/Fc to control slices (Control+TrKB/Fc) did not influence gephyrin cluster 
density (Fig. 3A, D; 311.9±25.6 versus 331.9±22.37, Two-Tailed Mann Whitney T-test P=0.62) 
and cluster volume (Fig. 3A, C, 0.16µm
3
±0.008 versus 0.16µm
3
±0.008, Two-Tailed Mann 
Whitney T-test P=1.0). OGD cultures replicated the significant decrease in the gephyrin cluster 
density compared to untreated control (Fig. 3D; 47.44±8.78 versus 331.9±22.37, Two-Tailed 
Mann Whitney T-test P <0.0001). In addition, OGD samples show a significant reduction of 
gephyrin cluster volume compared to control+90min, (Fig. 3C; 0.098µm
3
±0.017 versus 
0.16µm
3
±0.008, Two-Tailed Mann Whitney T-test P=0.0062). 
 
 
Figure 3: Blocking BDNF signaling post-OGD rescues gephyrin clustering in neurons. 
(A) DIV 21 organotypic hippocampal slice showing endogenous gephyrin clusters in control untreated neurons and 
in neurons treated with 1g/mL of TrKB/Fc post-90min treatment. Scale bar 2m. (B) DIV 21 organotypic 
hippocampal slice showing endogenous gephyrin clusters 90min post-OGD and in neurons treated with TrKB/Fc for 
90min  post-OGD. (C) Gephyrin cluster volume in m3 per confocal stack (512x512 images), *P<0.05 One-Way 
ANOVA followed by a Kruskall-Wallis test. (D) Gephyrin cluster density per confocal stack, ****P<0.0001 One-
Way ANOVA  followed by a Kruskall-Wallis test.  
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Samples treated with TrKB/Fc showed a prevention of gephyrin cluster density (Fig. 3B, D; 
302±29.5 versus 47.44±8.78, Two-Tailed Mann Whitney T-test P=0.0002) and volume (Fig. 3C; 
0.15µm
3
±0.008 versus 0.098µm
3
±0.017, Two-Tailed Mann Whitney T-test P=0.036). These 
observations confirm a role for BDNF in OGD-induced gephyrin cluster reduction in 
hippocampal CA1.  
 
The OGD treated slices are very fragile after 90 min recovery; to increase data reproducibility we 
tested organotypic cultures for gephyrin cluster loss 24 hr post-OGD (Fig. 4A). Similar to the 90 
min samples, 24 hr recovery also showed a significant loss of endogenous gephyrin clusters 
density (Fig. 4B; 59.78±7.3 versus 210.9±15.7, Two-Tailed Mann Whitney T-test P<0.0001) 
suggesting that many of the impairment observed at 90 min persists at 24 hr post-OGD. However, 
the remaining gephyrin clusters show basal cluster volume (Fig. 4C; 0.096µm
3
±0.008 versus 
0.091µm
3
±0.006; Two-Tailed Mann Whitney T-test P=0.63). 
 
 
 
Figure 4: Following gephyrin cluster loss post-OGD after 24hr recovery. 
(A) Immunostaining for endogenous gephyrin at 90min and 24hr post-OGD. Scale bar 2m. (B) For better 
visualisation of the differences the results has been normalised. Normalized gephyrin cluster density per confocal 
stack, ***P<0.0001 Paired Student t-test. (C) Normalized gephyrin cluster volume in m3 per confocal stack 
(512x512 images), ***P<0.001 Paired Student t-test.  
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Functional reduction of GABAergic transmission after OGD 
 
We have consistently shown in the past that morphological alterations in gephyrin scaffolding 
can be a direct correlate for functional changes in GABAergic transmission [93, 156]. Hence, we 
wondered whether OGD-induced impairment in gephyrin clustering also resulted in reduced 
GABAergic transmission. For this we performed whole-cell patch-clamp recordings of miniature 
inhibitory postsynaptic currents (mIPSCs) of CA1 pyramidal neurons 24 hr after OGD.  
 
Analysis of GABAergic mIPSCs showed a significant increase in the mean inter-event interval 
(IEI) 24 hr post-OGD compared to controls (Fig. 5A-E; 198.2ms±13.34, n=13cells versus 
146.0ms±10.25, n=15, Two-tailed Unpaired T-test P=0.0046). Cumulative probability 
distribution confirmed the reduction in IEI with a rightward shift in curve (Fig. 5D; KS test 
P<0.01). When we compared for differences in mIPSCs amplitude we found that 24 hr post-OGD 
the amplitude of the remaining mIPSCs were unaffected (Fig. 5G; 30.34pA±1.403, n=13 versus 
30.05pA±1.231, n=15, Two-tailed Unpaired T-test P=0.88). Cumulative probability distribution 
curves for the amplitude were also similar (Fig. 5F). Our data suggest that the OGD-induced 
reduction of mIPSC frequency (35%) correlates with the decrease in gephyrin clusters in CA1 
neurons. Consistent with these observations, staining for 1 (Fig. 6A, C; Paired Student’s T-test 
P=0.019) or 2 GABAARs (Fig. 6B, D; Paired Student’s T-test P<0.001) also shows a similar 
reduction of 30% from CA1 pyramidal neurons.  
 
 
Figure 5: Defects in GABAergic mIPSCs correlate with morphological loss of gephyrin clusters.   
(A-B) Example traces of GABAergic mIPSCs recording form CA1 hippocampal neurons control neurons (DIV 21, 
n=15 cells) and neurons after 24 hr recovery post-OGD (OGD+24h, n=13). (C) Average traces of mIPSCs (Two-
tailed Unpaired T-test). (D) Cumulative probability distribution of mIPSCs inter-event interval (IEI), **P<0.01 
Kolmogorov-Smirnov (KS) test. (E) Mean mIPSCs IEI. (F) Cumulative probability distribution of amplitudes in 
control and neurons after 24 hr recovery post-OGD. (G) Quantification of mean mIPSCs amplitudes (Two-tailed 
Unpaired T-test). (H-I) Example traces of mIPSCs recording from control neurons (DIV 28, n=13) and neurons one-
week post-OGD (n=15). (J) Average traces of mIPSCs. (K) Cumulative probability distribution of mIPSCs IEI in 
control neurons and neurons one-week post-OGD. (L) Quantification of mean mIPSCs IEI (Two-tailed Unpaired T-
test). (M) Cumulative probability distribution of mIPSCs amplitude. (N) Quantification of mean mIPSCs amplitudes. 
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Figure 5: Legend on the previous page. 
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Figure 6: OGD reduces 1- and 2- containing GABAARs. 
(A-B) DIV 21 organotypic hippocampal slice stained for endogenous gephyrin (blue) and endogenous 1-or 2- 
containing GABAARs subunits (red) in untreated and OGD treated neurons. Scale bar 2m. (C, D) Quantifications 
of mean puncta density of1- and 2- containing GABAARs per m dendrite. *P<0.01 Paired t-test.  
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Our morphological analysis one-week post-OGD showed that gephyrin cluster density returns to 
baseline levels. Hence, we wanted to test whether GABAergic mIPSCs also recovers one-week 
post-OGD. Our analysis of mIPSCs recorded after one week showed recovery of IEI that is 
consistent with the gephyrin morphology (Fig. 5H-L; 235.1ms±27.24, n=15 versus 
233.0ms±24.24, n=13, Two-tailed Unpaired T-test P=0.954). The cumulative probability 
distribution and the average values showed no difference in amplitude after one-week recovery 
(Fig. 5M-N; 35.77pA±2.48, n=15 versus 34.04pA±2.48, n=13; Two-tailed Unpaired T-test 
P=0.75).  
 
 
It is worthy to point out that mIPSCs IEI values in control neurons 24 hr post recovery is 
significantly lower than IEI values after one-week recovery (233.0ms±24.24, n=13versus 
146.0ms±10.25, n=15; Two-Tailed Unpaired T-test P=0.0037). This is surprising considering 
that the synapses within the hippocampal circuit mature between 3 to 4 weeks in culture and the 
IEI get usually smaller. Consistent with this idea, we also noticed a significant increase in the 
mean mIPSC amplitude in neurons with one-week recovery post-OGD (30.05pA±1.231, n=15 
versus 34.04pA±2.48, n=13; Two-Tailed Unpaired T-test P=0.016). 
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BDNF transcription is upregulated post-OGD 
 
Independent studies have reported that ischemia-induced increase in excitatory neurotransmission 
upregulates BDNF transcription and release [276, 297]. In order to test whether OGD resulted in 
a similar increase in BDNF in our experiments, we performed quantitative real time PCR (qRT-
PCR) from control slices and OGD slices post-24 hr OGD recovery to measure changes in bdnf 
transcript levels from the CA1 and CA3 areas (Fig. 7A). Analysis upon normalization using the 
house-keeping gene GAPDH showed a significant increase in bdnf transcript specifically from 
the CA1 region (P=0.046) but not CA3 (P=0.14). This results confirms that exposing organotypic 
slice cultures to transient OGD causes a similar rise in BDNF levels as reported earlier.  
 
BDNF facilitates structural changes at GABAergic synapses via gephyrin SUMOylation. 
Furthermore, it has been reported that there is a significant elevation of SUMO-1 and SUMO-2/3 
proteins levels following ischemia [253]. Elevated levels in SUMO proteins could be a 
consequence of increased SUMO transcription; hence, we tested for Sumo-1 and Sumo-2 
transcript changes following both 90 min and one-week post-OGD recovery. Quantification for 
mRNA levels showed no significant differences in Sumo-1 and Sumo-2 transcript levels between 
the control and OGD treated slices (Fig. 7B-C).  
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Figure 7: OGD results in increased BDNF transcript level. 
 (A) Real time qRT-PCR analysis of bdnf transcript in control and OGD samples 90 min and one-week post 
recovery. *P<0.01 Paired t-test (B-C) qRT-PCR analysis of Sumo-1 and Sumo-2 transcripts in control versus 90 
min and one-week post-OGD recovery. The analyses were done using organotypic hippocampal slice cultures from 3 
independent batches and a total of 5 slices for each condition. T-test showed no significant differences.   
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Blocking BDNF signaling   prevents the decrease in GABAergic inhibition after OGD 
 
Our data identifies elevated BDNF transcript levels after OGD. Furthermore, morphology 
analysis shows that scavenging BDNF using TrKB/Fc results prevents gephyrin cluster loss after 
OGD (Fig. 3). Hence, we wanted to test whether preservation of gephyrin clustering after 
scavenging BDNF also affected GABAergic inhibition. For this, we applied 1g/mL of TrKB/Fc 
after OGD during the 24 hr recovery process and performed whole-cell patch-clamp recordings 
of GABAergic mIPSCs from CA1 pyramidal neurons.  
 
We analyzed for changes in IEI and amplitude (Fig. 8A-C). In support of our earlier observations 
treatment of slices with TrkB/Fc to scavenge BDNF rescued GABAergic mIPSCs as we did not 
observe any significant difference in the IEI (Fig. 8D-E; 182.8ms±19.25, versus 141.9ms±15.49, 
Two-Tailed Unpaired T-test P=0.114). Furthermore, we also did not observe significant 
difference in the amplitude between control and TrKB/Fc treated slices after OGD (Fig. 8F-G; 
28.63pA±3.02, n=11, versus 28.77pA±2.6, n=11, Two-Tailed Unpaired T-test P=0.97).  
Our functional data is in line with the gephyrin morphology changes, wherein we show a direct 
correlation between BDNF upregulation, gephyrin cluster loss and increased IEI. Furthermore, by 
scavening BDNF using TrkB/Fc we demonstrate preservation of both gephyrin clusters and 
GABAergic mIPSCs.   
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Figure 8: Scavenging BDNF rescues GABAergic mIPSC loss after OGD.  
(A-B) Representative traces of GABAergic mIPSCs form DIV 21 CA1 pyramidal neurons 24 hr post-OGD (n=12) 
and cultures treated with TrKB/Fc (n=10). (C) Average traces of GABAergic mIPSCs. (D) Cumulative probability 
distribution of mIPSCs IEI: Control+24hr (n=11); Control+TrKB/Fc (n=11); OGD+24hr (n=12) and OGD+TrKB/Fc 
(n=10); **P<0.01 KS test. (E) Quantification of mean mIPSCs IEI. **P<0.001 One-Way ANOVA followed by a 
Tukeys Multicomparison test. (F) Cumulative probability distribution of mIPSCs amplitudes. (G) Quantification of 
mean mIPSCs amplitudes. Non-significant One-Way ANOVA followed by a Tukey s Multicomparison test. 
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Figure 9: Legend on the next page. 
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OGD alters the subcellular localisation of SUMO-2/3 and PIAS-3 in CA1 neurons 
 
Our experiments in primary hippocampal neurons showed that BDNF alters subcellular 
localization of SUMO-1, -2/3 and PIAS-3 from nucleus to cytoplasm (Chapter 1). Independent 
reports have shown up regulation of SUMO-2/3 under ischemic conditions [253, 283]. We 
wondered if the observed loss of gephyrin clusters in OGD slice cultures is also accompanied by 
a subsequent subcellular localization change in SUMO-2/3 and PIAS-3 to influence gephyrin 
clustering at GABAergic synapse. In order to test this we stained for endogenous SUMO-2/3 and 
endogenous PIAS-3 (Fig. 9; in red) and morphologically analysed for distribution difference 
between different pyramidal cell layers in the CA1 area. In order to label the neurons we stained 
our slice cultures with the neuron specific nuclear marker protein NeuN (Fig. 9; in green). .  
 
Under baseline conditions endogenous SUMO-2/3 staining showed a nuclear localization with a 
strong co-localization with NeuN (Fig. 9; yellow). This co-labeling was restricted to the Stratum 
Pyramidale where the pyramidal cell body is situated. However, in the Stratum Oriens and 
Radiatum, which contain the pyramidal cell dendrites we saw nuclear staining which we mostly 
attributed to the astrocytes. We could not observe any distinct dendritic labelling of the pyramidal 
cell neurons in Oriens or Radiatum.  
 
 
 
 
 
 
 
Figure 9: OGD alters sub-cellular localisation of SUMO-2/3 and PIAS-3 in CA1 area.   
(A-C) Organotypic slice cultures DIV 21 immunostained for endogenous SUMO-2/3 (red) and NeuN (green) within 
the three in Stratum Radiatum, Stratum Pyramidalis and Stratum Oriens, 90min post-OGD and one-week post-OGD. 
(D-F) Organotypic slice cultures DIV 21 immunostained for endogenous PIAS-3 (red) and NeuN (green). 
Localisation of endogenous PIAS-3 within the three different layers of hippocampal CA1 area; control condition, 
90min post-OGD, one-week after OGD. Scale bar 50m. 
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We then analysed slice cultures that had undergone OGD followed by either 90 min or one-week 
recover. At 90 min post-OGD, SUMO-2/3 showed a strong reduction in the Stratum Pyramidale, 
which, interestingly, recovered at one week post-OGD (Fig. 9B, D). Taken together, these results 
demonstrate that OGD alters the cellular localisation of endogenous SUMO-2/3 without affecting 
the transcript levels.  
 
When we analysed for PIAS-3, we found immunoreactivity both in the nucleus and soma of 
NeuN positive cells in the Stratum Pyramidalis (Fig. 9D; yellow). However, we also found some 
immunoreactivity for non-neuronal cells (NeuN negative) in the Stratum Oriens and Radiatum 
(Fig. 9D). After OGD and 90 min recovery, PIAS-3 was localized differently; we found a strong 
staining in Stratum Pyramidalis, Radiatum and Oriens (Fig. 9E). Interestingly, after one-week 
post-OGD we observed that PIAS-3 staining in Stratum Pyramidalis returned to baseline while 
also showing elevated levels in Stratum Radiatum (Fig. 9F).   
 
The localization difference of SUMO and PIAS-3 proteins within the neuronal dendrites in 
response to OGD is consistent with our observations in primary hippocampal neurons. Hence, we 
decided to evaluate and quantify specific morphological change in PIAS-3 in response to OGD. 
In order to achieve this we prepared organotypic slice cultures using transgenic mice that express 
myristoylated GFP in CA1 pyramidal neurons to facilitate the identification of dendritic 
structures at Radiatum and Oriens (Fig. 10A). We induced OGD and observed for subcellular 
distribution difference in PIAS-3 90 min and one-week later (Fig. 10A, B). We performed 
morphology analysis of the dendritic segments situated at the Radiatum and Oriens to quantify 
for PIAS-3 expression in apical and basal dendritic segments. We observed that PIAS-3 forms 
distinct puncta in the dendrites in addition to its nuclear labelling (Fig. 10A; zoom). Hence, we 
quantified for PIAS-3 cluster area and density change in response to OGD.  
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Figure 10: PIAS-3 dendritic puncta is altered in response to OGD.  
(A-B) Organotypic slice culture of CA1 pyramidal neurons expressing GFP stained for PIAS-3 (red), in 
Control+90min and OGD+90min slices. Different CA1 layers are indicated; SR Stratum Radiatum; CA1 Cornu 
Ammonis and SO Stratum Oriens. Scale bar 50m. High magnification image is on the right side show PIAS-3 sub-
cellular localisation in the apical and basal dendrites. Arrow show co-localised PIAS-3 on CA1 pyramidal neuron 
dendrite. Scale bar 5m. (C-D) Quantification of PIAS-3 puncta size within the apical and basal dendrites (**P<0.01 
KS test). (E-F) Quantifications of PIAS-3 puncta number per 1m length dendrite (non-significant One-way 
ANOVA). 
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Apical dendritic segments showed an increase in PIAS-3 puncta size after OGD (Fig. 10C; 
0.13µm²±0.016 versus 0.084µm²±0.006, KS test P=0.003). Interestingly, PIAS-3 puncta size was 
still significantly larger one-week after OGD (Fig. 10C; 0.11µm²±0.015 versus 0.13µm²±0.016, 
KS test P=0.072). We did not see any significant change in the PIAS-3 puncta size on the basal 
dendrite (Fig. 10D; 0.11µm²±0.015 versus 0.088µm²±0.005, KS test P=0.24). 
 
The density of PIAS-3 puncta remains unchanged in the apical dendrites (Fig. 10E; One-Way 
ANOVA F(3,36)=0.54, P=0.66) and in the basal dendrites (Fig. 10F; One-Way ANOVA 
F(3,35)=0.11, P=0.196) independently of any of the conditions. Interestingly, PIAS-3 puncta size is 
significantly increased in the apical dendrites condition (Fig. 10D; One-Way ANOVA 
P=0.0058). In contrary, PIAS-3 puncta size in the basal dendrites is unaffected regardless of the 
condition (Fig. 10D; One-Way ANOVA P=0.18). Thus, the main change is occurring at Stratum 
Radiatum where pyramidal CA1 neurons receive synaptic contacts from the CA3 mossy fibres. 
 
 
Gephyrin SUMO mutations prevent impaired postsynaptic clustering after OGD  
 
We have demonstrated that SUMOylation exerts bidirectional effects on gephyrin clustering, 
likely through the involvement of PIAS-3 and SENP-2/-6 to facilitate efficient SUMO 
conjugation and de-conjugation [Ghosh et al., submitted]. Furthermore, many independent 
studies have shown gephyrin scaffold regulation having direct implications on GABAergic 
transmission. Our results so far implicate ischemia-induced reduction in GABAergic transmission 
to gephyrin cluster loss. Moreover, our results also identify distinct effect of ischemia on 
subcellular localization difference for PIAS-3 and SUMO-2/-3. Taking together these 
observations, it is likely that ischemia-induced alterations at GABAergic synapse are facilitated 
by changes in gephyrin SUMOylation. We have recently identified and characterized SUMO-1 
(K148) and SUMO-2 (K724) conjugation sites on gephyrin. In primary neuron cultures, mutating 
these two SUMO conjugation sites via site directed mutagenesis stabilizes GABAergic synapses 
by rendering them insensitive to BDNF modulation. Hence, we decided to test whether 
expression of eGFP-K148R/K724R double mutation would make gephyrin resistant to ischemia-
induced alterations and prevent changes in postsynaptic clustering. We transfected mCherry-
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gephyrin or mCherry-K148R/K724R plasmids into organotypic slice cultures at DIV 14 and 
induced ischemia at DIV 16 (Fig. 11). Analysis for changes in eGFP-gephyrin clustering (Fig. 
11A) showed a significant reduction in cluster volume (Fig. 11C; 0.03µm
3
±0.002 versus 
0.019µm
3
±0.0018, KS test P<0.001) and density (Fig. 11D; 0.65±0.01/m versus 0.33±0.03; 
P=0.001) at 90 min post-recovery. Interestingly, analysis for mCherry-K148R/K724R (Fig. 11B) 
cluster volume (Fig. 11C; 0.03µm
3
±0.005 versus 0.046µm
3
±0.003, KS test P=0.116) and density 
(Fig. 11D; 0.75±0.15 versus 0.82±0.07; P=0.93) showed no change at OGD+90min. These 
observations confirm our idea that ischemia induced plasticity change at GABAergic postsynapse 
is primarility facilitated by PIAS-3 induced SUMO-conjugation on gephyrin at K148 and K724 
residues.  
Overall, our data demonstrates the significance of gephyrin SUMOylation in downregulating 
GABAergic transmission after OGD.   
 
 
  
Figure 11: Gephyrin SUMO-deficient mutant prevents impaired postsynaptic clustering after OGD.  
(A-B) DIV 14 hippocampal organotypic cultures co-transfected with td-Tomato and either WT gephyrin or gephyrin 
SUMO-deficient mutant eGFP-K148R+K724R (red puncta) using Gene Gun technique. Scale bar 3m. (C-D) 
Quantifications of gephyrin mean puncta volume and density per m dendritic length in control condition and 
OGD+90min. ***P<0.001 Student t-test.  
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Discussion 
 
In this study, we use organotypic hippocampal slice cultures and an in vitro model of ischemia, 
oxygen glucose deprevation (OGD) to investigate the role of BDNF-induced gephyrin 
SUMOylation for GABAergic synaptic plasticityin CA1 pyramidal neurons. We demonstrate that 
after OGD there is a specific elevation of BDNF transcription. Further, we identify SUMOylation 
downstream of TrkB signaling  as the mechanism responsible for the transient loss of gephyrin 
clusters after OGD. By expressing SUMO-insensitive gephyrin mutants, we provide proof of 
principle for this mechanism of ischemia-induced impairment of gephyrin scaffolding loss at 
GABAergic terminals, resulting in reduced GABAergic transmission.  
 
OGD effects on gephyrin scaffolding and inhibitory GABAergic transmission 
We present data showing disruption in gephyrin scaffolding and GABAergic mIPSC frequency in 
response to OGD. Although we see a 90% decrease in gephyrin expression after OGD, the 
reduction in GABAergic mIPSCs frequency is only 35%. Furthermore, we show a 20 to 30% 
reduction in the expression of 1 and 2 subunits-containing GABAARs after OGD. Quantitative 
nanoscopy measurements have shown that the stoichiometry of gephyrin to GABAAR is not 1:1, 
indeed it is likely to be 5:1 [132, 298]. This is based on the fact that each gephyrin molecule can 
bind multiple GABAAR subunits within a receptor. Direct interaction between gephyrin and 
GABAAR,  and  subunits has been reported [18, 130, 136], and usually 2, 2 and 
1subunits assemble together to form a pentameric ligand gated channel [20]. This could 
explain partially the higher loss of gephyrin expression compare to the GABAAR subunits.  
In recent years it has become evident that gephyrin cluster detection using the most commonly 
used monoclonal antibody (m7a) is influenced by gephyrin post-translational modification, 
especially phosphorylation. Phosphorylation at S270 residue renders the gephyrin clusters 
insensitive to m7a detection in neurons. Hence, another more simplistic explanation could be that 
OGD induced post-translational modification(s) on gephyrin could make morphological detection 
of endogenous gephyrin clusters difficult leading to a more dramatic decrease in cluster numbers 
compared to GABAARs.   
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BDNF and SUMO pathway regulate gephyrin scaffolding after OGD 
 
Here, we inhibit OGD induced loss of GABAergic synapse by scavenging BDNF. It has been 
shown that neurotrophin NT-4 signaling  can also reduce brain injury after stroke [299]. We 
eliminate the involvement of NT-4 in our ischemia model because in an independent study we 
identify a specific role for mature/processed BDNF for facilitating change at GABAergic synapse 
(Gill et al. in preparation). In this study, we could prevent OGD induced gephyrin cluster loss by 
blocking mature BDNF signaling  using the monoclonal antibody N9. Given this evidence it is 
likely that OGD mediated downregulation of gephyrin scaffolding in response to OGD is via the 
neurotrophin BDNF and not NT-4.  
 
We have demonstrated that BDNF regulates specific proteins of the SUMO pathway to influence 
gephyrin scaffolding property at GABAergic synapse (see Chapter 1). We also demonstrate the 
specificity of BDNF induced sub-cellular localization change of SUMO E3 ligase PIAS-3, and its 
subsequent influence on gephyrin scaffolding. Consistent with our earlier observations in primary 
neuron culture, our data using organotypic hippocampal slice culture also proves OGD induced 
sub-cellular localization change of PIAS-3 (Fig. 10). Interestingly, we do not observe any 
transcriptional change in PIAS-3 or Sumo transcripts, suggesting that OGD affects SUMO 
pathways signaling rather than SUMO availability and/or conjugation. In further support of this 
idea, we have seen BDNF induced sub-cellular localization changes for SENP-2/-6 (See Chapter 
1). Hence, it is possible that spatial and temporal availability of PIAS-3, SUMOs and SENP-2/-6 
influence gephyrin SUMOylation levels in response to OGD. It has been demonstrated that 
gephyrin is a novel SUMO substrate and is modified by SUMO-1 and SUMO-2 at K148 and 
K724 residues respectively [Ghosh et al., submitted]. Here, we build on this evidence and provide 
proof of principle by showing complete blockade of gephyrin cluster loss after OGD upon 
expression of SUMO-defective gephyrin mutants K148R/K724R in CA1 neurons (Fig. 11).   
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Role of BDNF and SUMOylation for recovery after an ischemic injury 
 
In an independent study we investigated the importance of gephyrin phosphorylation by ERK1/2 
and GSK3 kinase pathways for gephyrin scaffold stabilisation at GABAergic synapses in 
response to OGD. In this study, we identified that BDNF activates ERK1/2 and GSK3 pathways 
causing phosphorylation at gephyrin S268 and S270 residues resulting in proteolytic clipping of 
gephyrin scaffold by the protease calpain1 [Gill et al., in preparation]. This loss of gephyrin 
scaffold could provide a molecular basis for rapid removal of GABAergic synapses in CA1 
pyramidal neurons after OGD. Our observations of gephyrin degradation and removal from 
GABAergic synaptic sites is supported by independent report showing MCAO induced gephyrin 
loss via calpain1 activity [248]. We could successfully reverse OGD induced gephyrin cluster 
loss by the expression of gephyrin S268A/S270A phosphorylation defective mutations in CA1 
pyramidal neuron [Gill et al., in preparation].  
Given that gephyrin SUMO defective mutations enhance scaffolding at GABAergic synapses, it 
is likely that SUMO conjugation restricts gephyrin scaffolding properties [Ghosh et al., 
submitted]. We could also demonstrate that SUMOylation, phosphorylation and acetylation 
pathways cross-talk to influence gephyrin scaffolding. Furthermore, using an animal model 
lacking Gabra2 (2 GABAAR subunit), wherein we see a distinct loss of gephyrin scaffolding, 
we could successfully rescue gephyrin scaffolds via in vivo transgenic expression of eGFP-
K148R SUMO-defective mutation [Ghosh et al., submitted]. The successful rescue of gephyrin 
scaffold using the SUMO defective mutation suggested to us that SUMO pathway operates 
upstream of the phosphorylation pathway for gephyrin cluster regulation. In support of this 
interpretation, it has been reported that ERK 1/2 expression and activity undergo a long-lasting 
decrease during the recovery phase post-ischemia [300]. Hence, we can postulate that gephyrin 
SUMOylation prevents reestablishment of GABAergic synapses in the immediate aftermath of 
OGD. However, during the recovery phase, SENP-2/-6 mediated SUMO de-conjugation, along 
with suppressed ERK1/2 kinase activity facilitates gephyrin scaffold building and establishment 
of GABAergic inhibition, thus facilitating network activity. 
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Our idea is supported by observations from other groups showing a rapid and long-lasting 
increase in general SUMOylation levels, after global or focal middle cerebral artery occlusion 
(MCAO) [242, 253]. Further, another study shows a distinct correlation between inhibition of 
ERK activation and an elevation of GABAergic transmission after OGD [300]. Studies have also 
proposed a neuroprotective role for substrate SUMOylation post ischemic stress [242] [241]. 
Although transient focal ischemia in rodents also induces elevation in protein SUMOylation 
levels [242, 253, 301], no clear proof for neuroprotection has been demonstrated. One study 
using SUMO overexpression in SHSY5Y human neuroblastoma cells and in rat cortical neurons 
demonstrate resistance of the cells to OGD [302].  
The increase in the general SUMO conjugated proteins has been proposed to be beneficial at 
glutamatergic synapses by regulating the level glutamate receptors at synaptic sites [190, 221]. It 
has been shown that under physiological conditions kainate receptor GluR6 [226] is a SUMO 
substrate. GluR6 is abundantly expressed in the hippocampus and has been shown to be 
endocytosed after SUMOylation. This supports the idea of a possible downregulation of neuronal 
excitation following ischemic injury via the process of SUMOylation [220].  
Multiple studies show a beneficial role of BDNF for lowering the infarct volume or protecting 
against cellular damage [303, 304] or for motor recovery in models of stroke [305, 306]. In 
contrary, other studies have also shown the benefit of low BDNF levels for motor recovery, in the 
aftermath of stroke [307, 308]. Our study resolves some of these discrepancies in literature by 
demonstrating different effects for acute and chronic BDNF signaling.  
Overall, our study sheds light into some of the long-standing issues in the field of ischemia, such 
as what is the relationship between BDNF and GABAergic synapse loss. We dissect the 
molecular mechanism by linking BDNF signaling with gephyrin SUMOylation for GABAergic 
synaptic plasticity. This study offers a better understanding of the complexity underlying BDNF 
signaling during recovery following ischemic injury. 
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IV/ General discussion 
 
In this thesis, we demonstrate the importance of gephyrin regulation by PTM for its scaffolding at 
GABAergic postsynaptic sites and for the regulation of GABAergic IPSCs under patho-
physiological conditions. Most prominent among these PTMs is SUMOylation, a recently 
identified modulator of postsynaptic gephyrin clustering. Moreover, we identified BDNF as an 
upstream signaling molecule activating the SUMO pathway to regulate gephyrin cluster 
formation and maintenance. The relevance of this mechanism has been tested in a model of 
ischemia, where BDNF and SUMOylation are considered to provide neuroprotective signaling 
for recovery post-injury. Herein, I will summarize and discuss the main findings of this thesis.  
In our previous report [Ghosh et al. Submitted] and in Chapter 1, we present supportive data 
identifying the E3 ligase PIAS-3, as a key player of the dynamic modulation of gephyrin 
clustering at GABAergic postsynaptic sites. PIAS-3 regulates gephyrin clustering via two 
independent mechanisms involving a SUMO and a non-SUMO ligase function. Both mechanisms 
are under the control of the BDNF signaling. We demonstrate that acute BDNF exposure 
modulates gephyrin clustering via SUMOylation in primary hippocampal neurons. Direct 
evidence for gephyrin SUMOylation is provided by the inhibition of BDNF effect in cells 
overexpressing the SUMO-deficient gephyrin mutant constructs (eGFP-K148R/K724R). BDNF 
signaling inhibits PIAS-3 function and activates at the same time the kinases ERK1/2 and GSK3 
pathways. As a result, gephyrin becomes less SUMOylated and becomes more phosphorylated by 
these kinases, leading presumably to gephyrin cleavage (smaller clusters). Conversely, gephyrin 
phosphorylation by ERK1/2 and GSK3 regulate its SUMOylation propensity, providing a 
mechanism to rapidly adjust cluster size and density in response to extracellular signals. 
Recent reviews highlight the possibility that SUMOylation PTM might be a key component of 
recovery post-ischemic injury in vitro and in vivo [220, 234, 240, 242]. Likewise, there is strong 
evidence for the importance of BDNF after stroke [278, 304, 305, 309]. We observed in the OGD 
model of ischemia (Chapter 2) a profound reduction of gephyrin and GABAARs-containing 1 
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and 2 subunits clusters, accompanied by a downregulation of GABAergic transmission. These 
results are in line with previous studies [248]. Furthermore, these effects depend on BDNF 
signaling, as we could prevent them via scavenging BDNF by TrKB-Fc. Finally, gephyrin cluster 
loss post-OGD could be prevented via over-expressing the SUMO-deficient gephyrin mutant 
constructs. Taken together, we here provided a mechanism downstream of BDNF in the 
regulation of GABAergic synapse plasticity post-ischemic injury. It is tempting to speculate that 
it relies on the same signaling pathways as those uncovered in primary neurons. Moreover, based 
on BDNF negative modulation of GABAergic synapse function and structure, the data highly 
suggest a non-protective role of BDNF post-recovery. 
 
Ischemia and inhibitory transmission 
 
The importance of inhibitory neurotransmission for the maintenance of network activity might be 
even greater when studying a disease, such as stroke, than under baseline conditions. The 
hippocampus is a brain region highly vulnerable to ischemia [279, 310]. Cerebral ischemic stroke 
induces an early disruption of GABAergic transmission via dysregulating different component 
necessary in the maintenance and the proper function of GABAergic synapses. One study has 
demonstrated the downregulation of CA1 interneurons excitability following transient ischemia. 
This decrease in general excitability could be explained by a decrease in potassium channels 
NAv1.1 expression, which might suggest a reduction in GABA release. This voltage-gated 
channel play an essential role in the generation and propagation of action potential [311]. 
Intriguingly, impairment of inhibition would enhance pyramidal neurons excitability thereby 
facilitating NMDA excitotoxicity and contributing to neuronal cell death. Otherwise, in general, 
studies on ischemia report a general downregulation of GABAergic transmission occurring at the 
pre- and postsynaptic levels [248, 284].  
The studies that have been reporting some changes at GABAergic presynaptic terminals are 
controversial, because their conclusions vary with the ischemic paradigm used. One study 
reported a decrease in vesicular transporter vGAT following brain ischemia [312], while another 
one demonstrated a resistance (no change) of vGAT to different type of brain ischemia [313]. 
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There is agreement, however, that glutamic acid decarboxylase (GAD), the enzyme responsible 
for GABA synthesis, is unaffected by any type of brain ischemia [314]. 
Postsynaptically, a transient or focal ischemic injury leads to a decrease in GABAARs protein 
expression [284, 290, 315] and in GABAARs subunits mRNA levels [314], causing a general 
decrease in GABA-mediated responses [316]. Interestingly, an independent study has reported 
the downregulation of GABAARs and gephyrin to be a calpain-dependent mechanism. In 
addition, these authors demonstrated that the receptors undergo dephosphorylation by 
PP1/PP2A, in turn facilitating their endocytosis [248]. Moreover, this downregulation of 
GABAARs might also be the consequence of the reduction in the interaction between the 
receptors and gephyrin [252]. The loss of this interaction might contribute to the acceleration of 
GABAARs internalization. Gephyrin is important for trapping the receptors at the synapse, and 
without this interaction the receptors are more mobile at plasma membrane [87, 131, 136].  
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Figure Summary: consequences of ischemia on inhibitory synapses. 
In grey are stated the fact described within the literature. A question mark highlights the non-confirmed findings. In 
red and purples are the results obtained and presented in this thesis.  
 
Our work provides strong support to the notion that regulation of gephyrin PTM is a key 
component in the reduction of GABAergic function upon stroke. Therefore, show that BDNF 
release might paradoxically aggravate the effects of ischemia by directly down-regulating 
GABAergic transmission. Furthermore, we demonstrated in Chapter 1 that gephyrin 
SUMOylation cross-talks with gephyrin phosphorylation. Intrigued by these results, we have 
used the gephyrin phospho-deficient mutant (eGFP-S268A/S270A) in organotypic slice cultures 
and observed its resistance to OGD [Gill et al. Unpublished]. Therefore, both PTMs participate in 
the downregulation of gephyrin post-OGD and their inhibition would maybe contribute in the 
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maintenance of GABAergic function. Thus, the cross-talk between phosphorylation and 
SUMOylation is a striking example of the dynamic modulation of gephyrin, and thereby 
GABAergic synapse plasticity, under patho-physiological conditions (Figure Summary).  
Further, these data provide some support to the idea that stabilization of GABAARs surface 
expression would be neuroprotective in neurons subjected to ischemic injury [315]. Moreover, it 
has been shown that enhancing GABAergic transmission, using benzodiazepines, would prevent 
neuronal cell death right after ischemia, in adult hippocampus [247]. 
 
It would be of great interest to study whether the mechanisms described in this thesis also hold 
under in vivo ischemic stroke, such as studied by transient middle cerebral artery occlusion 
(MCAO). It is conceivable that stabilizing gephyrin would help retaining GABAARs in the PSD, 
contributing in maintaining GABAergic transmission. Thereby, enhancing inhibition of 
pyramidal neurons would help decreasing excitotoxicity. 
To test this possibility, it would be possible to overexpress gephyrin SUMO-deficient mutant 
constructs by transfection with an AAV virus injected directly in the brain region of interest. 
After leaving enough time for the virus to be expressed, the animal model would undergo MCAO 
treatment followed by 24h recovery. As we are interested in GABAergic synapses, it would be 
then interested to look if the infected target neurons would show resistant to MCAO against 
downregulation of gephyrin expression like obtained in vitro (Chapter 2). Addition staining of 
different markers at GABAergic synapses such as vGAT and GABAARs subunits, would be a 
support in the idea that gephyrin prevention would contribute in keeping the receptors at the 
synapse and so, prevent there endocytosis. Moreover, as it was speculated in the literature, it 
would be interesting to see whether the modulation of GABAergic synaptic transmission would 
contribute in the prevention of neuronal death. Morphological changes are always accompanied 
by functional changes; it would be of great interest to test whether over-expressing this gephyrin 
mutant would contribute in the maintenance of GABAergic synapse transmission. If gephyrin get 
stable in those infected cells, leading to the stabilization of GABAARs, it would be therefore 
expected to have prevented the downregulation of GABAergic mIPSCs post-ischemia. This 
would be possible to study via performing patch-clamp recording of CA1 pyramidal neurons of 
hippocampal slices made 24h-48h post-reperfusion. This experiment would also allow seeing, in 
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case of conservation of GABAergic synapses, the possible changes at glutamatergic synapses. In 
parallel, NMDA-mediated excitatory transmission would also be recorded in order to see if 
prevention of decrease inhibitory transmission would decrease glutamatergic excitability.  
However, ischemia induces a variety of molecular and cellular consequences that it would be 
possible that glutamatergic transmission might not be totally rescued or maintained in a steady-
state by only acting at GABAergic levels. Others cells such as glial cells have also been reported 
to be affected by ischemia. Microglia, oligodendrocytes and astrocytes play a crucial role in 
regeneration, survival and protecting brain function but also destroying in pathological 
conditions. The role of astrocytes in cerebral ischemia is quiet controversial and still need to be 
defined. So many questions have been raised since the last decade which can’t discriminate 
astrocytes from being neuroprotective or contributors to stroke injury [317]. It would be therefore 
interesting to look at their reactivity and see if they still, for example, lead to reactive gliosis even 
inhibitory synapses are more stable. Astrocytes have the capacity to limit the infarct size via the 
formation of the gliosis. Moreover, knowing that neurons can’t survive without glia cells, it 
would be of great interest to determine their survival rate in comparison to the neuronal loss. 
Oligodendrocytes died when deprived of substances leading to neuronal disruption [317].  
Thus, glial cells are crucial components to take in consideration when studying ischemia. 
 
SUMOylation and ischemic preconditioning  
 
In comparison to permanent or global, transient ischemia is known to induce non-lethal and 
smaller infarct size. Interestingly, ischemic preconditioning is the ability to have or induce very 
shorts ischemia, limiting the infarct size. A short ischemia seems to activate neuroprotective 
mechanisms important against a second ischemic insult which can be stronger. In the different 
independent studies made around neuroprotective effects, occurring following a short ischemic 
insult, point out the presence of an elevation of the general SUMO levels [253, 283, 318]. 
Moreover, it has been shown that over-expressing the different SUMOs paralogs in vitro, would 
contribute to the resistance of the primary neuronal cells to the ischemic insults such as OGD 
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[234, 241, 242]. Silencing SUMO-2/3, using lentiviral microRNA, facilitates neuronal death 
[241].  
Therefore, SUMOylation might participate in inducing ischemic tolerance. However, further 
work would be needed in order to identify the targets SUMO substrates responsible of this 
protective role of SUMOylation. Regarding our findings, our results presented in this thesis could 
provide a mechanism of regulation at GABAergic synapses after a non-harmful ischemic injury.  
It would be of great interest to see whether downregulating gephyrin clusters at GABAergic post-
synapses is part of the neuroprotective process. The use of gephyrin SUMO-deficient mutants 
expressed in cell or slices cultures would either or not be beneficial for make the cells resistant to 
OGD.  
Moreover, as highlighted previously, stabilizing GABA might not be sufficient to improve 
neurological function after stroke as many others components or cells are also involved in 
neuronal degeneration. Thus, it would be interesting to study the role of astroglia cells and 
microglia in addition at observing the different changes that would gender on glutamatergic 
synapses.   
 
For recovery, the neuronal network might need therapeutics interventions on the three main cells: 
GABAergic and glutamatergic neurons in addition to glial cells. All three are affected by cerebral 
ischemia and all three are playing different role which still need to be defined. However, it can be 
believed that acting on one of those cells can be helpful for recovery or prevention of certain 
cerebral damage but not be sufficient for full recovery. 
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VI/ Abbreviations 
 
ANOVA  Analysis of variance 
AP2   clathrin-adaptor protein 
ATP   Adenosine 5’ tri phosphate 
BDNF      Brain-Derived Neurotrophic Factor 
BZ      Benzodiazepine 
CA1 or CA3     Cornum Amonis 1 or 3 
CamK   Calmodulin Kinase 
CaMKII     Ca
2+
/calmodulin-dependent protein kinase II 
CASK   Ca
2+
/calmodulin-dependent serine protein kinase 
CB      Collybistin 
CCK   Colecystokinin 
CNS      Central Nervous System 
CREB   cAMP-responsive element binding protein 
DIV   Days in vitro 
Dlc   Dynein light chains 
DMSO   dimethyl sulfoxide 
eGFP     Enhanced Green Fluorescent Protein 
ERK      Extracellular signal-Regulated kinase 
FBS   Fetal Bovine serum 
FCS   Fetal Calf serum 
GABA     Amino Butyric Acid 
GABAARs     Amino Butyric Acid type A Receptors 
GABARAP  GABAAR-associated protein 
GAD      glutamic acid decarboxylase 
GAT      GABA transporter 
GFP   Green fluorescent protein 
GSK3      Glucogen Synthase Kinase 3
 
166 
  uman Embryonic Kidney cells 
HIF1   Hypoxic inducible factor 1 
IEI   nter-event interval 
IP      Immunoprecipitation 
JAK   Janus kinase 
KD   Knock-down 
KO   Knockout 
KS   Kolmogorov-Smirnov  
LTD   Long-term depression 
LTP   Long-term potential 
MAPK     Mitogen-activated protein kinase 
MEF2A  myocyte enhancer factor 2A 
Mena/VASP  Mammalian enabled/vasodilator stimulated phosphoprotein 
MITF     Microphtalmia Transcritption Factor
mIPSCs      miniatures Inhibitory Postsynaptic Currents 
mGluR  G-protein coupled metabotropic glutamate receptor 
MOCO  Molybdenum cofactor 
NL      Neuroligin 
NT   Neurotrophins
OGD      Oxygen and Glucose deprivation 
P75
NTR
     p75 Pan Neurotrophin 
PEI   Polyethylenimine 
PI   propidium iodide 
PI3K   Phophoinositide 3-Kinase 
PIAS       Protein Inhibitor of Activated STAT  
Pin1   Peptidyl-prolyl isomerase NIMA interacting protein 1 
PINIT     Pro-Ile-Asn-Ile-Thr 
PKA   Protein Kinase A 
PKC   Protein Kinase C 
PLC   Phopholipase C 
PP1   Protein phosphatase 1 alpha 
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PP2A   Protein phosphatase 2A 
PSD   Postsynaptic density 
PRIP1/2  phospholipase C-related catalytically inactive proteins 1/2 
proBDNF  Precursor BDNF 
PTM      Post-translational modification 
PV   Parvalbumin 
SAP   Scaffold Attachement factor-A/B 
SDS   Sodium Dodecyl Sulfate 
SENP     SUMO Sentrines Proteases   
SIM      SUMO-interacting motif 
SLM      Stratum Lacunosum-Moleculare  
SO       Stratum Oriens 
SR       Stratum Radiatum 
STAT     Signal transducer of Activated transcription 
STUbls  SUMO-targeted ubiquitin E3 ligase 
SUMO      Small Ubiquitin like modifier 
TBS   Tris Buffer Saline  
TrKB       Tropomyosin-related Kinase B 
TTX      Tetrodotoxin  
Ubc9   Ubiquitin-conjugating enzyme 9 
vGAT     Vesicular GABA transporter  
WB      Western Blot 
WT      Wild Type  
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